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ABSTRACT	
Typhoid	 fever	 continues	 to	 represent	 a	 significant	 threat	 to	 global	 health	 and	 currently	
licensed	vaccines	confer	incomplete	protection.		
In	 1975,	 an	 oral	 typhoid	 vaccine	 was	 developed	 through	 the	 chemical	 mutagenesis	 of	
pathogenic	Salmonella	enterica	serovar	Typhi	strain	Ty2.	This	vaccine,	which	is	designated	
Ty21a,	has	been	used	for	many	years	to	combat	disease;	it	is	well-tolerated	with	a	cumulative	
efficacy	of	approximately	58%	up	to	2	years	following	its	administration.	A	great	deal	of	data	
have	been	collected	concerning	peripheral	cellular	and	humoral	immune	responses	to	this	
vaccine;	however,	only	surrogate	measures	of	mucosal	immunity	exist.	
The	data	presented	within	this	thesis	demonstrate	the	value	of	direct	mucosal	sampling	and	
provide	 fresh	 insight	 into	 aspects	 of	 human	 immunity	 which	 have	 not	 previously	 been	
explored.	The	data	presented	describe	the	strength,	diversity	and	duration	of	mucosal	and	
peripheral	cellular	immune	responses	to	Ty21a.	In	addition,	the	data	demonstrate	the	wider	
impact	of	Ty21a	on	responses	to	non-related	pathogens.	Data	presented	here	support	the	
use	of	direct	mucosal	sampling	to	study	host-pathogen	interaction	and	the	development	of	
S.	Typhi	based	vectors.	
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CHAPTER	1: INTRODUCTION	
	
Salmonella	 enterica	 subspecies	 I	 serovar	 Typhi	 (S.	 Typhi)	 is	 a	 facultative	 intracellular	
pathogen	and	the	causative	agent	of	typhoid	fever.	This	bacterium	is	highly	adapted	to	its	
human	host	and	possesses	a	number	of	specialised	mechanisms,	which	combine	to	facilitate	
survival,	 replication	and	 transmission.	Disease	 is	endemic	 in	many	 resource-poor	nations,	
where	inadequate	sanitation	and	poor	food	hygiene	facilitates	faecal-oral	transmission.	
For	 a	 long	 time,	 vaccination	 has	 been	 used	 to	 combat	 disease.	 Unfortunately,	 currently	
licensed	vaccines	confer	incomplete	protection	and	are	ineffective	or	unsuitable	for	use	in	
young	children.	Following	the	successful	introduction	of	antibiotic	treatment,	the	pressure	
to	develop	new	vaccines	was	reduced	and	interest	waned.	The	emergence	of	antimicrobial	
resistant	 strains	 has	 redirected	 efforts	 towards	 the	 development	 of	 new	 vaccines.	
Unfortunately,	 development	has	been	hindered	by	our	 limited	understanding	of	mucosal	
immune	 defence,	mechanisms	 of	 protection	 and	 the	 absence	 of	 functional	 correlates	 of	
protection.	
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1.1. The	species	
S.	 enterica	 is	 a	 facultative	 intracellular	 Gram-negative	motile	 bacillus	 which	 comprises	 6	
subspecies,	50	serogroups	and	more	than	2,600	serovars	(Issenhuth-Jeanjean	et	al.,	2014).		
Approximately	 99%	 of	 serovars	which	 cause	 illness	 in	 humans	 reside	within	 subspecies	 I	
(Desai	et	al.,	2013).	The	vast	majority	of	these	serovars	have	a	broad	host	rage	and	cause	
self-limiting	 gastroenteritis	 in	 humans.	 These	 non-typhoidal	 serovars	 actively	 induce	
inflammation	at	the	intestinal	lumen	and	outcompete	other	bacteria	through	the	extraction	
of	 inflammatory-derived	 nutrients	 (Winter	 et	 al.,	 2010).	 In	 the	 presence	 of	
immunosuppressive	 illness,	 non-typhoidal	 serovars	 can	 cause	 an	 invasive	 bloodstream	
infection	in	humans,	known	as	invasive	non-typhoidal	disease	(Feasey	et	al.,	2015).		
A	 small	 number	 of	 serovars	 are	 human-host-restricted	 and	 cause	 typhoid/paratyphoid.	
These	typhoidal	serovars	are	believed	to	have	evolved	along	four	phylogenetically	unrelated	
lineages;	S.	Typhi,	S.	Paratyphi	B	and	S.	Paratyphi	C	each	form	single	lineages,	while	the	fourth	
lineage	 is	 formed	 by	 S.	 Paratyphi	 A	 and	 S.	 Sendai	 (Selander	 et	 al.,	 1990).	 It	 is	 likely	 that	
typhoidal	 serovars	 are	 descended	 from	 organisms	 that	 once	 caused	 gastroenteritis	 in	
humans.	 It	 has	 been	 demonstrated	 that,	 while	 204	 genes	 are	 functionally	 disrupted	 or	
inactive	in	the	typhoidal	serovar	S.	Typhi,	more	than	80%	their	homologs	are	functional	in	
the	non-typhoidal	serovar	S.	Typhimurium	(McClelland	et	al.,	2001).	
1.2. The	serovar	
S.	Typhi	is	believed	to	have	emerged	between	10,000	and	71,000	years	ago	(Roumagnac	et	
al.,	2006)	and	was	first	identified	as	the	causative	agent	of	typhoid	by	Karl	Joseph	Eberth	in	
1880	 (Marineli	et	al.,	2013).	Due	to	 the	risk	of	human	 infection,	S.	Typhi	 is	classified	as	a	
containment	level	3	organism	(Kohler,	2005).		
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The	 Kauffman–White	 scheme	 utilises	 antisera	 to	 classify	 serovars	 according	 to	 the	
expression	of	lipopolysaccharide	(LPS)	O-antigens,	flagella	H-antigens	and	the	virulence	(Vi)	
polysaccharide	antigen	(Judicial	Commission	of	the	International	Committee	on	Systematics	
of,	2005).	S.	Typhi	is	placed	in	group	D	based	on	the	expression	of	LPS	O-9	and	O-12	antigens,	
the	flagella	H1-d	antigen	and	the	Vi	polysaccharide	antigen	(Figure	1.1).	When	cultured	on	
blood	agar,	the	bacteria	form	smooth	white	colonies,	approximately	2	to	3	mm	in	diameter	
(Figure	1.2).	
	
Figure	1.1.	A	diagrammatic	representation	of	a	section	of	Salmonella	Typhi	showing	the	principal	antigens	
Key	structures	are	shown,	including	the	cell	wall,	lipopolysaccharide	(LPS)	core	and	O-antigen,	the	virulence	(Vi)	polysaccharide	
and	flagella	H-antigen.	
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Figure	1.2.	Salmonella	Typhi	strain	Ty21a	grown	on	Columbia	blood	agar	
(A)	Four	dilutions	plated	as	three	10	µL	spots.	(B)	A	single	dilution	plated	as	three	10	µL	streaks.	
	
There	is	approximately	1%	variation	in	the	core	genome	of	serovars	within	S.	enterica	(Baker	
and	 Dougan,	 2007).	 Alongside	 the	 core	 genome,	 there	 are	 virulence	 associated	 regions	
termed	Salmonella	Pathogenicity	 Islands	 (SPIs),	which	are	 thought	 to	have	been	acquired	
relatively	recently	through	horizontal	gene	transfer	(Hacker	and	Kaper,	2000).	SPI-1	and	SPI-
2	 encode	 type	 III	 secretion	 systems	 (T3SSs),	 these	 needle-like	 structures	 facilitate	
manipulation	of	host-cell	function	through	effector	protein	secretion	(Figure	1.3)	(Sukhan,	
2000).	SPI-7	encodes	the	capsular	Vi	polysaccharide,	which	masks	bacterial	antigens	(Nair	et	
al.,	 2004).	 The	 vast	majority	of	S.	 Typhi	 isolates	 that	have	been	 sequenced	possess	 SPI-7	
(Wain	 et	 al.,	 2005),	 which	 suggests	 that	 expression	 of	 the	 Vi	 polysaccharide	 provides	 a	
substantive	 selective	 advantage.	 Indeed,	 it	 has	 been	 demonstrated	 that	 strains	 which	
express	the	Vi	polysaccharide	are	more	virulent	than	those	that	do	not	(Hornick	et	al.,	1970,	
Hone	et	al.,	1988).		
A B 
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Figure	1.3.	Structure	of	the	Salmonella	type	III	secretion	systems	(T3SS)	(Haraga	et	al.,	2008)	
(A)	Electron	micrographs	of	a	Salmonella	enterica	serovar	TyphimuriumT3SS.	(B)	Electron	cryomicroscopy	and	surface	images	
of	the	structures	of	a	S.	Typhimurium	T3SS.		
	
S.	Typhi	typically	possesses	a	single,	monophasic	flagella	encoded	on	the	FliC	locus	(Frankel	
et	al.,	1989).	Flagella	are	 involved	 in	motility	and	cell	 invasion	(Grossman	et	al.,	1995).	S.	
Typhi	typically	expresses	the	H1-d	antigen;	however,	16%	of	Indonesian	isolates	alternately	
express	 the	 H1-j	 antigen	 (Grossman	 et	 al.,	 1995).	 Evidence	 suggests	 that	 isolates	 which	
express	the	H1-j	antigen	are	less	motile	and	less	invasive	than	those	which	express	the	H1-d	
antigen	 (Grossman	et	al.,	1995).	 Interestingly,	however,	H1-j	expression	 is	more	common	
among	 isolates	 collected	 from	 the	 elderly	 (Grossman	 et	 al.,	 1995).	 It	 is	 possible	 that	
expression	 of	 H1-j	 confers	 a	 selective	 advantage	 in	 the	 elderly	 through	 the	 evasion	 of	
adaptive	immune	responses	generated	through	repeated	environmental	exposure	to	H1-d.	
Expression	of	these	bacterial	components	varies	according	to	the	stage	of	the	infection.	High	
osmolarity	in	the	intestinal	lumen	is	thought	to	inhibit	Vi	polysaccharide	expression,	which	
facilitates	 bacterial	 adhesion	 and	 invasion	 across	 the	 intestinal	mucosa	 (Raffatellu	 et	 al.,	
2007).	 Within	 the	 mucosa,	 low	 osmolarity	 leads	 to	 expression	 of	 tviA,	 which	 results	 in	
A B 
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expression	of	the	Vi	polysaccharide	and	inhibition	of	SPI-1	and	flagella	expression	(Raffatellu	
et	al.,	2007).	Expression	of	the	Vi	polysaccharide	prevents	complement	activation	via	the	O-
antigen	 (Wilson	 et	 al.,	 2011)	 and	 the	 ligation	 of	 host-cell	 toll-like	 receptors	 (TLRs)	 via	
pathogen	associated	molecular	patterns	(PAMPs)	(Raffatellu	et	al.,	2005,	Wilson	et	al.,	2008).	
Expression	 of	 the	 Vi	 polysaccharide	 has	 also	 been	 shown	 to	 inhibit	 bacterial-guided	
neutrophil	chemotaxis	(Wangdi	et	al.,	2014).	Recognition	of	flagellin,	the	major	subunit	of	
flagellum,	within	a	cells	cytoplasm	results	in	inflammasome	activation	and	cell	death	(Winter	
et	al.,	2015).	Thus,	inhibition	of	flagella	expression	within	the	intracellular	space	facilitates	
intracellular	survival.	
1.3. Pathogenesis	
S.	Typhi	is	restricted	to	its	human	host	and	the	bulk	of	our	understanding	regarding	disease	
pathogenesis	 has	 been	 gathered	 from	 murine	 models	 of	 S.	 Typhimurium	 infection	 and	
models	utilising	human	cell-lines.		
Following	ingestion,	prior	to	invasion,	sufficient	numbers	of	bacteria	must	weather	gastric	
acidity	 and	 avoid	 enzymatic	 degradation.	 Individuals	 with	 impaired	 hydrochloric	 acid	
production,	either	as	a	result	of	antacid	consumption	or	gastrectomy,	are	at	increased	risk	
of	developing	disease	(Parry	et	al.,	2002).	SPI-1	plays	a	prominent	role	in	the	establishment	
of	 infection;	 through	 effector	 protein	 secretion,	 it	 disrupts	 the	 epithelial	 barrier	 and	
facilitates	host	cell	invasion	through	membrane	and	cytoskeletal	rearrangement	(Scherer	et	
al.,	2000,	Hayward	et	al.,	2000,	Zhou	et	al.,	2001).	S.	Typhi	preferentially	invades	via	microfold	
(M)-cells	overlying	Peyer’s	patches	in	the	terminal	ileum	(Kohbata	et	al.,	1986,	Jepson	and	
Clark,	2001).	M-cells	are	specialised	epithelial	cells	which	are	involved	in	sampling	antigen	
from	the	intestinal	lumen.	Due	to	their	folded	basal	structure,	M-cells	are	able	to	associate	
closely	 and	 deliver	 antigen	 to	 underlying	 immune	 cells	 through	 transcytosis	 (Jepson	 and	
Clark,	 2001).	 S.	Typhi	may	 also	 invade	 via	 intestinal	 epithelial	 cells	 (Takeuchi	 and	 Sprinz,	
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1967),	or	through	transmigration	following	disruption	of	the	epithelial	barrier	(Kops	et	al.,	
1996).	
Once	the	intestinal	barrier	has	been	breached,	salmonellae	invade	immune	cells,	primarily	
macrophage	cells,	where	they	persist	within	Salmonella	containing	vacuoles	(SCVs)	(Alpuche-
Aranda	 et	 al.,	 1994,	 Richter-Dahlfors	 et	 al.,	 1997).	 SPI-2	 plays	 an	 important	 role	 in	
intracellular	survival	within	SCVs;	through	effector	protein	secretion,	it	manipulates	host-cell	
function	in	order	to	facilitate	bacterial	replication	and	dissemination	(Figure	1.4)	(Haraga	et	
al.,	2008).	Murine	models	have	demonstrated	that	deletion	of	TLR-2,	TLR-4	and	TLR-9	inhibits	
upregulation	 of	 SPI-2	 and	 reduces	 bacterial	 virulence	 (Arpaia	 et	 al.,	 2011).	 These	 data	
indicate	 that	 the	 ligation	 of	 multiple	 TLRs	 is	 required	 for	 virulence	 in	 vivo.	 Salmonellae	
typically	 infect	 a	 high	 proportion	 of	 cells	 at	 low	 levels	 (Brown	 et	 al.,	 2006).	 Intracellular	
populations	 are	 typically	 heterogeneous,	 comprising	 both	 replicating	 and	 non-replicating	
bacteria	(Helaine	et	al.,	2014).	Mathematical	models	predict	that	S.	Typhi	may	be	released	
from	the	intracellular	environment	into	the	extracellular	space	at	any	time,	independent	of	
the	 intracellular	 burden	 (Brown	 et	 al.,	 2006,	 Dybowski	 et	 al.,	 2015).	 These	 phenomena	
combine	to	facilitate	efficient	systemic	bacterial	dissemination.	
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Figure	1.4.	Invasion	of	Salmonella	via	microfold	(M)-cells	(Haraga	et	al.,	2008)	
	
Intracellular	 salmonellae	 may	 disseminate	 via	 lymphatics	 or	 blood	 throughout	 the	
reticuloendothelial	system	(Parry	et	al.,	2002).	Extracellular	dissemination	may	also	occur;	
however,	 within	 the	 extracellular	 compartment,	 the	 bacteria	 are	 susceptible	 to	 B-cell-
mediated	 mechanisms	 of	 defence	 (Cunningham	 et	 al.,	 2007).	 Dissemination	 facilitates	
evasion	of	the	progressive	local	inflammatory	response	and	ensures	that	bacterial	replication	
does	not	become	nutritionally	or	spatially	limited	(Mastroeni	and	Grant,	2011).	
Data	acquired	from	bacteraemic	patients	demonstrate	that	the	bacterial	burden	in	blood	is	
higher	in	children	than	in	adults	(Saha	et	al.,	2001).	It	is	possible	that,	in	adults,	established	
adaptive	 immune	 responses,	 generated	 through	 repeated	 environmental	 exposure,	 limit	
bacterial	replication.	S.	Typhi	in	peripheral	circulation	are	trapped	by	Kuppfer	cells	in	the	liver	
and	are	subsequently	secreted	in	bile	leading	to	reinfection	of	Peyer’s	patches,	reinvasion	
via	the	small	bowel	and	shedding	in	stool	(Nguyen	et	al.,	2004).	
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1.4. Global	burden	of	disease	
The	burden	of	typhoid	fever	is	greatest	among	the	resource-poor	nations	of	Asia	and	sub-
Saharan	Africa	(Crump	and	Mintz,	2010).	In	resource-rich	nations,	cases	are	largely	restricted	
to	travellers	returning	from	regions	of	endemic	disease	(Mermin	et	al.,	1998,	Ackers	et	al.,	
2000).		
Isolation	of	S.	Typhi	from	bone	marrow	is	currently	the	gold	standard	diagnostic	for	typhoid	
fever	and	isolation	from	blood	the	next	best	(Wain	and	Hosoglu,	2008).	 In	the	developing	
world,	where	the	burden	of	disease	is	greatest,	bacterial	culture	is	not	routinely	performed	
and	there	remains	a	dependence	upon	other	less-accurate	methods.	The	Widal	test,	which	
is	based	on	the	detection	of	serum	immunoglobulin	to	O-antigens	and	H-antigens,	is	the	most	
commonly	 used	 method	 to	 inform	 diagnoses	 in	 the	 developing	 world.	 Unfortunately,	
geographical	 baseline	 variation,	 immunoglobulin	 cross-reactivity	 and	 non-specific	
seroconversion,	can	result	in	the	generation	of	misleading	diagnostic	output	(Olopoenia	and	
King,	2000).		
In	2010,	the	World	Health	Organisation	(WHO)	estimated	that	there	are	approximately	26.9	
million	cases	of	disease	annually,	with	an	associated	mortality	of	1%	(Buckle	et	al.,	2012).	
More	 recently,	meta-regression	 has	 estimated	 that	 there	 are	 approximately	 17.8	million	
cases	 of	 disease	 in	 low-income	 and	 middle-income	 countries	 (Antillon	 et	 al.,	 2017).	
Unfortunately,	since	these	estimates	remain	dependent	on	the	extrapolation	of	unreliable	
data	sets,	they	are	unlikely	to	reflect	the	true	burden	of	disease	(Crump	et	al.,	2004,	Mweu	
and	English,	2008,	Ochiai	et	al.,	2008,	Breiman	et	al.,	2012).	
1.5. Age	related	burden	of	disease	
It	is	estimated	that	58%	of	all	cases	of	disease	in	endemic	regions	occur	in	children	under	5	
years	(Buckle	et	al.,	2012).	A	study	conducted	in	Delhi	demonstrated	that	the	incidence	of	
disease	was	27.3	per	1,000	person	years	 in	children	 less	 than	5	years,	11.7	 in	 those	aged	
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between	5	and	19	years	and	1.1	in	those	aged	between	19	and	40	years	(Sinha	et	al.,	1999).	
A	study	conducted	in	Dhaka	demonstrated	that	the	incidence	of	disease	was	18.7	per	1,000	
person	years	 in	 children	aged	 less	 than	5	years	and	2.1	 in	 those	aged	more	 than	5	years	
(Brooks	et	al.,	2005).	Interestingly,	variation	has	been	observed	in	children	aged	less	then	5	
years,	with	4%	being	diagnosed	with	typhoid	in	the	first	year	of	life	compared	with	85%	in	
children	aged	between	2	and	4	years	(Brooks	et	al.,	2005).	This	may	be	due	to	a	reduced	level	
of	exposure	to	S.	Typhi	during	early	life,	or	as	a	result	of	protection	conferred	through	the	
passive	transfer	of	maternal	immunoglobulin.	
1.6. Controlled	human	infection	
Data	 collected	 from	murine	 models	 of	 S.	 Typhimurium	 infection	 are	 of	 limited	 value.	 A	
murine	model	of	S.	Typhi	infection	has	been	established	through	deletion	of	TLR-11	(Mathur	
et	al.,	2012);	however,	the	reproducibility	of	this	model	is	variable	(Song	et	al.,	2016,	Mathur	
et	al.,	2016).	Humanised	murine	models	have	also	been	developed,	through	engraftment	of	
severe	combined	immunodeficiency	mice	with	human	hematopoietic	stem	cells;	however,	
these	models	are	costly	and	subject	to	variability	as	a	result	of	the	genetic	heterogeneity	of	
donors	and	the	variable	degree	of	engraftment	(Firoz	Mian	et	al.,	2011).	
Considerable	insight	has	been	gleaned	from	studies	of	natural	S.	Typhi	infection	in	endemic	
regions;	however,	through	controlled	human	infection	it	 is	possible	to	study	transmission,	
pathogenesis,	 immunity	 and	 prophylactic	 intervention,	 in	 a	 setting	 where	 baseline	
measurements	may	be	made	and	the	exact	time	of	bacterial	challenge	is	known	(Pollard	et	
al.,	 2012).	 However,	 it	 should	 be	 noted	 that	 there	 are	 considerable	 differences	 between	
populations	enrolled	in	controlled	human	infection	and	those	at	risk	in	endemic	regions,	both	
with	regards	age	and	the	level	of	natural	exposure	to	the	pathogen.	Despite	this,	through	
controlled	human	infection	it	may	be	possible	to	identify	functional	correlates	of	protection,	
which	would	help	facilitate	the	development	and	licensure	of	new	vaccines.	
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In	1962,	the	first	model	of	controlled	human	infection	with	S.	Typhi	was	established	at	the	
University	 of	 Maryland	 (Hornick	 et	 al.,	 2007).	 In	 this	 model,	 participants	 were	 orally	
challenged	with	virulent	S.	Typhi	strain	Ty2	suspended	 in	milk.	Two	different	strains	were	
used	 in	 this	model;	 early	 trials	 used	 a	 strain	which	was	 isolated	 in	 Kherson	 (modern	day	
Ukraine)	in	1918	(Hornick	et	al.,	2007)	and	latter	trials	used	a	strain	which	was	isolated	from	
the	 gallbladder	 of	 a	 known	 chronic	 carrier	 in	 1958	 (Quailes	 strain)	 (Darton	 et	 al.,	 2014).	
Controlled	human	infection	at	the	University	of	Maryland	was	instrumental	in	the	validation	
of	chloramphenicol	treatment	and	for	the	licensure	of	the	live-attenuated	oral	Ty21a	vaccine	
(Hornick	et	al.,	2007).	In	1974,	due	to	ethical	issues	surrounding	the	use	of	prison	inmates	as	
study	participants,	this	model	was	terminated	(Lerner,	2007).	
More	recently,	in	2014,	a	model	of	controlled	human	infection	with	S.	Typhi	was	established	
at	the	University	of	Oxford	(Waddington	et	al.,	2014).	 In	this	model,	volunteers	are	orally	
challenged	with	the	same	Quailes	strain	originally	used	at	the	University	of	Maryland.	In	this	
model,	103	colony	forming	units	(CFUs)	suspended	in	a	sodium	bicarbonate	solution	has	an	
attack	rate	of	55%	and	104	CFUs	an	attack	rate	of	65%	(Waddington	et	al.,	2014).	Already,	a	
number	of	licensed	and	next-generation	vaccines	have	been	trialled	(Darton	et	al.,	2016,	Jin	
et	 al.,	 2017)	 and	 several	 novel	 findings	 concerning	 host-pathogen	 interaction	 have	 been	
reported	(Toapanta	et	al.,	2015,	McArthur	et	al.,	2015,	Toapanta	et	al.,	2016,	Blohmke	et	al.,	
2016,	Fresnay	et	al.,	2016,	Darton	et	al.,	2017).	Data	generated	using	this	model	are	discussed	
in	greater	detail	in	subsequent	sections	of	this	thesis.	
1.7. Clinical	presentation	and	treatment	
In	healthy	volunteers,	the	typical	infectious	dose	of	S.	Typhi	ranges	between	103	and	109	CFUs	
(Hornick	et	al.,	1970)	and	the	time	from	ingestion	to	clinical	presentation	ranges	between	3	
and	21	days	(Gordon,	2008).	Typhoid	fever	produces	a	wide	range	of	symptoms	and	most	
commonly	presents	as	a	non-specific	febrile	illness	with	hepatosplenomegaly	and	abdominal	
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pain	 (Gordon,	 2008).	 In	 some	 instances	 these	 symptoms	may	 be	 accompanied	 by	 chills,	
nausea,	anorexia,	diarrhoea,	constipation,	headache	and	bradycardia	(Gordon,	2008).		
Introduced	in	1948,	chloramphenicol	was	the	first	antibiotic	used	to	treat	patients	diagnosed	
with	typhoid	(Woodward	et	al.,	1948).	Chloramphenicol	reduced	case	fatality	from	26%	in	
1948	to	5%	in	1990	(van	den	Bergh	et	al.,	1999).	Treatment	also	reduced	recovery	time	as	
well	as	the	risk	of	secondary	complications	(van	den	Bergh	et	al.,	1999).	In	1950,	just	2	years	
after	the	introduction	of	chloramphenicol,	the	first	chloramphenicol-resistant	isolates	were	
identified	(Colquhoun	and	Weetch,	1950).	By	1975,	more	than	80%	of	all	isolates	collected	
from	Vietnam	were	 resistant	 to	 chloramphenicol	 (Linh	 and	 Arnold,	 1975).	 Initially,	 these	
isolates	 retained	 sensitivity	 to	 co-trimoxazole,	 ampicillin	 and	 amoxicillin;	 however,	 in	 the	
1980s,	the	first	multidrug	resistance	(MDR)	isolates,	resistant	to	all	frontline	antibiotics,	were	
identified	(Bhutta	et	al.,	1991).	
Available	 data	 indicate	 that	 the	 prevalence	 of	MDR	 is	 geographically	 variable,	with	MDR	
observed	in	0%	of	Chinese	isolates,	0%	of	Indonesian	isolates,	7%	of	Indian	isolates,	22%	of	
Vietnamese	isolates,	65%	of	Pakistani	isolates	(Ochiai	et	al.,	2008).	More	recently,	during	a	
recent	epidemic	in	Blantyre	in	2014,	97%	of	all	isolates	were	identified	as	MDR	(Feasey	et	al.,	
2015).	This	epidemic	was	associated	with	the	emergence	of	the	H58	lineage.	H58	has	spread	
throughout	Africa	and	Asia	over	the	last	30	years,	displacing	antibiotic-sensitive	isolates	and	
reshaping	the	global	population	structure	of	this	pathogen	(Wong	et	al.,	2015).	
Fluoroquinolone	antibiotics,	namely	ciprofloxacin	and	ofloxacin,	are	recommended	for	the	
treatment	of	infection	with	MDR	S.	Typhi	(Dutta	et	al.,	1993).	These	antibiotics	are	ideally	
suited	for	the	treatment	of	typhoid	fever	since	they	are	concentrated	in	macrophages,	bile	
and	 the	bowel,	 they	 are	 effective	within	 the	 intracellular	 compartment	 and	have	 an	oral	
efficacy	 equivalent	 to	 that	 achieved	 through	 intravenous	 administration	 (Hooper	 and	
Wolfson,	1991).	The	efficacy	of	these	drugs	for	the	treatment	of	infection	with	MDR	S.	Typhi	
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in	all	age	groups	has	been	established	in	randomised	control	trials	(Cao	et	al.,	1999,	Girgis	et	
al.,	1999).	Data	indicate	that	fluoroquinolones	have	97.9%	clinical	efficacy,	typically	resolving	
fever	in	just	3.9	days	(Parry	et	al.,	2002).	
Fluoroquinolones	are	not	licensed	for	use	in	children	due	to	concern	that	these	drugs	could	
cause	joint	toxicity	(Burkhardt	et	al.,	1990).	Off-license	use	of	these	drugs,	where	the	risk	has	
been	 deemed	 clinically	 acceptable,	 has	 provided	 evidence	 supporting	 the	 safety	 of	
fluoroquinolones	 in	 children	 (Schaad	 et	 al.,	 1991,	 Schaad	 and	Wedgwood,	 1992).	 In	 one	
study,	children	aged	between	1	and	14	years	treated	with	fluoroquinolones	presented	with	
no	 evidence	 of	 join	 toxicity	 and	 had	 comparable	 growth	 compared	 with	 age-matched	
controls	(Bethell	et	al.,	1996).	
In	1992,	the	first	fluoroquinolone-resistant	isolates	of	S.	Typhi	were	identified	(Umasankar	
et	al.,	1992).	The	prevalence	of	these	strains	has	increased,	rising	from	4%	in	1993	to	76%	in	
1998	in	Vietnam	(Parry	et	al.,	1998)	and	from	2%	in	1998	to	40%	in	2001	in	India	(Mehta	et	
al.,	 2001).	 While	 isolates	 of	 S.	 Typhi	 have	 been	 identified	 which	 are	 fully	 resistant	 to	
ciprofloxacin,	 they	 have,	 thus	 far,	 retained	 susceptibility	 to	 ceftriaxone	 and	 azithromycin	
(Chuang	et	al.,	2009).	Ceftriaxone	is	as	effective	as	chloramphenicol	over	a	3	day	or	7	day	
course	 (Lasserre	 et	 al.,	 1991,	 Islam	 et	 al.,	 1988).	 Treatment	 of	 fluoroquinolone-resistant	
isolates	 is	 dependent	 upon	 the	 delivery	 of	 high	 dosage	 therapy	 and	 is	 associated	with	 a	
prolonged	period	of	infection	and	an	increased	risk	of	treatment	failure	(Wain	et	al.,	1997,	
Parry	et	al.,	1998).	
1.8. Innate	immunity	
Immunity	to	typhoid	is	complex	and	our	understanding	of	the	mechanisms	which	mediate	
protection	 incomplete.	 Cells	 of	 the	 innate	 immune	 system	 are	 able	 to	 efficiently	 engage	
pathogens	immediately,	in	a	semi-specific	manor,	via	TLRs	which	recognise	PAMPs.	Innate	
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immune	cells	play	a	prominent	role	in	early	defence	as	well	as	in	the	induction	of	adaptive	
immune	responses.		
Dendritic	 cells	 (DCs)	 are	 professional	 antigen	 presenting	 cells	 (APCs),	 derived	 from	
monocytes,	which	are	believed	to	play	a	particularly	important	role	in	the	generation	of	T-
cell-mediated	 immunity	 to	 typhoid.	 Infected	 DCs	 are	 able	 to	 present	 S.	 Typhi	 antigens	
directly	sampled	from	within	their	cytoplasm	(Salerno-Goncalves	and	Sztein,	2009).	DCs	are	
also	able	to	phagocytose	S.	Typhi	infected	cells	and	present	antigens	through	suicide	cross-
presentation	 (Salerno-Goncalves	 and	 Sztein,	 2009).	DCs	may	also	 activate	 T	 cells	 through	
cytokine	production	(Salerno-Goncalves	and	Sztein,	2009,	Toapanta	et	al.,	2015).	
Controlled	 human	 infection	 has	 demonstrated	 that,	 in	 volunteers	 resistant	 to	 infection,	
monocyte	 and	 DC	 capacity	 for	 binding	 is	 increased	 immediately	 following	 challenge	
(Toapanta	et	al.,	2015).	In	contrast,	in	volunteers	susceptible	to	infection,	monocyte	and	DC	
capacity	for	binding	 is	only	 increased	during	the	course	of	 infection,	 in	the	days	following	
diagnosis	of	disease	(Toapanta	et	al.,	2015).	This	suggests	that	monocytes	and	DCs	play	an	
important	role	in	early	defence	and	also	likely	contribute	towards	the	elimination	established	
infection.	
Murine	 models	 have	 demonstrated	 that	 epithelial	 TLR-5	 ligation	 by	 flagella	 induces	
expression	 of	 chemotaxis	 chemokine	 ligand	 (CCL)20	 which	 results	 in	 the	 migration	 of	
immature	DCs	to	the	intestinal	mucosa	(Sierro	et	al.,	2001).	Controlled	human	infection	has	
demonstrated	 that,	 in	 volunteers	 susceptible	 to	 infection,	 in	 the	 days	 leading	 to	 and	
immediately	following	diagnosis	of	disease,	α4β7	is	upregulated	among	monocytes	but	not	
among	DCs	 (Toapanta	et	al.,	 2015).	No	changes	were	observed	 in	 volunteers	 resistant	 to	
infection	 among	 either	 monocytes	 or	 DCs	 (Toapanta	 et	 al.,	 2015).	 This	 suggest	 that,	 in	
humans,	monocytes	and	DCs	migrate	to	different	tissues	during	the	course	of	infection.		
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Murine	 models	 of	 infection	 have	 observed	 the	 accumulation	 of	 neutrophils	 in	 Peyer’s	
patches	and	mesenteric	 lymph	nodes	during	 the	course	of	 infection	 (Rydstrom	and	Wick,	
2007).	Neutrophils	are	a	prominent	source	of	interferon	(IFN)-γ	during	acute	infection	and	
their	depletion	is	associated	with	increased	bacterial	burden	in	the	liver	24	hours	following	
challenge	(Conlan,	1996,	Spees	et	al.,	2014).	In	humans	and	mice,	interleukin	(IL)-12	or	IFN-
γ	deficiency	is	associated	with	increased	susceptibility	to	Infection	(Jouanguy	et	al.,	1999).	
These	data	suggest	that	neutrophils	contribute	toward	early	defence	through	the	inhibition	
of	bacterial	dissemination.	
1.8.1. Mucosal	homing	
The	mucosal	surface	of	the	gastrointestinal	tract	is	protected	by	specialised	components	of	
the	 innate	and	adaptive	 immune	system	(Figure	1.6).	These	cell	populations	 facilitate	 the	
generation	of	specialised	immune	responses	tailored	to	defence	against	mucosal	pathogens.		
	
Figure	1.6.	Defences	of	the	gastrointestinal	tract	(Abreu,	2010)	
	
M-cells,	which	overly	 Peyer’s	 patches	 in	 the	 small	 intestine,	 are	 responsible	 for	 sampling	
antigen	 from	 the	 intestinal	 lumen.	 Their	 complex	 folded	 basal	 structure	 facilitates	 close	
association	 with	 innate	 and	 adaptive	 immune	 cell	 subsets.	 DCs	 found	 at	 the	 intestinal	
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mucosa	possess	 a	 unique	morphology	which	 facilitates	 antigen	 sampling	 from	within	 the	
intestinal	lumen	(Soloff	and	Barratt-Boyes,	2010).	Gut-associated	DCs,	unlike	extra-intestinal	
DCs,	 are	 able	 to	metabolise	 vitamin	 A	 in	 order	 to	 produce	 all-trans	 retinoic	 acid,	 which	
induces	expression	of	α4β7	and	C-C	chemokine	receptor	(CCR)9	on	adaptive	immune	cells	(De	
Calisto	 et	 al.,	 2012).	Migration	 of	 adaptive	 immune	 cells	 is	 dependent	 upon	 interactions	
between	these	molecules	and	others	expressed	at	the	intestinal	mucosa;	specifically,	α4β7	
interacts	with	mucosal	addressin	cell	adhesion	molecule-1	(MAdCAM-1)	and	CCR9	interacts	
with	CCL25	(De	Calisto	et	al.,	2012,	Mavigner	et	al.,	2012).	Cellular	residence	at	the	intestinal	
mucosa	is,	in	part,	mediated	through	the	expression	of	αεβ7	(Berlin	et	al.,	1993,	Cepek	et	al.,	
1994).		
Through	oral	vaccination	it	is	possible	to	utilise	these	specialised	mechanisms	of	defence	to	
more	efficiently	target	pathogens	which	invade	via	the	intestinal	mucosa.	As	a	result,	during	
the	assessment	of	oral	vaccines,	the	expression	of	α4β7	and	CCR9	is	commonly	assessed	in	
peripheral	blood	as	a	surrogate	measure	of	mucosal	immunogenicity	(Pasetti	et	al.,	2011).		
1.9. Adaptive	immunity	
Data	collected	at	a	Royal	Air	Force	base	in	Egypt,	during	two	separate	outbreaks	of	disease,	
revealed	an	attack	rate	of	20.4%	in	individuals	previously	diagnosed	with	typhoid,	compared	
with	 31.2%	 in	 individuals	 not	 previously	 diagnosed	with	 typhoid	 (Marmion	 et	 al.,	 1953).	
Similarly,	controlled	human	infection	has	demonstrated	an	attack	rate	of	23%	in	volunteers	
previously	diagnosed	with	typhoid,	compared	with	30%	in	naïve	volunteers	not	previously	
diagnosed	with	typhoid	(Dupont	et	al.,	1971).	These	data	suggest	that	wild-type	S.	Typhi	is	
able	 to	 evade	 adaptive	 immune	 responses	 generated	 during	 the	 course	 of	 infection;	
however,	 since	currently	 licensed	vaccines	do	confer	a	moderate	 level	of	protection,	 it	 is	
clear	that	the	human	immune	system,	if	correctly	primed,	has	the	potential	to	defend	against	
disease.		
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The	adaptive	immune	system	serves	as	the	basis	for	vaccine-mediated	prophylaxis	(Levine	
and	Sztein,	2004).	Broadly	speaking,	adaptive	immunity	is	conferred	through	two	lymphocyte	
populations	–	B	lymphocytes	(B	cells)	and	T	lymphocytes	(T	cells).	These	populations	possess	
unique	effector	 functions	and	both	 likely	contribute	towards	 immunity	 to	 typhoid.	The	Vi	
polysaccharide	 vaccine	 is	 effective,	 which	 demonstrates	 that	 B	 cells	 alone	 can	 confer	
protection	against	disease;	however,	since	intracellular	bacteria	are	largely	protected	from	
immunoglobulin	effector	function,	T	cells	likely	play	a	prominent	role	in	the	elimination	of	
established	intracellular	infection.		
1.10. B-cell-mediated	immunity	to	S.	Typhi	
B	cells	are	able	to	recognise	antigens	secreted	by	a	pathogen	as	well	as	those	expressed	on	
their	surface.	Recognition	of	antigen	by	the	B-cell	receptor	(BCR)	expressed	on	the	surface	
of	B	cells	results	in	activation	of	effector	function.	In	a	T-cell-dependent	fashion,	memory	B	
cells	may	be	generated.	
During	extracellular	phases	of	the	infection	cycle,	S.	Typhi	are	susceptible	to	B-cell-mediated	
mechanisms	 of	 defence.	 The	 importance	 of	 intracellular	 immune	 evasion	 has	 been	
demonstrated	 by	 murine	 models	 which	 have	 demonstrated	 that	 salmonellae	which	 are	
unable	 to	 establish	 themselves	 within	 the	 intracellular	 niche	 are	 avirulent	 (Fields	 et	 al.,	
1986).		
1.10.1. Memory	B	cells	to	S.	Typhi	
Memory	B	cells	are	long-lived	cells	which	are	responsible	for	preservation	of	immunity	to	the	
antigen	recognised	by	the	BCR.	Following	oral	vaccination	with	live-attenuated	S.	Typhi,	IgG	
and	IgA	memory	B	cells	specific	to	flagella,	Vi	polysaccharide	and	LPS	have	been	observed	in	
peripheral	 blood	 for	 up	 to	 1	 year	 (Wahid	 et	 al.,	 2011).	 Controlled	 human	 infection	 has	
demonstrated	that	in	volunteers	susceptible	to	infection,	around	the	time	of	diagnosis,	fewer	
memory	B	cells	persist	in	peripheral	blood	and	there	is	a	reduction	in	the	expression	of	α4β7	
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(Toapanta	et	al.,	2016).	Based	on	these	data,	it	is	reasonable	to	hypothesise	that	memory	B	
cells	expressing	high	levels	of	α4β7	are	depleted	from	peripheral	blood	and	sequestered	at	
the	intestinal	mucosa.	
1.10.2. Plasma	B	cells	to	S.	Typhi	
Memory	B	cells,	following	recognition	of	antigen	via	the	BCR,	are	able	to	rapidly	differentiate	
into	plasma	B	cells.	These	cells	secrete	 large	quantities	of	 immunoglobulin	specific	 to	 the	
antigen	recognised	by	the	BCR.	Factors	which	have	been	shown	to	influence	the	strength	of	
plasma	B-cell	responses	in	humans	include:	
a) Vaccine	type	–	live	vaccines	produce	stronger	plasma	B-cell	responses	compared	
with	inactivated	vaccines	(Kantele	et	al.,	1991).	
b) Vaccine	dosing	schedule	–	three	doses	of	Ty21a	produces	stronger	plasma	B-cell	
responses	 than	 two	doses.	 Six	 doses,	 does	 not	 impact	 the	 strength	 of	 the	 of	
plasma	B-cell	responses,	but	does	extended	the	period	of	peripheral	circulation	
(Kantele,	1996).	
c) Vaccine	formulation	–	whether	vaccines	are	administered	via	gelatine	capsules,	
enterically-coated	capsules	or	as	a	liquid	suspension	influences	the	strength	of	
plasma	B-cell	responses	(Kantele,	1990,	Kantele,	1996).	In	models	of	controlled	
human	infection,	stomach	acid	neutralisation	facilitates	the	use	of	 lower	dose	
inoculum	 and	 results	 in	 a	 more	 consistent	 pattern	 of	 clinical	 infection	
(Waddington	et	al.,	2014).		
Following	oral	vaccination	with	attenuated	S.	Typhi,	IgA	plasma	B	cells	are	most	abundant,	
IgM	plasma	B	cells	are	the	second	most	abundant,	with	only	low	numbers	of	IgG	plasma	B	
cells	observed	in	peripheral	blood;	however,	these	observations	are	subject	to	considerable	
inter-individual	 variation	 (Kantele,	 1990,	 Kantele,	 1996).	 It	 has	 previously	 been	
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demonstrated	that	levels	of	serum	immunoglobulin	correlate	with	plasma	B-cell	numbers;	
however,	when	plasma	B-cell	numbers	are	low,	levels	of	immunoglobulin	in	sera	may	drop	
below	 the	 lower	 limit	 of	 detection	 (Kantele,	 1990).	 Plasma	 B	 cells	 are	 most	 abundant	
between	4	and	10	days	post-vaccination	(Kantele	et	al.,	1986,	Kantele,	1990,	Kantele	et	al.,	
1991).	Following	a	period	of	peripheral	circulation,	plasma	B	cells	are	believed	to	migrate	to	
mucosal	 effector	 sites;	 however,	 in	 cases	 of	 prolonged	 exposure	 to	 antigen,	 extended	
periods	peripheral	circulation	have	been	observed	(Kantele,	1996).	
1.10.1. Mucosal	homing	of	plasma	B	cells	to	S.	Typhi	
Controlled	human	infection	has	demonstrated	that	that	in	volunteers	susceptible	to	disease,	
around	the	time	of	diagnosis,	plasma	B	cells	in	peripheral	blood	express	higher	levels	of	α4β7	
(Toapanta	et	al.,	2016).	Through	high	level	expression	α4β7,	these	plasma	B	cells	may	rapidly	
migrate	to	the	intestinal	mucosa	and	contribute	towards	clearance	of	the	pathogen.	
Plasma	B	cells	generated	through	oral	vaccination	with	attenuated	S.	Typhi	have	the	same	
receptor	 profile	 as	 those	 generated	 through	 natural	 infection	 (Kantele	 et	 al.,	 2013).	 The	
majority	of	IgA	plasma	B	cells,	primed	through	oral	vaccination,	express	the	mucosal	homing	
receptor	α4β7	(Kantele	et	al.,	1997,	Kantele	et	al.,	1999a).	IgG	and	IgA	α4β7+	plasma	B	cells	
specific	to	LPS	have	been	observed	which	do	and	do	not	express	CD62L.	This	is	consistent	
with	populations	having	the	capacity	to	migrate	to	intestinal	and	peripheral	lymphoid	tissue	
(Wahid	et	al.,	2012).	It	is	likely	that	these	populations	contribute	towards	the	elimination	of	
intestinal	and	systemic	infection,	respectively.		
1.10.2. Immunoglobulins	to	S.	Typhi	
Immunoglobulins	are	potent	immune	effector	molecules.	They	are	comprised	of	a	variable	
region,	which	facilitates	antigen	recognition	and	a	constant	region,	which	defines	function;	
IgG	has	two	high-affinity	antigen	binding	domains	and	accounts	for	approximately	75%	of	all	
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serum	 immunoglobulin;	 IgA	 has	 four	 high-affinity	 antigen	 binding	 domains	 and	 is	 most	
abundant	in	mucosal	secretions;	IgM	has	10	low-affinity	antigen	binding	domains.		
In	early	trials	of	the	live-attenuated	oral	Ty21a	vaccine,	seroconversion	of	IgG	specific	to	LPS	
correlated	with	protection	(Levine	et	al.,	1989,	Levine	et	al.,	2001).	Thus,	seroconversion	of	
immunoglobulin	specific	to	LPS	has	been	used	to	inform	the	development	of	next-generation	
orally-administered	typhoid	vaccines	(Hohmann	et	al.,	1996a,	Tacket	et	al.,	1997,	Tacket	et	
al.,	2000,	Tacket	et	al.,	2004,	Kirkpatrick	et	al.,	2005).	
The	production	of	immunoglobulin	specific	to	Vi	polysaccharide,	flagella	and	LPS	has	been	
detected	in	acute	and	convalescent	serum	samples	(Levine	et	al.,	1978,	Calderon	et	al.,	1986,	
Losonsky	 et	 al.,	 1987,	 Jesudason	 et	 al.,	 1998,	 Herath,	 2003).	 Interestingly,	 however,	 in	
endemic	 regions,	 susceptibility	 to	 disease	 persists	 in	 the	 presence	 of	 raised	 levels	 of	
immunoglobulin	to	the	Vi	polysaccharide,	flagellin	and	LPS	(Dupont	et	al.,	1971,	Levine	et	al.,	
1978).	Controlled	human	infection	has	demonstrated	that	there	is	no	association	between	
levels	 of	 serum	 immunoglobulin	 specific	 to	 these	 antigens	 prior	 to	 challenge	 and	
susceptibility	 to	disease	 (Waddington	et	 al.,	 2014).	 Immunoglobulin	 responses	 specific	 to	
flagella	 and	 LPS	 have	 been	 observed	 in	 volunteers	 susceptible	 to	 infection	 but	 not	 in	
volunteers	 resistant	 to	 infection	 (Waddington	 et	 al.,	 2014).	 In	 this	 model,	 no	 responses	
specific	 to	 the	 Vi	 polysaccharide	 have	 been	 observed	 in	 either	 susceptible	 or	 resistant	
volunteers	(Waddington	et	al.,	2014).	This	may	be	a	result	of	the	differential	expression	of	
the	Vi	polysaccharide	in	vivo	(Tran	et	al.,	2010a,	Wilson	et	al.,	2011).		
1.10.1. Immunoglobulin	function	against	S.	Typhi	
In	 regions	 of	 endemic	 disease,	where	 S.	 Typhi	 is	 likely	 to	 be	 encountered	 intermittently,	
bactericidal	immunoglobulin	function	has	been	shown	to	increase	with	age	(Pulickal	et	al.,	
2009).	 Immunoglobulin	 generated	 through	 oral	 vaccination	with	 attenuated	 S.	 Typhi	 has	
been	 shown	 to	 enhance	 direct	 bactericidal	 activity,	 opsonophagocytic	 activity	 and	
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immunoglobulin-dependent	cellular	cytotoxicity	(Tagliabue	et	al.,	1986,	Lindow	et	al.,	2011,	
Wahid	et	al.,	2014).	
IgA	specific	to	S.	Typhi	antigens	has	been	detected	in	tears,	saliva,	nasal	wash,	vaginal	wash,	
intestinal	 fluids	 and	 stool	 following	 natural	 infection	 and	 following	 oral	 vaccination	with	
attenuated	S.	Typhi	(Forrest,	1992,	Cancellieri	and	Fara,	1985,	Herath,	2003,	Pakkanen	et	al.,	
2010).	IgA	selectively	engages	M	cells	in	order	to	more	efficiently	deliver	antigen	and	engage	
adaptive	 responses	 (Rey	 et	 al.,	 2004,	 Boullier	 et	 al.,	 2009).	 Murine	 models	 have	
demonstrated	 that	 IgA	 specific	 to	 LPS	 prevents	 S.	 Typhi	 adherence	 and	 invasion	 via	 the	
intestinal	mucosa	(Michetti	et	al.,	1994,	Forbes	et	al.,	2008).	Indeed,	in	mice,	secretion	of	IgA	
specific	to	LPS	into	the	intestinal	lumen	can	protect	against	disease	(Michetti	et	al.,	1992).		
1.10.2. B	cells	–	beyond	immunoglobulin	
In	addition	to	immunoglobulin	production,	B	cells	may	contribute	towards	immune	defence	
through	 antigen	 presentation	 and	 cytokine	 production.	 Murine	 models	 of	 Salmonella	
infection	 have	 demonstrated	 that	 B	 cells	 play	 a	 prominent	 role	 in	 the	 development	 of	
protective	T-cell	responses	(Ugrinovic	et	al.,	2003,	Nanton	et	al.,	2012,	Barr	et	al.,	2010).	B	
cells	can	present	antigen	via	major	histocompatibility	complex	(MHC)	class	II	to	CD4+	T	cells	
and	through	cross-presentation	via	MHC	class	I	to	CD8+	T	cells	(Souwer	et	al.,	2009,	de	Wit	
et	al.,	2010).	Due	to	their	capacity	for	efficacious	presentation	of	antigen	via	MHC	class	I	and	
MHC	class	II,	ex	vivo	studies	commonly	utilise	infected	Epstein-Barr	virus	(EBV)-transformed	
B	cells	for	re-stimulation	of	CD4+	and	CD8+	T	cells	(Wahid	et	al.,	2007,	Wahid	et	al.,	2008,	
Salerno-Goncalves	et	al.,	2010,	McArthur	and	Sztein,	2012).		
Susceptibility	 to	disease	has	been	assessed	 in	wild-type,	B-cell-deficient,	 immunoglobulin-
deficient	 and	 class-switched-immunoglobulin-deficient	 mice	 immunised	 with	 live-
attenuated	Salmonella	(Nanton	et	al.,	2012).	It	was	observed	that,	while	B-cell-deficient	mice	
were	 susceptible	 to	 infection,	 wild-type,	 immunoglobulin-deficient	 and	 class-switched-
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immunoglobulin-deficient	 mice	 were	 all,	 rather	 surprisingly,	 protected	 from	 infection	
(Nanton	et	al.,	2012).	Since	immunoglobulin-deficient	and	class-switched-immunoglobulin-
deficient	mice	were	protected	from	infection,	it	is	reasonable	to	hypothesise	that,	in	mice,	
B-cell	antigen	presentation	and/or	cytokine	production	may	be	more	important	with	regards	
the	generation	of	protective	immune	responses	than	the	direct	action	of	immunoglobulin.	It	
is,	however,	unclear	whether	this	is	the	case	in	human	disease.	
1.11. T-cell-mediated	immunity	to	S.	Typhi	
In	 contrast	with	 B	 cells,	 T-cell	 effector	 function	 is	 not	 restricted	 to	 pathogens	within	 the	
extracellular	environment.	T	cells	recognise	peptides	displayed	by	MHC	molecules	expressed	
on	 the	 surface	 of	 host-cells.	 MHC	 class	 I	 is	 recognised	 by	 cytotoxic	 CD8+	 T	 cells	 and	 is	
expressed	on	 the	 surface	of	almost	all	 cell	 types,	 it	 is	 responsible	 for	 the	presentation	of	
peptides	derived	 from	proteins	sampled	 from	within	 the	 intracellular	compartment.	MHC	
class	II	is	recognised	by	CD4+	T	cells	and	is	expressed	on	the	surface	of	APCs,	it	is	responsible	
for	the	presentation	of	peptides	derived	from	proteins	sampled	from	the	extracellular	space.	
Recognition	of	antigen	by	the	T-cell	receptor	(TCR)	results	in	activation	of	effector	function.	
Memory	T	cells	may	also	be	generated	during	the	course	of	this	response;	these	cells	are	
responsible	 for	 the	 preservation	 long-term	 T-cell-mediated	 immunity	 to	 the	 antigen	
recognised	by	the	TCR.	
While	B-cell-mediated	immunity	can	protect	against	cell	invasion	and	disease	acquisition,	T-
cell-mediated	 immune	 defences,	 which	 are	 able	 to	 target	 intracellular	 pathogens,	 are	
believed	to	play	a	key	role	in	the	clearance	of	established	infection.	The	importance	of	T	cells	
in	the	elimination	of	established	infection	has	been	demonstrated	by	murine	models	which	
have	demonstrated	that	CD4+	T-cell	depletion	increases	the	bacterial	burden	in	the	spleen	
(Nauciel,	1990)	and	results	in	re-emergence	of	latent	infection	(van	Diepen	et	al.,	2005).	
CHAPTER	1	
23	
1.11.1. T-cell	cytokine	production	against	S.	Typhi	
T-cell	 responses	 in	 vitro	 are	 influenced	 by	 the	 nature	 of	 the	 stimulant;	 in	 particular,	 the	
dependence	 of	 soluble	 antigenic	 preparations	 on	 cross-presentation	 to	 engage	 cytotoxic	
CD8+	 T	 cells.	 Thus,	 broadly	 speaking,	 CD4+	 T	 cells	 are	 more	 likely	 to	 respond	 to	 soluble	
antigenic	preparations	than	CD8+	T	cells	(Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	
et	al.,	2003,	Sztein,	2007).		
In	 humans,	 pro-inflammatory	 cytokine	 production	 has	 been	 observed	 amongst	 CD4+	 and	
CD8+	T	cells	following	ex	vivo	stimulation	with	soluble	S.	Typhi	antigens	(Sztein	et	al.,	1994,	
Salerno-Goncalves	 et	 al.,	 2002,	 Salerno-Goncalves	 et	 al.,	 2003,	 Salerno-Goncalves	 et	 al.,	
2004).	 Following	 oral	 vaccination	with	 attenuated	S.	 Typhi,	 CD4+	 and	 CD8+	 T	 cells,	which	
produce	IFN-γ	in	response	to	LPS	and	flagella	antigens,	persist	in	peripheral	blood	for	up	to	
56	days	(Sztein	et	al.,	1994,	Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	et	al.,	2003).		
Multiphasic	 CD8+	 central	memory	 T	 (TCM)-cell,	 effector	memory	 T	 (TEM)-cell	 and	 terminal	
effector	 memory	 T	 (TEMRA)-cell	 responses,	 which	 persist	 for	 at	 least	 2	 years,	 have	 been	
described	 following	 oral	 vaccination	 with	 attenuated	 S.	 Typhi	 (Salerno-Goncalves	 et	 al.,	
2010).	 CD8+	 TCM	 cells,	 TEM	 cells	 and	 TEMRA	 cells,	 stimulated	 with	 S.	 Typhi-infected	 EBV-
transformed	 host	 B	 cells,	 have	 demonstrated	 the	 capacity	 to	 simultaneously	 produce	 as	
many	 as	 six	 cytokines/chemokines	 (Salerno-Goncalves	 et	 al.,	 2010,	McArthur	 and	 Sztein,	
2012).	 Polyfunctional	 T	 cells	 –	 those	 which	 simultaneous	 produce	 multiple	
cytokines/chemokines	 –	have	been	 shown	 to	 correlate	with	 vaccine	mediated	protection	
against	 other	 intracellular	 infections	 (Darrah	 et	 al.,	 2007,	 Kannanganat	 et	 al.,	 2007).	 The	
generation	 of	 polyfunctional	 T	 cells	 has	 also	 been	 observed	 following	 environmental	
exposure	 to	 intracellular	 pathogens,	 including	 human	 immunodeficiency	 virus	 (HIV)	 and	
Mycobacterium	 tuberculosis	 (Betts	 et	 al.,	 2006,	 Caccamo	 et	 al.,	 2010,	 Qiu	 et	 al.,	 2012).	
Recently,	controlled	human	infection	has	demonstrated	that	polyfunctional	CD8+	T	cells	are	
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associated	 with	 protection	 against	 disease	 when	 volunteers	 are	 challenged	 with	
approximately	 103	 CFU	 (Fresnay	 et	 al.,	 2016),	 but	 are	 associated	 with	 an	 increased	
susceptibility	 to	 disease	 when	 volunteers	 are	 challenged	 with	 approximately	 104	 CFU	
(Fresnay	et	al.,	2017).	The	authors	have	acknowledged	the	relatively	small	sample	sizes	used	
in	these	studies;	however,	they	have	suggested	that	these	observations	may	be	attributed	
to	the	strength	of	the	inflammatory	response	induced	through	exposure	to	103	or	104	CFU	
(Fresnay	 et	 al.,	 2017).	 They	 suggest	 that	 the	 higher	 dose	 inoculum	 generates	 stronger	
inflammatory	 responses	 than	 the	 lower	 dose	 inoculum	 and	 that	 exposure	 to	 this	
inflammatory	environment	may	favour	systemic	dissemination	(Fresnay	et	al.,	2017).	It	has	
been	demonstrated,	in	murine	models,	that	S.	Typhi	gene	expression	and	virulence	is,	in	part,	
dependent	upon	multiple	TLR	ligation	(Arpaia	et	al.,	2011).	Thus,	it	is	entirely	possible	that	
exposure	 to	 other	 components	 of	 the	 human	 immune	 system,	 including	 inflammatory	
factors,	 may	 influence	 S.	 Typhi	 gene	 expression	 and	 virulence.	 Further	 study	 should	 be	
undertaken	to	assess	the	validity	of	these	hypotheses.	
1.11.2. T	cell	cytotoxicity	against	S.	Typhi	
Cellular	apoptosis	limits	the	opportunity	for	intracellular	replication	and	exposes	S.	Typhi	to	
the	extracellular	environment	and	B-cell-mediated	mechanisms	of	defence.	
Oral	vaccination	with	attenuated	S.	Typhi	has	been	shown	to	generate	CD8+	T	cells	with	direct	
cytotoxic	potential	(Sztein	et	al.,	1995,	Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	et	
al.,	2003).	Data	 indicate	 that	 the	killing	of	S.	Typhi-infected	cells	by	CD8+	T	cells	 is	 largely	
mediated	through	granular	exocytosis,	through	classical	MHC	class	I	and	non-classical	MHC	
class	I	antigen	E	presentation	(Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	et	al.,	2003,	
Salerno-Goncalves	et	al.,	2004).	It	should	be	noted	that	murine	models	have	generated	data,	
using	in	MHC	class	I-deficient	mice,	which	suggests	that	CD8+	T	cells	play	only	a	modest	role	
in	the	resolution	of	primary	infection	and	play	no	role	in	resolution	of	secondary	infection	
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(Lee	et	al.,	 2012).	 These	data	would	 suggest	 that	 the	 role	of	 cytotoxicity	 is	 limited	 in	 the	
resolution	of	secondary	infection;	however,	it	is	unclear	whether	this	is	the	case	in	human	
disease.	
1.11.1. Mucosal	homing	of	T	cells	to	S.	Typhi	
It	 has	 been	 suggested	 that	 the	multiphasic	 nature	 of	 peripheral	 T-cell	 responses	may	 be	
attributed	to	the	migration	of	T	cells	to	the	gut	and	other	 lymphoid	tissues	as	well	as	the	
circulation	of	new	T	cells	generated	in	lymphoid	organs.	The	generation	of	CD4+	and	CD8+	T	
cells	with	enhanced	mucosal	homing	potential	following	oral	vaccination	with	attenuated	S.	
Typhi	has	been	observed	(Lundin	et	al.,	2002,	Salerno-Goncalves	et	al.,	2005,	Wahid	et	al.,	
2008).	Memory	T	cells	which	express	high	levels	of	integrin	β7	have	been	shown	to	produce	
approximately	ten	times	more	IFN-γ	compared	with	memory	T	cells	expressing	low	levels	of	
integrin	β7	(Lundin	et	al.,	2002).		
Following	oral	vaccination	with	attenuated	S.	Typhi,	CD8+	memory	T	cells	are	generated	with	
increased	 capacity	 for	mucosal	 homing;	 they	 simultaneously	 express	 high	 levels	 of	 α4β7,	
intermediate	levels	of	CCR9	and	low	levels	of	CD103	(Salerno-Goncalves	et	al.,	2005).	It	has	
been	 further	 demonstrated	 that	 memory	 CD4+	 and	 CD8+	 T-cell	 subsets	 possess	 varied	
capacities	for	mucosal	homing;	while	most	CD4+	TCM	cells	and	CD8+	TEMRA	cells	express	integrin	
α4β7,	CD4+	TEM	cells	and	CD8+	TEM	cells	comprise	populations	which	do	and	do	not	express	
α4β7	(Wahid	et	al.,	2008).	The	varied	expression	of	α4β7	is	likely	a	reflection	of	the	contrasting	
contributions	 these	 populations	make	 towards	 the	 elimination	 of	 intestinal	 and	 systemic	
infection.	
Interestingly,	T	cells,	with	increased	mucosal	homing	potential,	have	been	shown	to	persist	
in	peripheral	circulation	for	at	least	90	days	(Wahid	et	al.,	2008).	These	cells	are	able	to	travel	
throughout	 the	 body	 via	 the	 peripheral	 circulatory	 system,	 where	 they	may	 or	may	 not	
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encounter	antigen,	whilst	retaining	their	ability	to	rapidly	migrate	to	the	mucosa	in	response	
to	infection.	
1.11.1. Innate-like	T	cells	to	S.	Typhi	
Interestingly,	 T-cell	 responses	 to	 S.	 Typhi	 antigens	 are	 commonly	 observed	 among	 naïve	
individuals	with	no	history	of	immunisation	against,	or	infection	with,	the	pathogen	(Lundin	
et	al.,	2002,	Salerno-Goncalves	et	al.,	2010,	Pennington	et	al.,	2016).	These	responses	may	
simply	be	the	result	of	established	adaptive	immune	responses	generated	through	previous	
exposure	to	other	enteric	pathogens	baring	cross-reactive	antigens;	however,	innate-like	T	
cells	 –	 γδ	 T	 cells,	 NKT	 cells	 as	 well	 as	 MAIT-cells	 –	 may	 also	 contribute	 towards	 these	
observations	(Salerno-Goncalves	et	al.,	2014).	Indeed,	it	has	been	demonstrated	in	humans	
that	γδ	T	cells	and	NKT	cells	are	able	to	produce	larger	amounts	of	IFN-γ	than	CD4+	and	CD8+	
T	cells	in	response	to	stimulation	with	live	S.	Typhimurium	(Nyirenda	et	al.,	2010).	Murine	
models	have	demonstrated	 that	γδ	T-cell	depletion	 reduces	 the	50%	 lethal	dose	300-fold	
(Mixter	et	al.,	1994)	and	that	 inhibition	of	γδ	T-cell	migration	 to	 the	 intestinal	epithelium	
increases	disease	severity	(Edelblum	et	al.,	2015).	
Controlled	human	infection	has	demonstrated	that,	 in	volunteers	susceptible	to	 infection,	
during	 the	 course	 of	 infection,	 there	 is	 a	 sharp	 decline	 in	 the	 number	 of	 MAIT	 cells	 in	
peripheral	 blood	 (Salerno-Goncalves	 et	 al.,	 2017).	 Interestingly,	 in	 these	 volunteers,	 the	
frequency	 of	 activated	 MAIT	 cells	 expressing	 CCR9	 increased	 significantly	 following	
diagnosis,	much	more	so	in	volunteers	challenged	with	103	CFU	than	in	volunteers	challenged	
with	 104	 CFU	 (Salerno-Goncalves	 et	 al.,	 2017).	 No	 changes	 were	 observed	 in	 volunteers	
resistant	to	infection	(Salerno-Goncalves	et	al.,	2017).	This	observation	may	be	a	reflection	
of	the	strength	of	recruitment	in	volunteers	challenged	with	the	higher	dose	inoculum.	
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1.11.2. Regulatory	T	cells	to	S.	Typhi	
Regulatory	T	cells	(TREG)	are	able	to	migrate	to	sites	of	infection	in	order	to	maintain	control	
over	inflammatory	immune	responses	through	direct	suppression	of	inflammatory	effector	
populations	and/or	immunosuppressive	cytokine	secretion.	
It	 has	 been	 suggested	 that	 heightened	 inflammation	 may	 actually	 favour	 systemic	
dissemination	 (Fresnay	et	al.,	2017).	Murine	data	 indicate	 that	 the	balance	between	pro-
inflammatory	 T-cell	 and	 TREG	 responses	 influences	 clearance	 of	 infection	 (Johanns	 et	 al.,	
2010).	In	humans,	oral	vaccination	with	Ty21a	has	been	show	to	generate	IL-10	responses	
(Wyant	et	al.,	1999).	Consistent	with	their	anti-inflammatory	role,	depletion	of	TREG	has	been	
shown	to	enhance	C8+	T-cell	cytokine	production	in	response	to	ex	vivo	stimulation	with	S.	
Typhi-infected	 EBV-transformed	 host	 B	 cells	 (McArthur	 et	 al.,	 2015).	 Controlled	 human	
infection	has	demonstrated	that,	in	response	to	challenge,	the	expression	of	α4β7	is	reduced	
and	 other	 molecules	 associated	 with	 enhanced	 activation	 are	 increased	 among	 TREG	
populations	in	peripheral	blood	in	volunteers	diagnosed	with	typhoid	disease	(McArthur	et	
al.,	2015).	Based	on	these	data,	it	is	reasonable	to	hypothesise	that	TREG	expressing	high	levels	
of	α4β7	are	depleted	in	peripheral	blood	and	sequestered	at	the	intestinal	mucosa	following	
challenge.		
1.12. Innate	immune	memory	–	‘trained	immunity’	
Immunological	 studies	have	demonstrated	 that	 innate	 immune	 cells,	 upon	exposure	 to	 a	
pathogen/vaccine,	 are	 altered	 in	 such	 a	 way	 as	 to	 induce	 qualitative	 and	 quantitative	
changes	in	response	to	re-exposure	to	identical	or	heterologous	antigens.	Thus,	the	dogma	
that	only	components	of	the	adaptive	immune	system	are	able	to	generate	immunological	
memory	has	been	challenged.	Indeed,	evidence	collected	from	plants	(Luna	and	Ton,	2012,	
Kachroo	and	Robin,	2013),	invertebrates	(Sadd	and	Schmid-Hempel,	2006,	Rodrigues	et	al.,	
2010)	and	vertebrates	(Di	Luzio	and	Williams,	1978,	Tribouley	et	al.,	1978,	Krahenbuhl	et	al.,	
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1981,	Bistoni	et	al.,	1986,	van	der	Meer	et	al.,	1988,	Bistoni	et	al.,	1988,	Vecchiarelli	et	al.,	
1989,	van	't	Wout	et	al.,	1992,	O'Leary	et	al.,	2006,	Barton	et	al.,	2007,	Munoz	et	al.,	2010,	
Quintin	et	al.,	2012,	Marakalala	et	al.,	2013,	Ribes	et	al.,	2014,	Zhang	et	al.,	2014,	Chen	et	al.,	
2014),	 supports	 the	 notion	 that	 innate	 immune	 cells	 are	 also	 able	 to	 generate	memory	
through	a	process	termed	trained	immunity.		
While	 adaptive	 immune	 responses	 are	 the	 result	 of	 receptor	 gene	 rearrangement	 and	
affinity	maturation,	 the	 generation	of	 innate	 immune	memory	 is	 the	 result	 of	 epigenetic	
reprogramming.	 Typically,	 genes	 which	 encode	 inflammatory	 factors	 are	 packaged	 in	 a	
repressed	configuration,	inhibiting	transcriptional	activation	(Smale	et	al.,	2014);	however,	
upon	activation,	stimulation-responsive	transcription	factors	and	promoters	are	recruited	to	
these	 loci,	 resulting	 in	 increased	 accessibility	 and	 facilitating	 high-level	 gene	 expression	
(Ghisletti	 et	 al.,	 2010,	 Heinz	 et	 al.,	 2010,	 Barozzi	 et	 al.,	 2014,	 Smale	 and	 Natoli,	 2014).	
Following	 stimulation,	 trained	 immunity	 is	 generated	 through	 a	 process,	which	 is	 in-part	
dependent	 upon	 changes	 in	 cellular	 metabolism	 as	 well	 as	 structural	 histone	 and	 DNA	
modification	(Krawczyk	et	al.,	2010,	Pantel	et	al.,	2014).	These	changes	facilitate	enhanced	
transcriptional	 access,	 resulting	 in	 stronger	 cellular	 responses	 following	 re-stimulation	
(Ramirez-Carrozzi	et	al.,	2006,	Ramirez-Carrozzi	et	al.,	2009).	Since	microRNAs	(miRNAs)	are	
known	to	persist	for	long	periods	with	the	cytoplasm	and	since	myeloid	cells	have	a	limited	
proliferative	 capacity,	miRNAs	within	 the	 cytoplasm	are	 able	 to	persist,	 having	 long-term	
impact	on	cell	function	(Krol	et	al.,	2010).	Ultimately,	data	indicate	that	it	is	the	persistence	
of	these	modifications	which	confers	the	selective	advantage	which	has	been	associated	with	
the	generation	of	trained	immunity	(Foster	et	al.,	2007).	
Epidemiological	evidence	indicates	that	the	Bacillus	Calmette–Guérin	(BCG)	vaccine,	the	live-
oral	 polio	 vaccine	 and	 measles	 containing	 vaccines	 all	 possess	 the	 capacity	 to	 confer	
protection	against	pathogens	other	than	those	targeted	by	those	vaccines	(Goodridge	et	al.,	
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2016).	Immunological	studies	have	demonstrated	that	monocyte	phenotype	is	altered	for	at	
least	12	months	following	administration	of	BCG	(Kleinnijenhuis	et	al.,	2014);	however,	to	
date,	 no	data	has	 been	presented	which	demonstrates	 that	 these	 kind	of	 immunological	
observations	are	clinically	relevant	in	humans	(Pollard	et	al.,	2017).	Since	data	indicate	that	
monocytes	 typically	 only	 persist	 in	 circulation	 for	 a	 single	 day	 (Yona	 et	 al.,	 2013),	 it	 is	
reasonable	to	assume	that	trained	immunity	is	imprinted	at	the	progenitor	level.	Due	to	the	
semi-specific	nature	of	 innate	immune	cell	populations,	 it	 is	clear	how	any	change	among	
these	populations	could	broadly	influence	the	host	response	to	a	wide	array	of	pathogens.	
While	trained	immunity	is	more	short-lived	than	traditional	adaptive	responses,	due	to	the	
role	that	innate	immune	cell	populations	play	in	the	generation	of	adaptive	responses,	the	
effects	 of	 trained	 immunity	 likely	 also	 influence	 the	 generation	 of	 subsequent	 long-lived	
adaptive	responses.		
It	has	been	demonstrated	that	pre-priming	of	the	immune	system	through	BCG	vaccination	
enhances	functional	immunoglobulin	responses	as	well	as	cytokine	production	generated	in	
response	to	 influenza	vaccination	(Leentjens	et	al.,	2015).	Data	have	also	been	presented	
indicating	that	commensals	at	the	mucosal	surface	of	the	gastrointestinal	tract	influence	an	
individual’s	 response	 to	 vaccination	 through	 TLR	 engagement	 (Oh	 et	 al.,	 2014).	 It	 has,	
therefore,	been	 suggested	 that	 intestinal	 commensals	may	be	considered	as	endogenous	
adjuvants.	In	view	of	these	data,	it	is	reasonable	to	hypothesise	that	a	live-attenuated	orally-
administered	vaccine,	 such	as	Ty21a,	may	have	a	 similar	 impact	 to	BCG	via	 the	 intestinal	
mucosa.	
1.13. Prevention	of	disease	
Humans	represent	the	only	host	and	reservoir	for	S.	Typhi.	Inadequate	sanitation	and	poor	
food	hygiene	facilitates	faecal-oral	transmission.	In	rare	cases,	sexual	transmission	has	also	
been	 observed	 (Reller	 et	 al.,	 2003).	 Towards	 the	 end	 of	 the	 19th	 century,	 resource-rich	
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nations	 made	 efforts	 to	 increase	 the	 availability	 of	 clean,	 or	 chlorinated	 water,	 and	 to	
improve	 sanitation	 infrastructure	 (Smith	 and	 Tennant,	 1899).	 The	 implantation	 of	 these	
measures	was	associated	with	a	marked	decline	 in	 the	 incidence	of	 typhoid	 fever	 (Smith,	
1920).	Typhoid	fever	continues	to	persist	 in	many	resource-poor	nations,	where	access	to	
treated	water	is	limited	and/or	where	living	conditions	are	unsanitary	(Figure	1.5).	The	risk	
of	acquiring	 typhoid	 fever	has	been	associated	with	 the	consumption	of	untreated	water	
(Tran	et	al.,	2005,	Srikantiah	et	al.,	2007,	Ram	et	al.,	2007).	In	Indonesia,	individuals	living	in	
households	without	a	toilet	are	at	an	increased	risk	of	acquiring	typhoid	fever	(Vollaard	et	
al.,	2004).	Conversely,	in	Bangladesh,	individuals	living	in	households	where	a	latrine	is	used	
are	at	reduced	risk	of	acquiring	typhoid	fever	(Ram	et	al.,	2007).	
	
Figure	1.5.	Global	distribution	of	typhoid	fever	(Crump	et	al.,	2004)	
	
Temporal	variation	in	the	incidence	of	typhoid	fever	is	thought	to	be	the	result	of	seasonal	
variation	 in	 the	 supply	of	 clean	water	 (Siddiqui	et	al.,	2006,	Crump	et	al.,	2008).	 In	 some	
locations,	 the	 incidence	of	 typhoid	 fever	 is	highest	during	 the	dry	 season	due	 to	 reduced	
rainfall	and	pressure	on	water	sources	(Velema	et	al.,	1997,	Lin	et	al.,	2000,	Crump	et	al.,	
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2008).	 In	other	 locations,	the	incidence	of	typhoid	fever	 is	highest	during	the	wet	season,	
when	the	influx	of	large	quantities	of	water	overwhelms	sanitation	infrastructure	leading	to	
the	contamination	of	clean	water	by	sewage	(Saha	et	al.,	2001,	Karkey	et	al.,	2008).		
1.14. Licensed	typhoid	vaccines	
Since	 S.	 Typhi	 is	 restricted	 to	 its	 human	 host,	 efficacious	 vaccination	 may	 lead	 to	 the	
eradication	of	disease.	The	successful	eradication	of	smallpox	was,	 in	part,	due	to	human	
host	 restricted	 nature	 of	 the	 small	 pox	 virus	 (Metzger	 et	 al.,	 2015).	 In	 the	 face	 of	 rising	
antimicrobial	resistance,	the	WHO	has	recommended	the	introduction	of	typhoid	vaccines	
into	 vaccination	 programmes	 in	 endemic	 regions	 to	 prevent	 transmission	 and	 to	 combat	
outbreaks	of	disease	(2008).	To	date,	several	typhoid	vaccines	have	been	granted	licensure	
(Table	1.1).	
1.14.1. Inactivated	whole-cell	
In	1896,	 the	 first	 inactivated	whole-cell	 typhoid	vaccine	was	 introduced.	This	vaccine	was	
administered	parenterally,	as	a	single	dose	of	 inactivated	preserved	preparations	of	wild-
type	S.	Typhi	 in	 liquid	suspension	(Groschel	and	Hornick,	1981).	A	trial	conducted	 in	1953	
demonstrated	 that	 heat-inactivated	 phenol-preserved	 preparations	 were	 superior	 to	
alcohol-inactivated	 alcohol-preserved	 preparations	 (1957).	 The	 heat-inactivated	 phenol-
preserved	preparation	was	later	shown	to	confer	a	70%	protective	efficacy	for	at	least	5	years	
(Ashcroft	et	al.,	1964,	Ashcroft	et	al.,	1967).	
While	the	whole-cell	typhoid	vaccine	was	efficacious,	localised	and	systemic	inflammatory	
immune	 responses	 were	 routinely	 observed;	 localised	 responses	 occurring	 in	 70-80%	 of	
individuals	and	systemic	responses	occurring	in	20-25%	of	individuals	(Hejfec	et	al.,	1966).	
Due,	in	part,	to	the	severity	of	these	reactions,	the	whole-cell	typhoid	vaccine	was	eventually	
withdrawn.
		
Table	1.1.	Past	and	present	–	licensed	typhoid	vaccines	
Vaccine	type	 Brand	name	 Manufacturer	 Number	of	doses	 Field	trial	efficacy	 Minimum	administration	age	
Inactivated	whole	cell	
(Injectable)	 N/A	 No	longer	in	production	 2	 ~60–80%	 N/A	
Live-attenuated	
(Oral)		 Vivotif	 Crucell		 3-4	 ~60–80%	 ≥6	years	
Vi	polysaccharide	
(Injectable)	
Typhim	Vi	 Sanofi	Pasteur	 1	 ~55–72%	 ≥2	years	
Typherix	 GlaxoSmithKline	 1	 61%	 ≥2	years	
Typbar	 Bharat	Biotech	 1	 No	data	available	 ≥2	years	
Vax-TyVi	 Finlay	Instituto	 1	 No	data	available	 ≥2	years	
TyViVac	 Dalat	Vaccine	Company	 1	 No	data	available	 ≥2	years	
BioTyphi	 BioMed	 1	 No	data	available	 ≥2	years	
Vi	polysaccharide	
combination	(Injectable)	
Hepatyrix	 GlaxoSmithKline	 1	 No	data	available	 ≥15	years	
ViATIM	 Sanofi	Pasteur	 1	 No	data	available	 ≥16	years	
Vi	polysaccharide	
conjugate	(Injectable)	
Pedatyph	 BioMed	 2	 No	data	available	 ≥3	months	
Typbar-TCV	 Bharat	Biotech	 1	 No	data	available	 ≥6	months	
Table	adapted	from	(Sztein	et	al.,	2014).	
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1.14.1. Live-attenuated	oral	Ty21a	
In	1975,	the	first	live-attenuated	typhoid	vaccine	was	introduced.	This	vaccine,	designated	
Ty21a,	was	generated	by	non-specific	chemical	mutagenesis	of	pathogenic	S.	Typhi	strain	Ty2	
(Germanier	and	Fuer,	1975).	Ty21a	is	administered	orally,	in	a	lyophilised	form	via	enterically	
coated	capsules	(Germanier	and	Fuer,	1975).		
Over	 20	 different	mutations	 have	 been	 identified	 in	 Ty21a	 (Germanier	 and	 Fuer,	 1975).	
Amongst	these,	a	galE	mutation	has	rendered	Ty21a	unable	to	express	the	Vi	polysaccharide.	
For	a	long	time	this	mutation	was	thought	to	have	been	responsible	for	the	attenuation	of	
the	pathogen;	however,	studies	have	since	revealed	that,	alone,	this	mutation	is	insufficient	
to	fully	attenuate	pathogenesis	(Hone	et	al.,	1988).	
Ty21a	was	originally	trialled	using	controlled	human	infection	at	the	University	of	Maryland	
in	1977.	During	this	trial,	5-8	oral	doses	were	consumed	at	3-4	day	intervals;	a	single	dose	
comprised	1010	viable	Ty21a	suspended	in	45	mL	milk	followed	by	(after	a	5	minute	interval)	
60	mL	dH2O	containing	2	g	NaHCO3.	This	trial	revealed	that,	when	cultured	in	the	presence	
of	an	exogenous	source	of	galactose,	Ty21a	conferred	a	87%	protective	efficacy	(Gilman	et	
al.,	1977).		
Two	 subsequent	 field	 trials	 demonstrated	 the	 variable	 efficacy	 of	 this	 vaccine;	 a	 96%	
protective	 efficacy	was	 demonstrated	 after	 3	 years	 in	 Egypt	 (1978-1981)	 (Wahdan	 et	 al.,	
1982)	and	a	67%	protective	efficacy	was	demonstrated	after	3	years	 in	Chile	 (1983-1986)	
(Levine	et	al.,	1987).	More	recently,	a	systematic	review	calculated	a	cumulative	efficacy	of	
58%	up	to	2	years	following	vaccination	(Anwar	et	al.,	2014).	By	virtue	of	there	being	less	
individuals	susceptible	to	infection,	rates	of	transmission	are	reduced	and	additional	benefits	
associated	with	the	generation	of	herd	immunity	have	been	observed	(Levine	et	al.,	1989).	
The	safety	of	Ty21a	is	well	established	(Gilman	et	al.,	1977);	however,	limitations	do	exist.	
Vaccination	 is	dependent	upon	the	administration	of	 three	spaced	doses	and	 the	vaccine	
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possesses	 only	modest	 immunogenicity	 (Anwar	 et	 al.,	 2014).	 In	 addition,	 children	 in	 the	
developing	world	tend	to	be	hyporesponsive	to	orally-administered	vaccines	(Levine	et	al.,	
1987,	 Olanratmanee	 et	 al.,	 1992);	 however,	 it	 has	 been	 demonstrated	 that	 when	
administered	in	liquid	suspension,	Ty21a	is	immunogenic	in	children	aged	between	2	and	6	
years	(Olanratmanee	et	al.,	1992,	Bhuiyan	et	al.,	2014).	
1.14.2. Purified	Vi	polysaccharide	
In	1994,	following	successful	trials,	the	first	subunit	typhoid	vaccine	was	introduced	(Keitel	
et	 al.,	 1994).	 This	 vaccine	 is	 administered	 parenterally	 as	 a	 single	 dose	 of	 purified	 Vi	
polysaccharide	in	liquid	suspension.		
Early	 trials	 demonstrated	 that	 purified	 Vi	 polysaccharide	 alone	 was	 unable	 to	 confer	
protection	against	disease	(Gaines	et	al.,	1961).	As	a	result,	the	pursuit	of	Vi	polysaccharide	
based	vaccines	was	abandoned.	Interest	was	reignited	when	evidence	was	presented	which	
demonstrated	that	expression	of	the	Vi	polysaccharide	enhanced	the	protective	efficacy	of	
heat-killed	 vaccine	 preparations	 (Wong	 et	 al.,	 1974).	 It	 was	 later	 determined	 that	
conformational	 changes	 brought	 about	 during	 isolation	 of	 the	 polysaccharide	 were	
responsible	 for	 previous	 vaccine	 failure	 (Landy	 et	 al.,	 1961).	 A	 refined	 method	 of	
polysaccharide	 isolation,	 which	 was	 developed	 for	 the	 generation	 of	 vaccines	 targeting	
meningococcus	(Gotschlich	et	al.,	1969),	was	later	used	to	isolate	and	develop	an	effective	
Vi	polysaccharide	based	vaccine	targeting	typhoid	fever.	
Two	large-scale	field	trials	have	demonstrated	the	efficacy	of	this	vaccine;	a	75%	protective	
efficacy	 was	 demonstrated	 over	 17	 months	 in	 Nepal	 (Acharya	 et	 al.,	 1987)	 and	 a	 77%	
protective	efficacy	over	21	months	in	South	Africa	(Klugman	et	al.,	1987).	A	recent	systematic	
review	calculated	a	cumulative	efficacy	of	55%	3	years	following	vaccination	(Anwar	et	al.,	
2014).	 Additional	 benefits	 associated	 with	 the	 generation	 of	 herd	 immunity	 have	 been	
observed	(Sur	et	al.,	2009).		
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Decline	in	the	levels	of	circulating	immunoglobulin	over	the	3	years	following	administration	
of	the	Vi	polysaccharide	vaccine	has	been	observed	and	there	are	no	data	which	suggest	that	
efficacy	persists	beyond	3	years	(Froeschle	and	Decker,	2010).	As	is	the	case	for	all	purified	
polysaccharide	 vaccines,	 immune	 responses	 are	 T-cell	 independent;	 thus,	 no	 immune	
memory	 is	 generated	 and	 responses	 may	 not	 be	 boosted	 through	 repeated	 vaccination	
(Lesinski	and	Westerink,	2001).	Although	trials	have	not	been	conducted	in	young	children,	
vaccination	with	purified	Vi	polysaccharide	is	unlikely	to	be	efficacious	due	to	the	immaturity	
of	 the	 splenic	 marginal	 zone	 which	 is	 required	 for	 the	 generation	 of	 T-cell	 independent	
responses	(Pulickal	and	Pollard,	2007).	
1.15. Next-generation	typhoid	vaccines	
Interventions	aimed	at	improving	the	availability	of	clean	drinking	water	and	programmes	
which	 provide	 education	 in	 sanitation	 and	 food	 hygiene	 could	 dramatically	 reduce	 the	
burden	of	typhoid	fever	 in	endemic	regions	(2008).	Unfortunately,	 the	 implementation	of	
these	 measures	 is	 occurring	 at	 a	 discouragingly	 slow	 pace.	 Thus,	 due	 to	 the	 successful	
implementation	of	mass	vaccination	in	areas	of	endemic	disease	(Bodhidatta	et	al.,	1987),	
efforts	have	been	directed	towards	the	development	of	new,	more	effective	vaccines,	which	
may	be	more	easily	delivered	to	areas	where	they	are	most	needed	(Table	1.2).		
	
		
Table	1.2.	Typhoid	vaccines	in	development	
Vaccine	type	 Name	 Manufacturer	 Number	of	doses	 Field	trial	efficacy	 Minimum	administration	age	
Live-attenuated	
(Oral)		
CVD	908	 University	of	Maryland	 1	 No	data	available	 No	data	available	
CVD	908-htrA	 University	of	Maryland	 1	 No	data	available	 No	data	available	
CVD	909	 University	of	Maryland	 1	 No	data	available	 No	data	available	
Ty800	 University	of	Maryland	 1	 No	data	available	 No	data	available	
M01ZH09	 Massachusetts	General	Hospital		 1	 No	data	available	 No	data	available	
Vi-conjugate	
(Injectable)	
Vi-TT	 BioMed	 1	 100%	 ≥6	months	
Vi-rEPA	 NIH	 2	 89%	 ≥2	years	
Vi-CRM197	 Novartis	Vaccines	Institute	 1	 No	data	available	 ≥2	years	
Table	adapted	from	(Sztein	et	al.,	2014).	
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1.15.1. Next-generation	live-attenuated	orally-administered	vaccines	
Orally-administered	 vaccines	 are	 able	 to	 generate	 responses	 tailored	 to	 defence	 at	 the	
intestinal	mucosa.	 The	 orally-administered	 Ty21a	 vaccine	 is	more	well-tolerated	 clinically	
and	easier	 to	administer	 than	parenterally-administered	alternatives	 (Anwar	et	al.,	2014).	
Ty21a	 is,	however,	 limited	by	 its	modest	 immunogenicity	and	dependence	upon	multiple	
spaced	doses	to	confer	protection	(Anwar	et	al.,	2014).	A	number	of	live-attenuated	orally-
administered	typhoid	vaccines	are	currently	 in	development,	which	are	 intended	to	be	as	
well-tolerated	as	Ty21a,	yet	more	immunogenic	and	effective	as	a	single	dose.	
CVD	909	
CVD	 909	 is	 a	 refinement	 of	 CVD	 908-htrA	 and	 its	 predecessor	 CVD	 908.	 CVD	 908	 was	
engineered	from	pathogenic	S.	Typhi	strain	Ty2	through	deletion	of	aroC	and	aroD	(Tacket	et	
al.,	1992).	The	ΔaroC/ΔaroD	double	mutation	prevents	synthesis	of	chorismic	acid,	rendering	
the	bacteria	auxotrophic	for	p-aminobenzoic	acid	and	2,3-dihydroxybenzoate,	compounds	
not	available	to	the	bacteria	within	mammalian	tissue	(Tacket	et	al.,	1992).	CVD	908	has	been	
shown	to	be	well-tolerated	and	immunogenic;	however,	 its	administration	was	associated	
with	a	silent,	self-resolving	vaccinaemia	(Tacket	et	al.,	1992).	
In	 an	effort	 to	prevent	 vaccinaemia,	CVD	908	was	 further	 attenuated;	CVD	908-htrA	was	
engineered	 through	 deletion	 of	 htrA.	 The	 ΔhtrA	 mutation	 prevents	 expression	 of	 a	 heat	
shock	protein	 involved	 in	 intracellular	 survival	and	replication	 (Johnson	et	al.,	1991).	CVD	
908-htrA	has	been	shown	to	be	as	immunogenic	CVD	908,	but,	crucially,	was	not	associated	
with	vaccinaemia	(Tacket	et	al.,	2000,	Salerno-Goncalves	et	al.,	2003).	
Since	the	parenterally-administered	Vi	polysaccharide	vaccine	does	confer	a	moderate	level	
of	protection	against	disease	(Anwar	et	al.,	2014),	efforts	were	made	to	enhance	immunity	
generated	to	this	antigen	by	CVD	908-htrA;	CVD	909	was	engineered	to	constitutively	express	
the	 Vi	 polysaccharide	 by	 switching	 the	 tviA	 promoter,	 which	 regulates	 Vi	 polysaccharide	
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expression,	with	 the	 constitutive	 tac	 promoter.	 CVD	909	has	been	 shown	 to	generate	an	
enhanced	response	to	the	Vi	polysaccharide	(Tacket	et	al.,	2004).	IgG	responses	specific	to	
the	Vi	polysaccharide	have	been	observed	in	80%	of	volunteers	receiving	1	or	2	doses	of	106	
–	109	CFU	CVD	909.	It	is	significant	that	these	responses	may	be	boosted	through	subsequent	
administration	of	the	parenterally-administered	purified	Vi	polysaccharide	vaccine,	since	this	
demonstrates	 that	 CVD	 909	 generates	 memory	 B	 cells	 specific	 to	 the	 Vi	 polysaccharide	
(Wahid	et	al.,	2011).		
Ty800	
Ty800	was	engineered	 from	pathogenic	S.	 Typhi	 strain	Ty2	 through	deletion	of	phoP	 and	
phoQ	 (Hohmann	et	al.,	1996b).	The	ΔphoP/ΔphoQ	double	mutation	 inhibits	expression	of	
multiple	virulence	factors,	including	those	which	facilitate	intracellular	survival	(Hohmann	et	
al.,	1996b).	Ty800	has	been	shown	to	be	well-tolerated	and	immunogenic	(Hohmann	et	al.,	
1996a).	 IgG	 responses	 specific	 to	 S.	 Typhi	 antigens	 were	 observed	 in	 81%	 of	 volunteers	
vaccinated	with	Ty800	and	in	62.5%	of	volunteers	vaccinated	with	Ty21a	(Hohmann	et	al.,	
1996a).	The	development	of	this	promising	candidate	has	not	been	pursued.	
M01ZH09	
M01ZH09	was	engineered	from	pathogenic	S.	Typhi	strain	Ty2	through	deletion	of	aroC	and	
ssaV	 (Kirkpatrick	 et	 al.,	 2005).	 The	 ΔaroC	 mutation	 disrupts	 synthesis	 of	 chorismic	 acid,	
rendering	 the	 bacteria	 auxotrophic	 for	 2,3-dihydroxybenzoate,	 a	 compound	which	 is	 not	
available	to	the	bacteria	within	mammalian	tissue.	The	ΔssaV	mutation	disrupts	expression	
of	SPI-2	which	impacts	intracellular	survival	(Coombes	et	al.,	2005,	Kirkpatrick	et	al.,	2006,	
Lyon	et	al.,	2010).	M01ZH09	has	been	shown	to	be	well-tolerated	and	immunogenic	in	both	
adults	and	children	(Kirkpatrick	et	al.,	2006,	Tran	et	al.,	2010b).	 In	one	trial,	children	aged	
between	5	and	14	years	were	given	5	×	109	CFU	M01ZH09.	Seroconversion,	defined	as	a	1.7-
fold	 increase	 in	 levels	 of	 IgG	 and	 a	 1.5-fold	 increase	 in	 levels	 of	 IgA	 specific	 to	 LPS,	was	
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observed	in	97%	of	vaccinated	volunteers	(Tran	et	al.,	2010b).	Controlled	human	infection	
has	 since	 demonstrated	 that,	 despite	 its	 immunogenicity,	 administered	 as	 a	 single	 dose,	
M01ZH09	has	a	protective	efficacy	of	just	13%	(Darton	et	al.,	2016).	In	the	same	trial,	Ty21a	
was	estimated	to	have	a	protective	efficacy	of	just	35%	(Darton	et	al.,	2016).	This	is	consistent	
with	the	calculated	cumulative	efficacy	of	Ty21a	of	35%	up	to	1	year	following	vaccination	
(Anwar	et	al.,	2014).		
1.15.2. Next-generation	protein	conjugate	parenterally-administered	
vaccines	
A	 number	 of	 parenterally-administered	 Vi	 polysaccharide	 protein	 conjugate	 vaccines	 are	
currently	 in	 development.	 The	 conjugation	 of	 polysaccharide	 to	 protein	 facilitates	 T-cell	
engagement,	 enabling	 immunoglobulin	 affinity	 maturation,	 immunoglobulin	 isotype	
switching	and	the	development	immunological	memory	in	both	adults	and	children	(Levine	
et	 al.,	 2001,	 Pulickal	 and	 Pollard,	 2007).	 The	 development	 of	 this	 technology	 has	
revolutionised	vaccine	development.	
Conjugation	of	 the	Vi	 polysaccharide	 to	 a	 nontoxic,	 recombinant	 protein	 –	Pseudomonas	
aeruginosa	 exotoxin	 –	 was	 first	 described	 in	 1987	 (Szu	 et	 al.,	 1987).	 Administration	 of	
multiple	doses	of	Vi	polysaccharide	protein	conjugate	vaccines	enhances	immunity	and	does	
not	 result	 in	 immune	 hypo-responsiveness,	 which	 is	 associated	 with	 administration	 of	
multiple	 doses	 of	 unconjugated	Vi	 polysaccharide	 vaccines	 (An	 et	 al.,	 2012).	 Based	 upon	
these	 data,	 a	 number	 of	 pharmaceutical	 companies	 have	 developed	 Vi	 polysaccharide	
protein	conjugate	vaccines	using	a	number	of	different	carrier	proteins,	which	are	at	various	
stages	of	development	(Table	2)	(van	Damme	et	al.,	2011,	Thiem	et	al.,	2011).	
Vi-rEPA	(Pseudomonas	aeruginosa)	conjugate	
Vi-rEPA	was	developed	by	linking	the	Vi	polysaccharide	to	P.	aeruginosa	exoprotein	A.	Dose-
immunogenicity	studies	have	demonstrated	that	administration	of	25	μg	Vi-rEPA	produces	
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stronger	immunoglobulin	responses	than	administration	of	12.5	μg	or	5	μg	Vi-rEPA	(Canh	et	
al.,	2004).	In	one	trial,	2	doses	of	22.5	μg	Vi-rEPA,	administered	6	weeks	apart,	was	shown	to	
be	well-tolerated	with	a	89%	protective	efficacy	in	children	aged	between	2	and	5	years,	over	
46	months	(Lin	et	al.,	2001,	Mai	et	al.,	2003).	Levels	of	IgG	specific	to	the	Vi	polysaccharide	
increased	by	at	least	10-fold	in	all	vaccinated	volunteers	4	weeks	following	administration	of	
the	second	dose	of	 the	vaccine	(Lin	et	al.,	2001).	 It	was	also	observed	that,	 in	vaccinated	
volunteers	who	developed	disease,	severity	was	lessened	(Lin	et	al.,	2001,	Mai	et	al.,	2003).		
Vi-rEPA	has	also	been	shown	to	be	well-tolerated	and	immunogenic	in	infants	(Thiem	et	al.,	
2011).	Specifically,	it	was	demonstrated	that	4	doses	of	25	μg	Vi-rEPA,	administered	at	2,	4,	
6	and	12	months	of	age,	increased	levels	of	IgG	specific	to	the	Vi	polysaccharide	above	the	
estimated	protective	level	in	95%	of	infants	1	month	following	administration	of	the	fourth	
dose	 (Thiem	 et	 al.,	 2011).	 In	 this	 trial,	 Vi-rEPA	 was	 administered	 alongside	 Expanded	
Programme	on	Immunisation	(EPI)	vaccines	and	no	detrimental	impact	on	EPI	vaccines	was	
reported	(Thiem	et	al.,	2011).	
Vi-CRM197	(diphtheria	toxoid)	conjugate	
Vi-CRM197	was	developed	by	linking	the	Vi	polysaccharide	to	diphtheria	toxoid	(CRM197).	This	
vaccine	has	been	shown	to	be	well-tolerated	and	immunogenic	 in	adults	(18	to	45	years),	
children	(24	to	59	months),	older	infants	(9	to	12	months)	and	infants	(6	to	8	weeks)	(Bhutta	
et	al.,	2014).	Levels	of	IgG	specific	to	the	Vi	polysaccharide	significantly	increased	in	adults,	
children	and	older	 infants	1	months	 following	administration	of	1	dose	of	5	μg	Vi-CRM197	
(Bhutta	et	al.,	2014).	Significant	 responses	were	also	observed	 in	younger	 infants	but	 the	
levels	of	IgG	were	consistently	lower	than	those	observed	in	older	age	groups	(Bhutta	et	al.,	
2014).	 In	children	and	older	 infants,	a	second	dose	of	5	μg	Vi-CRM197	was	administered	2	
months	following	administration	of	the	first;	however,	 levels	of	 immunoglobulin	were	not	
increased	 further	 (Bhutta	 et	 al.,	 2014).	 It	 should	 also	 be	 noted	 that,	 in	 both	 adults	 and	
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children,	6	months	following	administration	of	the	final	dose,	 levels	of	 immunoglobulin	 in	
volunteers	vaccinated	with	Vi-CRM197	were	similar	 to	 those	 in	volunteers	vaccinated	with	
unconjugated	purified	Vi	polysaccharide	(Bhutta	et	al.,	2014).	In	infants	and	older	infants,	Vi-
CRM197	was	administered	alongside	EPI	vaccines	and	no	significant	detrimental	impact	on	EPI	
vaccines	was	reported	(Bhutta	et	al.,	2014).	
Vi-TT	(tetanus	toxoid)	conjugate	
Vi-TT	was	developed	by	linking	the	Vi	polysaccharide	to	tetanus	toxoid.	In	one	trial,	2	doses	
of	 5	 μg	Vi-TT,	 administered	 6	weeks	 apart,	was	 shown	 to	 be	well-tolerated	with	 a	 100%	
protective	efficacy	in	children	aged	between	6	months	and	12	years,	over	12	months	(Mitra	
et	al.,	2016).	Seroconversion,	defined	as	a	4-fold	increase	in	levels	of	IgG	specific	to	the	Vi	
polysaccharide,	 was	 observed	 in	 100%	 of	 vaccinated	 volunteers	 at	 6	 weeks	 and	 83%	 of	
vaccinated	volunteers	at	12	months	(Mitra	et	al.,	2016).		
More	 recently,	 controlled	human	 infection	has	been	used	 to	 assess	 the	efficacy	of	Vi-TT.	
When	 a	 comprehensive	 all-encompassing	 definition	 of	 typhoid	 was	 applied,	 Vi-TT	 was	
estimated	to	have	a	54.6%	protective	efficacy	(Jin	et	al.,	2017);	however,	when	a	broader	
definition	was	used,	more	in	line	field	trial	definitions,	Vi-TT	was	estimated	to	have	a	87.1%	
protective	efficacy	(Jin	et	al.,	2017).	This	estimate	is	similar	to	the	field	trial	efficacy	of	Vi-
rEPA	 (Lin	et	al.,	2001,	Mai	et	al.,	2003),	but	 less	 than	 that	 reported	 in	 field	 trials	of	Vi-TT	
(Mitra	et	al.,	2016).	Interestingly,	as	was	the	case	for	Vi-rEPA	vaccinated	volunteers	(Lin	et	
al.,	 2001,	Mai	 et	 al.,	 2003),	 it	 was	 observed	 that	 disease	 severity	 was	 lessened	 in	 Vi-TT	
vaccinated	volunteers	(Jin	et	al.,	2017).	
The	implications	of	Vi	polysaccharide	protein	conjugate	vaccine	efficacy	are	profound.	The	
adoption	of	these	vaccines,	which	possess	efficacy	in	those	most	at	risk	of	disease,	into	EPI	
could	well	lead	to	the	eradication	of	S.	Typhi	as	a	cause	of	human	disease.		
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1.15.3. Vaccines	with	broad	serovar	coverage	
Vi	polysaccharide-based	vaccines	may	only	target	serovars	which	express	this	antigen.	Of	the	
more	than	2,600	S.	enterica	serovars,	only	S.	Typhi,	S.	Paratyphi	C	and	S.	Dublin	express	the	
Vi-polysaccharide	 (Hashimoto	 and	 Khan,	 1997).	 In	 addition,	 Vi	 polysaccharide	 negative	
strains	of	S.	Typhi	have	been	isolated	from	individuals	 living	 in	 India	and	Nepal	diagnosed	
with	typhoid	fever	(Mehta	and	Arya,	2002,	Wain	et	al.,	2005).	Thus,	since	pathogenicity	is	
not	dependent	upon	expression	of	the	Vi	polysaccharide,	vaccines	targeting	this	antigen	may	
simply	apply	pressure	for	the	selection	of	Vi-negative	strains	of	S.	Typhi.		
The	identification	of	protein	antigens	which	are	conserved	across	serovars	could	lead	to	the	
development	of	a	universal	Salmonella	vaccine,	targeting	both	typhoidal	and	non-typhoidal	
serovars.	 It	has	already	been	demonstrated	that	vaccination	with	 live-attenuated	S.	Typhi	
generates	cross-reactive	B-cell	and	T	cell	responses	with	efficacy	against	a	range	of	typhoidal	
(Wahid	et	al.,	2014,	Pakkanen	et	al.,	2015,	Wahid	et	al.,	2016)	and	non-typhoidal	serovars	
(Kantele	et	al.,	2012,	Pakkanen	et	al.,	2015).	In	humans,	vaccination	with	outer	membrane	
proteins	 (OMPs)	 from	 S.	 Typhi	 has	 been	 shown	 to	 be	 well-tolerated	 and	 capable	 of	
generating	both	B-cell	and	T	cell	responses	(Salazar-Gonzalez	et	al.,	2004).	Murine	models	
have	demonstrated	that	responses	generated	though	vaccination	with	OMPs	from	S.	Typhi	
can	confer	protection	against	a	range	of	non-typhoidal	serovars	(Tabaraie	et	al.,	1994,	Isibasi	
et	al.,	1988).	Further	work	would	be	required	to	identify	viable	immunogenic	antigens	which	
may	be	used	to	provide	broad	serovar	coverage.	
1.16. Aims	and	objectives	of	this	thesis	
This	thesis	aims	to	assess	the	human	immune	response	to	live-attenuated	S.	Typhi	(Ty21a)	
through	the	following	objectives:	
• To	characterise	the	short-term	impact	of	Ty21a	on	adaptive	human	immunity	in	
peripheral	blood	and	at	the	duodenal	and	colonic	mucosa	
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• To	characterise	the	long-term	impact	of	Ty21a	on	adaptive	human	immunity	in	
peripheral	blood	and	at	the	duodenal	mucosa	
• To	characterise	the	non-specific	effects	of	Ty21a	on	innate	cell	phenotype	and	
its	impact	on	immune	responses	to	an	array	of	pathogens	
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CHAPTER	2: MATERIALS	AND	METHODS	
	
This	chapter	sets	out	the	methodologies	used	to	generate	the	data	which	are	presented	in	
subsequent	chapters.		
2.1. Ethical	approval	
All	studies	were	compliant	with	Good	Clinical	Practice	(GCP)	and	with	the	principles	set	out	
in	 the	 Declaration	 of	 Helsinki	 (World	Medical,	 2013).	 All	 studies	were	 approved	 by	 local	
Research	Ethics	Committees	(RECs)	which	are	part	of	the	United	Kingdom	National	Research	
Ethics	Service	(NRES)	(Table	2.1).	
Table	2.1.	Ethical	approval	and	REC	information	
Project	title	 REC	 Reference	 Results	
Mucosal	Responses	to	
Oral	Vaccination	 North	West	–	Liverpool	Central	 10/H1005/20	 Chapter	3	
Understanding	
Immunity	to	Typhoid	 North	West	–	Liverpool	Central	 13/NW/0282	 Chapter	4	
Non-specific	Effects	of	
Typhoid	Vaccination	 North	West	–	Liverpool	East	 14/NW/1455	 Chapter	5	
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2.2. Recruitment	and	Consent	
All	volunteers	provided	written	informed	consent.	Volunteers	were	recruited	by	electronic	
and	poster	 advertisement	 at	 the	University	 of	 Liverpool,	 the	 Liverpool	 School	 of	 Tropical	
Medicine	 and	 the	 Royal	 Liverpool	 University	 Hospital.	 All	 volunteers	 were	 screened	
according	to	strict	inclusion	and	exclusion	criteria	(Table	2.2).	These	criteria	were	in	place	to	
ensure	that	volunteers	were	able	to	provide	full	informed	consent	and	to	minimise	variability	
within	the	cohort.	
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Table	2.2.	Study	inclusion	and	exclusion	criteria	
Study	reference	 Criteria	
Chapter	3	
Inclusion	
Have	capacity	to	give	informed	consent	
Are	aged	between	18	and	60	years	
Are	in	good	health	
Are	fluent	in	English	
Exclusion	
Are	currently	involved	in	another	study	
Are	taking	medication	that	affects	the	immune	system	
Have	smoked	more	than	20	cigarettes	a	day	for	10	years	
Are	currently	pregnant	
Are	not	fluent	in	English	
Additional	vaccine	group	criteria:	
Previous	adverse	reaction	to	vaccination	
Chapter	4	
Inclusion	
Have	capacity	to	give	informed	consent	
Are	aged	between	18	and	60	years	
Are	in	good	health	
Are	fluent	in	English	
Exclusion	
Are	currently	involved	in	another	study	
Are	taking	medication	that	affects	the	immune	system	
Are	currently	pregnant	
Are	not	fluent	in	English	
Additional	control	group	criteria:	
Have	visited	or	lived	in	a	typhoid	endemic	region	
Previously	vaccinated	against	typhoid	
Chapter	5	
Inclusion	
Have	capacity	to	give	informed	consent	
Are	aged	between	18	and	60	years	
Are	in	good	health	
Are	fluent	in	English	
Exclusion	
Are	currently	involved	in	another	study	
Are	taking	medication	that	affects	the	immune	system	
Are	currently	pregnant	
Are	not	fluent	in	English	
Have	a	chronic	illness	
Have	visited	or	lived	in	a	typhoid	endemic	region	
Previously	vaccinated	against	typhoid	
	
2.3. Vaccination	
Volunteers	 were	 vaccinated	 with	 Ty21a	 (Vivotif;	 Crucell).	 Volunteers	 were	 instructed	 to	
consume	 a	 single	 enteric-coated	 vaccine	 capsule	 (Table	 2.3)	 on	 days	 0,	 2	 and	 4,	
approximately	 one	 hour	 before	 a	meal,	with	 a	 cold	 or	 lukewarm	 drink,	 according	 to	 the	
manufacturer’s	instructions.	
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Table	2.3.	Typical	composition	of	a	single	Vivotif	vaccine	capsule	
Component	 Quantity	
Viable	S.	Typhi	(Ty21a)	 2.0	–	10.0	×	109	CFU	
Non-viable	S.	Typhi	(Ty21a)	 5.0	–	50.0	×	109	CFU	
Sucrose	 3.3	–	34.2	mg	
Ascorbic	acid	 0.2	–	2.4	mg	
Amino	acid	mixture	 0.3	–	3.0	mg	
Lactose	 Up	to	180	–	200	mg	
Magnesium	stearate	 3.6	–	4.0	mg	
	
2.4. Clinical	procedures	
2.4.1. Clinical	consumables	
Table	2.4.	Clinical	consumables	for	sample	collection	
Name	 Manufacturer	 Product	code	
BD	Vacutainer	Safety-Lok	 BD	Biosciences	 368654	
S-Monovette	7.5	mL	Z	 Sarstedt	 01.1601.001	
BD	Vacutainer	10	mL	 BD	Biosciences	 367874	
Vacuette	9	mL	 Greiner	Bio-One	 455084	
Single-Use	Radial	Jaw	4	Large	Capacity	Forceps	 Boston	Scientific	 M00513320	
133	mL	Fleet	Phosphate	Liquid	Enema	 Fleet	Laboratories	 2027266	
	
2.4.2. Venesection	and	peripheral	sampling	
Peripheral	blood	samples	were	collected	from	the	antecubital	fossa	using	a	BD	Vacutainer	
Safety-Lok	blood	collection	set.	The	sampling	site	was	prepared	using	isopropyl	alcohol	wipes	
and	universal	precautions	used.	Blood	samples	were	collected	in	clotting	activator	tubes	for	
serum	isolation	and	heparinised	tubes	for	 isolation	of	peripheral	blood	mononuclear	cells	
(PBMCs)	(Table	2.5).	
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Table	2.5.	Peripheral	blood	collection	tubes	
Study	reference	 Name	 Description	
Chapter	3	 S-Monovette	7.5	mL	Z	 Clotting	activator	for	serum	isolation	BD	Vacutainer	10	mL	 Sodium	heparin	for	PBMC	isolation	
Chapter	4	
S-Monovette	7.5	mL	Z	 Clotting	activator	for	serum	isolation	
Vacuette	9	mL	 Lithium	heparin	for	PBMC	isolation	
Chapter	5	 S-Monovette	7.5	mL	Z	 Clotting	activator	for	serum	isolation	
Vacuette	9	mL	 Lithium	heparin	for	PBMC	isolation	
	
2.4.3. Endoscopy	and	mucosal	sampling	
Volunteers	fasted	from	midnight	the	evening	before	their	procedure.	Volunteers	arrived	at	
the	 Department	 of	 Gastroenterology	 at	 the	 Royal	 Liverpool	 University	 Hospital	 for	
endoscopy	 at	 approximately	 0800	 hours.	 Consent	 for	 endoscopic	 procedures	 was	
reconfirmed	 by	 the	 endoscopist,	 according	 to	 standard	 National	 Health	 Service	 (NHS)	
procedures.	 Sedation	was	 offered	 to	 all	 volunteers;	 those	who	 requested	 sedation	were	
given	up	to	5	mg	midazolam	intravenously.	O2	was	administered	at	a	rate	2	L/minute	via	a	
nasal	 cannula	 and	 O2	 saturation	was	monitored	 throughout	 the	 procedure	 using	 a	 pulse	
oximeter.	
Gastroscopy	
12-15	 single-bite	 biopsies	 were	 acquired	 from	 the	 duodenum	 at	 D2-D3	 using	 Single-Use	
Radial	Jaw	4	large	capacity	forceps.	Biopsies	were	placed	directly	 into	50	mL	Falcon	tubes	
containing	40	mL	R15	medium	 (Table	2.11)	 and	 stored	on	 ice	pending	 laboratory	 sample	
processing.	Following	the	procedure,	volunteers	were	observed	for	up	to	two	hours,	given	a	
drink	and	a	snack	and	then	discharged.	
Sigmoidoscopy	
A	133	mL	Fleet	Phosphate	Liquid	Enema	was	administered	20	minutes	prior	to	the	procedure.	
12-15	single-bite	biopsies	were	acquired	from	the	sigmoid	colon	at	an	insertion	distance	of	
20-25	cm	using	Single-Use	Radial	Jaw	4	large	capacity	forceps.	Biopsies	were	placed	directly	
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into	50	mL	Falcon	tubes	containing	40	mL	R15	medium	(Table	2.11)	and	stored	on	ice	pending	
laboratory	sample	processing.	Following	the	procedure,	volunteers	were	observed	for	two	
hours,	given	a	drink	and	a	snack	and	then	discharged.	
2.5. Laboratory	procedures	
2.5.1. Laboratory	consumables	
Table	2.6.	General	laboratory	consumables	
Name	 Manufacturer	 Product	code	
96-well	plates	(sterile	non-treated)	 Corning	 3367	
50	mL	Falcon	tubes	 Corning	 352070	
15	mL	Falcon	tubes		 Corning	 352095	
70	µm	cell	strainers	 Corning	 352350	
LeucoSep	centrifuge	tubes	 Greiner	Bio-One	 227290	
Sterile	treated	24-well	plates	 Greiner	Bio-One	 662160	
Cryovials	 Fisher	Scientific	 50001020	
Mr.	Frosty	freezing	container		 Fisher	Scientific	 51000001	
Pasteur	pipettes	 StarLab	 E14140311	
Reagent	reservoirs	 StarLab	 E23101010	
16-gauge	blunt-ended	needles	 Stemcell	 28110	
	
Table	2.7.	Consumables	for	ELISA	
Name	 Manufacturer	 Product	code	
Anti-human-IgA	 AbD	Serotec	 205008	
Streptavidin:alkaline	phosphotase	 AbD	Serotec	 STAR6B	
96	well	flat-bottom	microtitre	plates	 NUNC	 442404	
Lyophilised	bovine	serum	albumin	(BSA)		 Sigma-Aldrich	 A2153	
Anti-human-IgG	 Sigma-Aldrich	 A3188	
Carbonate-bicarbonate	capsules	 Sigma-Aldrich	 C3041	
Lyophilised	S.	Typhi	LPS	 Sigma-Aldrich	 L2387	
Tween-20	 Sigma-Aldrich	 P1754	
Phosphate	buffered	saline	(PBS)	tablets	 Sigma-Aldrich		 P4417	
p-nitrophenyl	phosphate	 Sigma-Aldrich	 	
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Table	2.8.	Consumables	for	tissue	culture	
Name	 Manufacturer	 Product	code	
Lymphoprep	 Axis-Shield	 1114544	
CTL-Cryo	ABC	media		 Cellular	Technology	 CTLABC300	
96-well	plates	(sterile	treated)	 Corning	 3894	
Ficoll-Paque	PLUS	 GE	Healthcare	 11778538	
Hanks’	balanced	salt	solution	(Ca-/Mg-)	(HBSS-/-)	 GE	Healthcare	 11546291	
Foetal	bovine	serum	(FBS)	 Invitrogen	 10270106	
Dulbecco's	PBS	Ca-/Mg-	(PBS-/-)	 Invitrogen	 14190169	
Antibiotic/antimitotic	 Invitrogen	 15240062	
0.5	M	EDTA	 Invitrogen	 15575020	
RPMI-1640	(+	L-glutamine	+	HEPES)	 Invitrogen	 22400089	
Histopaque-1077	 Sigma-Aldrich	 10771	
Collagenase	 Sigma-Aldrich	 C1764	
DNase	I	 Sigma-Aldrich	 DN25	
Trypan	Blue	0.4%	 Sigma-Aldrich	 T5154	
	
Table	2.9.	Consumables	for	cytokine	detection	by	flow	cytometry	
Name	 Manufacturer	 Product	code	
Cytofix/Cytoperm		 BD	Biosciences	 554714	
Perm/Wash	 BD	Biosciences	 554723	
BD	GolgiStop	 BD	Biosciences	 554724	
BD	GolgiPlug	 BD	Biosciences	 555029	
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2.5.2. Reagent	preparation	
Table	2.10.	Reagents	for	ELISA	
Reagent	 Preparation	
PBS	
Five	PBS	tablets	were	dissolved	in	1	L	of	sterile,	pyrogen	free	
water	(dH2O).	Once	prepared,	PBS	was	stored	at	room	
temperature	for	up	to	1	month.	
PBS-tween	 500	µL	of	Tween-20	was	added	to	1	L	of	PBS.	Once	prepared,	PBS-tween	was	stored	at	room	temperature	for	up	to	1	month.	
Carbonate-
bicarbonate	buffer	
The	contents	of	five	carbonate-bicarbonate	capsules	were	
dissolved	in	500	mL	of	dH2O.	Once	prepared,	carbonate-
bicarbonate	buffer	was	stored	at	4˚C	for	up	to	1	month.	
1.0%	BSA	 5	g	of	lyophilised	BSA	was	dissolved	in	500	mL	of	PBS.	Once	prepared,	1.0%	BSA	was	stored	at	4˚C	for	up	to	1	month.	
0.1%	BSA	 50	mL	of	1.0%	BSA	was	added	to	450	mL	of	PBS.	Once	prepared,	0.1%	BSA	was	stored	at	4˚C	for	up	to	1	month.	
S.	Typhi	LPS	
10	mg	lyophilised	S.	Typhi	LPS	was	suspended	in	dH20	at	a	
concentration	of	5	mg/mL.	Once	prepared,	the	LPS	antigen	was	
stored	at	4˚C.	
p-nitrophenyl	
phosphate	
One	single	p-nitrophenyl	phosphate	tablet	was	dissolved	in	40	
mL	dH2O.	
	
Table	2.11.	Reagents	for	tissue	culture	
Reagent	 Preparation	
Complete	medium	
50	mL	FBS	was	added	to	450	mL	RPMI-1640	(+	L-glutamine	+	
HEPES).	Once	prepared,	complete	medium	was	stored	at	4˚C	for	
up	to	one	week.	
DNase	I	medium	
50	mL	FBS	and	5	mL	DNase	I	(2	mg/mL)	was	added	to	445	mL	
RPMI-1640	(+	L-glutamine	+	HEPES).	DNase	I	medium	was	used	
on	the	day	of	preparation.	
R15	medium	
75	mL	FBS	and	5	mL	antibiotic/antimitotic	(10,000	units/mL	of	
penicillin,	10,000	µg/mL	of	streptomycin	and	25	µg/mL	of	Gibco	
Amphotericin	B)	was	added	to	420	mL	RPMI-1640	(+	L-glutamine	
+	HEPES).	Once	prepared,	R15	medium	was	stored	at	4˚C	for	up	
to	one	week.	
R20	medium	
100	mL	FBS	and	5	mL	antibiotic/antimitotic	was	added	to	395	mL	
RPMI-1640	(+	L-glutamine	+	HEPES).	Once	prepared,	R20	medium	
was	stored	at	4˚C	for	up	to	one	week.	
CII-S	medium	 50	mg	collagenase	was	added	to	100	mL	MR15	medium.	CII-S	medium	was	used	on	the	day	of	preparation.	
Wash	buffer	
10	mL	FBS	and	2	mL	0.5	M	EDTA	was	added	to	488	mL	Dulbecco's	
PBS-/-.	Once	prepared,	wash	buffer	was	stored	at	4˚C	for	up	to	
one	week.	
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2.5.3. Bacterial	dilution	plating	
The	bacterial	source	was	serially	diluted	1:10	across	a	range	from	101	to	106	in	Dulbecco's	
PBS-/-	 in	 sterile	 untreated	 96-well	 plates.	 LB-agar	 plates	 were	 divided	 into	 four	 sections,	
which	were	 labelled	103,	 104,	 105	 and	106.	 Three	10	µL	 spots	were	 added	 to	each	of	 the	
corresponding	 sections	and	 the	plate	allowed	 to	dry.	Plates	were	 inverted	and	 incubated	
overnight	at	37°C	in	5%	CO2.	The	next	day	the	largest	number	of	countable	colonies	in	a	single	
section	were	enumerated	and	the	following	equation	used	to	calculate	CFU/µL:	
!"#$%&	()	*(+(,-%.	*(",/%01".2%,.-(,	3(+"#%	2+4/%0 	×	6789:7;<	=>?:;@ 	= BCD/µG	 		
2.5.4. Serum	isolation	
Peripheral	 blood	 samples	 were	 collected	 in	 clot	 activator	 collection	 tubes	 (Table	 2.5).	
Samples	were	left	at	room	temperature	for	no	less	than	30	minutes.	Clotted	samples	were	
centrifuged	at	1,300	g	for	5	minutes	and	the	serum	supernatant	aliquoted	into	Eppendorf	
tubes	in	100	µL	volumes	and	stored	at	-80˚C.	
2.5.5. PBMC	isolation	
Chapter	3	and	Chapter	4	
Peripheral	blood	samples	were	collected	in	heparinised	collection	tubes	(Table	2.5).	Samples	
were	diluted	with	an	equal	 volume	of	Dulbecco's	PBS	and	 layered	on	either	 Lymphoprep	
(Chapter	 3)	 or	 Histopaque-1077	 (Chapter	 4)	 in	 50	 mL	 Falcon	 tubes.	 Samples	 were	 then	
centrifuged	at	800	g	for	18	minutes	at	room	temperature	without	brake.	Cells	were	isolated	
using	 a	 sterile	 Pasteur	 pipette,	washed	 twice	 (centrifuged	 at	 250	 g	 for	 10	minutes)	 with	
Dulbecco's	PBS-/-	and	resuspended	in	1mL	complete	medium.	A	sample	of	the	cell	suspension	
was	diluted	1:1	by	adding	10	µL	of	the	cell	suspension	to	10	µL	0.4%	Trypan	Blue.	The	number	
of	 viable	 cells	 was	 then	 enumerated	 using	 an	 Improved	 Neubauer	 Haemocytometer	
(CamLab;	1127884).	The	following	equation	was	used	to	calculate	cells/mL:	
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H9IJK@	;=	?K88L	?;9<:KM	×	6789:7;<	=>?:;@ 	×	10P 	= ?K88L/IG	
The	concentration	of	 the	cell	 suspension	was	adjusted	with	complete	medium	to	1	×	107	
cells/mL.	100	µl	of	the	cell	suspension	was	then	added	to	each	well	of	a	96-well	plate,	as	
required.	
Chapter	5	
Peripheral	blood	samples	were	collected	in	heparinised	collection	tubes	(Table	2.5).	Samples	
were	layered	on	Ficoll-Paque	PLUS	using	LeucoSep	centrifuge	tubes	and	centrifuged	at	800	
g	 for	 18	minutes	 at	 room	 temperature	without	 brake.	 Cells	were	 isolated	 using	 a	 sterile	
Pasteur	 pipette,	 washed	 twice	 (centrifuged	 at	 250	 g	 for	 10	 minutes)	 with	 HBSS-/-	 and	
resuspended	in	10mL	HBSS-/-.	A	sample	of	the	cell	suspension	was	diluted	1:1	by	adding	10	
µL	of	the	cell	suspension	to	10	µL	0.4%	Trypan	Blue.	The	number	of	viable	cells	was	then	
enumerated,	as	previously	described.		
Cells	were	stored	using	CTL-Cryo	ABC	media.	Cells	were	washed	once	(centrifuged	at	250	g	
for	10	minutes)	with	HBSS-/-	and	the	cell	pellet	resuspended	in	CryoC	at	a	concentration	of	2	
×	107	cells/mL.	Samples	were	then	placed	on	ice	and	an	equal	volume	of	CryoA:CryoB	(4:1)	
was	slowly	added	to	achieve	a	final	concentration	of	1	×	107	cells/mL.	The	cell	suspension	
was	aliquoted	 into	cryovials	 in	1	mL	volumes.	Cryovials	were	then	placed	 in	a	cooled	Mr.	
Frosty	freezing	container	and	transferred	to	-80˚C.	After	24	hours	cryovials	were	transferred	
on	dry	ice	to	-200˚C	storage.	
2.5.6. PBMC	thawing	and	overnight	‘rest’	
Chapter	5	
Cells	were	 removed	 from	-200˚C	storage	and	 incubated	at	37°C	 for	10	minutes.	Cryovials	
were	inverted	twice	and	the	contents	of	the	cryovial	transferred	into	15	mL	Falcon	tubes.	
Cryovials	were	washed	once	with	1	mL	prewarmed	DNase	I	medium	in	order	to	collect	any	
remaining	cells.	An	additional	8	mL	prewarmed	DNase	I	medium	was	added	to	the	15	mL	
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Falcon	tubes	at	a	rate	of	1	mL	every	five	seconds.	Samples	were	washed	twice	(centrifuged	
at	 330	 g	 for	 10	minutes)	 with	 prewarmed	 DNase	 I	 medium	 and	 resuspended	 in	 600	 µL	
prewarmed	complete	medium.	A	sample	of	the	cell	suspension	was	diluted	1:1	by	adding	10	
µL	of	the	cell	suspension	to	10	µL	0.4%	Trypan	Blue.	The	number	of	viable	cells	was	then	
enumerated,	as	previously	described.		
The	concentration	of	 the	cell	 suspension	was	adjusted	with	complete	medium	to	1	×	107	
cells/mL.	100	µL	of	the	cell	suspension	was	then	added	to	each	well	of	a	96-well	plate,	as	
required.	Cells	were	then	‘rested’	overnight	at	37°C	in	5%	CO2.	The	following	day,	plates	were	
centrifuged	at	330	g	 for	10	minutes,	 the	 supernatant	 removed	and	 the	 cells	 in	each	well	
resuspended	in	100	µL	prewarmed	complete	medium.	
2.5.7. Mucosal	 mononuclear	 cell	 (MMC)	 isolation	 and	 overnight	
‘rest’	
Samples	were	centrifuged	at	400	g	for	10	minutes	at	room	temperature	without	brake.	The	
supernatant	was	removed	and	the	biopsies	resuspended	in	20	mL	prewarmed	CII-S	medium	
and	 placed	 at	 37°C	 for	 30	minutes	 at	 a	 45°	 angle	with	 shaking	 (220	 rpm).	 Biopsies	were	
mechanically	disrupted	by	passing	 the	 tissue	suspension	 through	a	16-gauge	blunt-ended	
needle	five	times.	The	suspension	was	then	passed	through	a	70	µm	cell	strainer	and	the	cell	
suspension	 stored	on	 ice.	Tissue	 fragments	 captured	 in	 the	cell	 strainer	were	 transferred	
back	 into	the	original	 tube	by	rinsing	the	cell	strainer	with	prewarmed	CII-S	medium.	The	
process	 of	 incubation,	 disruption	 and	 filtration	 was	 then	 repeated	 twice	 more.	 Cell	
suspensions	were	pooled	and	centrifuged	at	400	g	for	10	minutes	without	brake.	Cells	were	
resuspended	in	1	mL	R20	medium.	A	sample	of	the	cell	suspension	was	diluted	1:1	by	adding	
10	µL	of	the	cell	suspension	to	10	µL	0.4%	Trypan	Blue.	The	number	of	viable	cells	was	then	
enumerated,	as	previously	described.	The	concentration	of	the	cell	suspension	was	adjusted	
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with	R20	medium	to	1	×	106	cells/mL.	The	entire	cell	suspension	was	then	distributed,	in	2	
mL	volumes,	in	24-well	plates.	Samples	were	then	rested	overnight	at	37°C	in	5%	CO2.		
The	 following	day,	 cells	were	harvested	 from	wells	 and	 the	wells	washed	with	 1	mL	R20	
medium.	Cell	suspensions	were	then	centrifuged	at	400	g	for	10	minutes	and	resuspended	
in	1	mL	complete	medium.	A	sample	of	the	cell	suspension	was	diluted	1:1	by	adding	10	µL	
of	 the	 cell	 suspension	 to	 10	 µL	 0.4%	 Trypan	 Blue.	 The	 number	 of	 viable	 cells	 was	 then	
enumerated,	as	previously	described.	The	concentration	of	the	cell	suspension	was	adjusted	
with	complete	medium	to	no	less	than	0.5	×	107	cells/mL.	100	µl	of	the	cell	suspension	was	
then	added	to	each	well	of	a	96-well	plate,	as	required.	
2.5.8. Phenotypic	analysis	of	‘rested’	monocytes	
Cells	were	washed	(centrifuged	at	330	g	for	10	minutes)	with	200	µL	wash	buffer.	Cells	were	
re-suspended	in	50	µL	wash	buffer	containing	viability	dye.		
Table	2.12.	Viability	dye	for	the	analysis	of	monocyte	phenotype	
Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	5	 LIVE/DEAD	 Pacific	Orange	 LifeTechnologies	 0.02	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	resuspened	in	50	µL	wash	buffer	containing	the	following	antibodies:	
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Table	2.13.	Surface	marker	antibody	panel	for	analysis	of	monocyte	phenotype	
Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Chapter	5	
CD14	 MφP9	 PerCP/Cy5.5	 BD	Biosciences	 3.5	µL	
CD16	 FcγRIII	 APC/Cy7	 BioLegend	 3.5	µL	
CD64	 HI10a	 BV605	 BioLegend	 3.5	µL	
CD18	 TS1/18	 PE/Cy7	 BioLegend	 3.5	µL	
CD11b	 ICRF44	 AF700	 BD	Biosciences	 3.5	µL	
CD11c	 Bu15	 Pacific	Blue	 BioLegend	 3.5	µL	
CD123	 6H6	 BV711	 BioLegend	 3.5	µL	
CD206	 19.2	 PE/CF594	 BD	Biosciences	 3.5	µL	
CD284	 HTA125	 APC	 BioLegend	 3.5	µL	
CD285	 624915	 FITC	 R&D	Systems	 3.5	µL	
CD303	 201A	 PE	 BioLegend	 3.5	µL	
CD161	 L243	 BV785	 BioLegend	 3.5	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	 washed	 once	 more	 with	 wash	 buffer,	 resuspended	 in	 200	 µL	 wash	 buffer	 and	
transferred	into	Falcon	5	mL	round	bottom	polystyrene	test	tubes.	Tubes	were	stored	in	the	
absence	of	light	at	4°C	until	acquisition.	
2.5.9. Antigens	used	in	in	vitro	assays	
Various	 antigens	 were	 used	 to	 stimulate	 cell	 ex	 vivo	 in	 order	 to	 probe	 immunological	
function.	
		
Table	2.14.	Ex	vivo	antigen	preparation	
Study	reference	 Description	 Manufacturer/Supplier	 Preparation	of	stimuli	
Chapter	3	
Complete	medium	 -	 100	µL	complete	medium	
Heat-killed	Ty21a	(Vivotif)	 Crucel	 100	µL	complete	medium	containing	1	×	106	CFU	heat-killed	Ty21a	
Subunit	Influenza	(Influvac)	 Abbott	Laboratories	
100	µL	complete	medium	containing	45	ng	hemagglutinin	and	
neuraminidase	from,	in	equal	quantities,	a	A/Brisbane/59/2007	H1N1-like	
strain,	a	A/Brisbane/10/2007	H3N2-like	strain	and	a	B/Brisbane/60/2008-
like	strain	
Staphylococcal	enterotoxin	B	
(SEB)	 Sigma	 100	µL	complete	medium	containing	100	ng	SEB	
Chapter	4	
Complete	medium	 -	 100	µL	complete	medium	
Heat-killed	Ty21a	 Crucel	 100	µL	complete	medium	containing	1	×	106	CFU	heat-killed	Ty21a	
Flagella	(FliC)	 Gift	from	Prof	A.	F.	Cunningham	 100	µL	complete	medium	containing	5	µg	FliC	protein	
SEB	 Sigma	 100	µL	complete	medium	containing	100	ng	SEB	
Chapter	5	
Complete	medium	 -	 100	µL	complete	medium	
Heat-killed	Ty21a	 Crucel	 100	µL	complete	medium	containing	2	×	106	CFU	heat-killed	Ty21a	
Heat-killed	Candida	albicans	 Gift	from	Prof	M.	G.	Netea	 100	µL	complete	medium	containing	2	×	10
6	CFU	heat-killed	C.	albicans	
Purified	protein	derivative	
from	M.	tuberculosis	(TB	PPD)	 Statens	Serum	Institut	 100	µL	complete	medium	containing	5	µg	TB	PPD	
Tetanus	toxoid	 Sigma	 100	µL	complete	medium	containing	20	µg	tetanus	toxoid	
Split	Viron	Influenza		 Sanofi	Pasteur	
100	µL	complete	medium	containing	180	ng	hemagglutinin	from,	in	equal	
quantities,	a	A/California/7/2009	H1N1-like	strain,	a	A/Texas/50/20122	
H3N2-like	strain	and	a	B/Massachusetts/2/2012-like	strain	
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2.5.10. Ex	vivo	cell	stimulation	and	staining	
Seeded	cells	were	stimulated	with	antigens	 listed	 in	Table	2.14.	Following	the	addition	of	
antigen,	cells	were	incubated	at	37°C	in	5%	CO2	for	two	hours.	Cells	were	then	treated	with	
protein	transport	inhibitors	resulting	in	the	accumulation	of	protein	within	the	Golgi	complex	
for	detection	by	flow	cytometry	(Table	2.15).		
Table	2.15.	Protein	transport	inhibitors	
Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	3	 BD	GolgiPlug	 Contains	brefeldin	A	 BD	Biosciences	 1	µL	
Chapter	4	
BD	GolgiPlug		 Contains	brefeldin	A	 BD	Biosciences	 1	µL	
BD	GolgiStop	 Contains	monensin	 BD	Biosciences	 1	µL	
Chapter	5	 BD	GolgiPlug		 Contains	brefeldin	A	 BD	Biosciences	 1	µL	
BD	GolgiStop		 Contains	monensin	 BD	Biosciences	 1	µL	
	
Cells	were	then	incubated	at	37°C	in	5%	CO2	for	16	hours.	Plates	were	centrifuged	at	330	g	
for	10	minutes,	the	supernatant	was	removed	and	the	cells	washed	with	200	µL	wash	buffer.	
Cells	were	resuspened	in	50	µL	wash	buffer	containing	viability	dye:	
Table	2.16.	Viability	dyes	for	analysis	of	intracellular	cytokine	production	
Study	reference	 Name	 Description	 Manufacturer	 Per	test	
Chapter	3	 LIVE/DEAD	 Pacific	Blue	 LifeTechnologies	 1	µL	
Chapter	4	 LIVE/DEAD	 Pacific	Blue	 LifeTechnologies	 0.02	µL	
Chapter	5	 LIVE/DEAD	 Pacific	Orange	 LifeTechnologies	 0.02	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	resuspened	in	50	µL	wash	buffer	containing	the	following	antibodies:	
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Table	2.17.	Surface	antibody	panel	for	identification	of	cell	subsets	
Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Chapter	3	
CD3	 HIT3a	 APC	 BD	Biosciences	 10	µL	
CD4	 SK3	 APC/Cy7	 BD	Biosciences	 5	µL	
CD8	 RPA-T8s	 PE/Cy7	 BD	Biosciences	 1	µL	
Integrinβ7	 FIB504	 PE/Cy5	 BD	Biosciences	 2	µL	
CD14	 M5E2	 HorizonV450	 BD	Biosciences	 2	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 2	µL	
Chapter	4	
CD3	 OCT3	 BV/510	 BioLegend	 1	µL	
CD4	 SK3	 PE/Cy7	 BD	Biosciences	 1	µL	
CD8	 SK1	 APC/H7	 BD	Biosciences	 1	µL	
CD14	 MφP9	 HorizonV450	 BD	Biosciences	 1	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 1	µL	
Chapter	5	
CD3	 SK7	 APC/H7	 BD	Biosciences	 1	µL	
CD4	 SK3	 PerCP/Cy5.5	 BioLegend	 1	µL	
CD8	 SK1	 BV/650	 BioLegend	 1	µL	
CD14	 MφP9	 APC/H7	 BD	Biosciences	 1	µL	
CD20	 2H7	 Pacific	Blue	 BioLegend	 1	µL	
CD161	 HP-3G10	 BV/785	 BioLegend	 1	µL	
TCRγδ	 11F2	 PE/Cy7	 BD	Biosciences	 1	µL	
Vα7.2	 3C10	 PE/Dazzle594	 BioLegend	 1	µL	
	
Cells	were	 incubated	for	20	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
wash	buffer	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	 resuspened	 in	 100	 µL	 Cytofix/Cytoperm	 and	 incubated	 for	 20	 minutes	 at	 room	
temperature	 in	 the	absence	of	 light.	100	µL	Perm/Wash	was	added	 to	each	well	and	 the	
plates	 centrifuged	at	 330	g	 for	 10	minutes.	 Cells	were	 resuspended	 in	50	µL	Perm/Wash	
containing	the	following	antibodies:	
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Table	2.18.	Intracellular	antibody	panel	for	identification	of	cell	subsets	
Study	reference	 Target	 Clone	 Fluorophore	 Manufacturer	 Volume	
Chapter	3	
IFN-γ	 B27	 AF700	 BD	Biosciences	 1	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2.5	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 10	µL	
Chapter	4	
CD69	 FN50	 PE/CF594	 BD	Biosciences	 2	µL	
MIP-1β	 24006	 APC	 R&D	Systems	 2	µL	
IFN-γ	 B27	 AF700	 BD	Biosciences	 2	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 2	µL	
IL-17A	 eBio64DEC17	 PerCP/Cy5.5	 eBioscience	 2	µL	
Chapter	5	
IFN-γ	 4S.B3	 PE	 BioLegend	 2	µL	
TNF-α	 MAb11	 FITC	 BioLegend	 2	µL	
IL-17A	 N49-653	 AF700	 BD	Biosciences	 2	µL	
IL-4	 MP4-25D2	 BV711	 BD	Biosciences	 2	µL	
TGF-β	 TW4-6H10	 APC	 BioLegend	 2	µL	
	
Cells	were	 incubated	for	30	minutes	at	room	temperature	 in	the	absence	of	 light.	150	µL	
Perm/Wash	was	added	to	each	well	and	the	plates	centrifuged	at	330	g	for	10	minutes.	Cells	
were	 washed	 once	 more	 with	 Perm/Wash,	 resuspended	 in	 200	 µL	 wash	 buffer	 and	
transferred	into	Falcon	5	mL	round	bottom	polystyrene	test	tubes.	Tubes	were	stored	in	the	
absence	of	light	at	4°C	until	acquisition.	
2.5.11. Flow	cytometric	acquisition	and	analyses	
Flow	 cytometric	 data	were	 acquired	 using	 either	 a	 LSR	 II	 flow	 cytometer	 (Chapter	 3	 and	
Chapter	4;	BD	Biosciences)	or	a	FACSAria	III	(Chapter	5;	BD	Biosciences).	Standard	procedures	
were	 used	 to	 maintain	 both	 machines	 and	 quality	 control	 was	 performed	 daily.	
Compensation	matrices	were	created	using	compensation	beads	(BD	Biosciences).	Analysis	
were	 performed	 using	 FlowJo	 version	 7.6.5	 (Chapter	 3	 and	 Chapter	 4;	 Treestar	 Inc.)	 and	
FlowJo	version	10.2	(Chapter	5;	Treestar	Inc.).		
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2.5.12. LPS	ELISA	
Plate	coating	
100	µL	of	carbonate-bicarbonate	buffer	containing	50	ng	S.	Typhi	LPS	was	added	to	each	well	
of	96	well	flat-bottom	microtitre	plate.	Plates	were	sealed	and	incubated	at	4°C	overnight.	
Plate	blocking	
Plates	were	washed	three	times	with	PBS-tween	and	100	µL	1.0%	BSA	was	added	to	each	
well.	Plates	were	sealed	and	incubated	at	room	temperature	for	two	hours.	
Preparation	and	addition	of	sera	
A	 standard	was	 created	 using	 serum	 obtained	 from	 a	 patient	 previously	 diagnosed	with	
typhoid	(IgG;	1:450	–	1:328,050	and	IgA;	1:50	–	1:36,450).	Volunteer	samples	were	diluted	
1:3	four	times	across	a	range	selected	for	optimum	comparison	against	the	standard	(IgG;	
1:150	–	1:4,050	and	IgA;	1:50	–	1:1,350).	
Once	samples	had	been	prepared,	plates	were	washed	three	times	with	PBS-tween	and	200	
µL	of	each	sample	was	added	in	duplicate.	Plates	were	sealed	and	incubated	at	4°C	overnight.	
Detection	antibody	
Plates	were	washed	three	times	with	PBS-tween.		
• For	the	detection	of	IgG,	a	1:4,000	dilution	of	anti-human-IgG	was	created	using	
0.1%	BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	
room	temperate	for	two	hours.		
• For	the	detection	of	IgA,	1:4,000	dilution	of	anti-human-IgA	was	created	using	
0.1%	BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	
room	temperate	for	two	hours.	Plates	were	washed	three	times	with	PBS-tween.	
A	1:2,000	dilution	of	streptavidin:alkaline	phosphatase	was	created	using	0.1%	
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BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	room	
temperate	for	one	hour.	
Development	and	analyses	
Plates	were	washed	three	times	with	PBS-tween	and	100	µL	of	p-nitrophenyl	phosphate	was	
added	to	each	well.	Plates	were	 incubated	at	 room	temperate	 for	a	 fixed	period	 (IgG;	90	
minutes	and	IgA;	30	minutes)	and	the	optical	density	of	each	well	measured	at	405	nm	using	
a	 FLUOstar	Omega	 ELISA	microplate	 reader	 (BMG	 Labtech).	 The	 average	 blank	 corrected	
value	was	 calculated	 for	each	 sample	and	 the	data	analysed	using	Omega	Analysis	 (BMG	
Labtech).	
2.5.13. Influenza	ELISA	
Plate	coating	
100	 µL	 of	 carbonate-bicarbonate	 buffer	 containing	 25	 ng	 influenza	 hemagglutinin	 and	
neuraminidase	 antigens	 (Influvac	 containing,	 in	 equal	 quantities,	 a	 A/Brisbane/59/2007	
H1N1-like	 strain,	 a	 A/Brisbane/10/2007	 H3N2-like	 strain	 and	 a	 B/Brisbane/60/2008-like	
strain)	 to	 each	well	 of	 96	well	 flat-bottom	microtitre	 plate	 (NUNC;	 442404).	 Plates	were	
sealed	and	incubated	at	4°C	overnight.	
Plate	blocking	
Plates	were	washed	three	times	with	PBS-tween	and	100	µL	1.0%	BSA	was	added	to	each	
well.	Plates	were	sealed	and	incubated	at	room	temperature	for	two	hours.	
Preparation	and	addition	of	sera	
A	 standard	was	 created	 using	 serum	 obtained	 from	 a	 patient	 previously	 diagnosed	with	
typhoid	(IgG;	1:450	–	1:328,050	and	IgA;	1:50	–	1:36,450).	Volunteer	samples	were	diluted	
1:3	four	times	across	a	range	selected	for	optimum	comparison	against	the	standard	(IgG;	1:	
4,050	–	1:109,350	and	IgA;	1:150	–	1:4,050).	
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Once	samples	had	been	prepared,	plates	were	washed	three	times	with	PBS-tween	and	200	
µL	of	each	sample	was	added	in	duplicate.	Plates	were	sealed	and	incubated	at	4°C	overnight.	
Detection	antibody	
Plates	were	washed	three	times	with	PBS-tween.		
• For	the	detection	of	IgG,	a	1:4,000	dilution	of	anti-human-IgG	was	created	using	
0.1%	BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	
room	temperate	for	two	hours.		
• For	the	detection	of	IgA,	1:4,000	dilution	of	anti-human-IgA	was	created	using	
0.1%	BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	
room	temperate	for	two	hours.	Plates	were	washed	three	times	with	PBS-tween.	
A	1:2,000	dilution	of	streptavidin:alkaline	phosphatase	was	created	using	0.1%	
BSA	and	100	µL	added	to	each	well.	Plates	were	sealed	and	incubated	at	room	
temperate	for	one	hour.	
Development	and	analyses	
Plates	were	washed	three	times	with	PBS-tween	and	100	µL	of	p-nitrophenyl	phosphate	was	
added	to	each	well.	Plates	were	 incubated	at	 room	temperate	 for	a	 fixed	period	 (IgG;	90	
minutes	and	IgA;	30	minutes)	and	the	optical	density	of	each	well	measured	at	405	nm	using	
a	 FLUOstar	Omega	 ELISA	microplate	 reader	 (BMG	 Labtech).	 The	 average	 blank	 corrected	
value	was	 calculated	 for	each	 sample	and	 the	data	analysed	using	Omega	Analysis	 (BMG	
Labtech).	
2.6. Sample	acquisition	
Chapter	3	
Samples	were	acquired	from	vaccinated	volunteers	and	control	group	volunteers	at	baseline	
(Day	0)	and	at	day	18	–	 full	details	of	sampling	can	be	 found	 in	Figure	2.1.	Samples	were	
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acquired	at	day	18	since	data	suggested	that,	following	an	early	increase	in	the	frequency	of	
antigen-specific	T	cells	in	peripheral	blood	at	2	to	4	days,	a	reduction	was	observed	from	7	
days	 up	 to	 between	 28	 and	 56	 days	 (Salerno-Goncalves	 et	 al.,	 2010).	 It	 was,	 therefore,	
hypothesised	 that	during	 this	period	peripheral	T	cells	 traffic	 to	 the	gut.	The	day	18	 time	
point	 allowed	 us	 to	 efficiently	 utilise	 the	 endoscopy	 suite	 and	 sat	 within	 this	 period	 of	
peripheral	decline.	
Chapter	4	
Volunteers	were	recalled	as	soon	as	possible	once	ethical	approval	had	been	granted	for	this	
study	–	full	details	of	sampling	can	be	found	in	Figure	2.2.	Control	group	volunteers	were	
recruited	to	facilitate	unpaired	comparison.	
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Samples	were	acquired	from	vaccinated	volunteers	and	control	group	volunteers	at	baseline	
(Day	0),	14	days,	3	months	and	6	months	–	full	details	of	sampling	can	be	found	in	Figure	2.3.	
Samples	 were	 acquired	 at	 these	 time	 points	 since	 changes	 in	 monocyte	 phenotype	 and	
cytokine	 production	 had	 previously	 been	 observed	 at	 similar	 time	 points	 following	
vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).
		
	
Figure	2.1.	Consort	flow	diagram	showing	numbers	of	vaccinated	and	control	volunteers	from	Chapter	3,	with	sampling	information	at	each	time	point	as	well	as	experimental	output	
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Figure	2.2.	Consort	flow	diagram	showing	numbers	of	vaccinated	and	control	volunteers	from	Chapter	4,	with	sampling	information	at	each	time	point	as	well	as	experimental	output
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Figure	2.3.	Consort	flow	diagram	showing	numbers	of	vaccinated	and	control	volunteers	from	Chapter	5,	with	sampling	information	at	each	time	point	as	well	as	experimental	output		
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2.7. Data	management	and	statistical	analyses	
Chapter	3	
• Paired	t	tests	were	performed	using	logarithmically	transformed	data;	P	values	
are	2-tailed	and	considered	significant	at	P	<	.05	Prism	(Prism;	GraphPad)	
• Unpaired	t	tests	were	performed	using	untransformed	data;	P	values	are	2-tailed	
and	considered	significant	at	P	<	.05	Prism	(Prism;	GraphPad)	
• Associations	were	measured	using	the	Pearson	correlation	coefficient;	P	values	
are	2-tailed	and	considered	significant	at	P	<	.05	(Prism;	GraphPad)	
Chapter	4	
• Paired	t	tests	were	performed	using	logarithmically	transformed	bootstrapped	
data;	data	were	considered	significant	if	95%	confidence	interval	did	not	cross	0	
(SPSS;	IBM)	
• Unpaired	t	tests	were	performed	using	untransformed	bootstrapped	data;	data	
were	considered	significant	if	95%	confidence	interval	did	not	cross	0	(SPSS;	IBM)	
Chapter	5	
• Paired	t	tests	were	performed	using	untransformed	data;	P	values	are	2-tailed	
and	considered	significant	at	P	<	.05	(Prism;	GraphPad)	
• Each	volunteer	was	assigned	a	numerical	value	based	on	whether	there	was	a	
reduction	 in	 output	 (-1;	 <80%	 of	 baseline),	 no	 change	 in	 output	 (0;	 between	
£80%	and	³120%	of	baseline),	or	increased	output	(+1;	<120%	of	baseline)	at	T1,	
T2	and	T3.	Linear	discriminant	analysis	of	principal	components	(DAPC)	was	used	
to	 determine	 the	 capacity	 to	 model	 data	 to	 determine	 vaccine	 status	 (R;	 R	
Foundation	for	Statistical	Computing)
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CHAPTER	3: THE	 ADAPTIVE	 IMMUNE	 RESPONSE	 TO	 TY21A	 AT	
DAY	18	
	
3.1. Introduction	
Ty21a	is	able	to	induce	humoral	and	cellular	immune	responses,	both	of	which	have	been	
implicated	in	protection	against	disease.	While	opsonophagocytic	immunoglobulin	function	
(Wahid	et	al.,	2014),	cellular	cytotoxicity,	proliferation	and	cytokine	production	functionality	
have	been	assessed	in	peripheral	blood	following	vaccination	with	Ty21a	(Salerno-Goncalves	
et	 al.,	 2002,	 Lundin	et	 al.,	 2002,	 Salerno-Goncalves	et	 al.,	 2004,	 Salerno-Goncalves	et	 al.,	
2005,	Salerno-Goncalves	et	al.,	2010,	McArthur	and	Sztein,	2012),	cellular	immunity	at	the	
human	 intestinal	 mucosa	 has	 never	 been	 directly	 assessed.	 Numerous	 studies	 have	
demonstrated	that	cellular	immune	responses	generated	through	vaccination	with	Ty21a	are	
primed	for	mucosal	homing	(Kantele	et	al.,	1997,	Kantele	et	al.,	1999b,	Lundin	et	al.,	2002),	
highlighting	the	importance	of	mucosal	immunity	in	defence	against	disease.	Furthermore,	
it	 has	 been	 demonstrated	 that	 the	 assessment	 of	 vaccine	 immunogenicity	 by	 peripheral	
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sampling	alone	provides	an	incomplete	reflection	of	vaccine	immunogenicity	(Thome	et	al.,	
2014).	
It	 has	 previously	 been	 observed	 in	 murine	 models	 that	 previously	 primed	 T	 cells	 of	
heterologous	specificities	are	recruited	to	the	lung	during	influenza	virus	infection	(Chapman	
et	al.,	2005).	Although	this	phenomenon	has	not	been	observed	in	humans,	we	hypothesised	
that	vaccination	with	Ty21a	could	enhance	T-cell	responses	to	heterologous	antigens	at	the	
mucosal	surface	by	a	similar	mechanism.	
Through	the	direct	assessment	of	immunity	at	the	intestinal	mucosa,	it	may	be	possible	to	
identify	 mechanisms	 involved	 in	 the	 induction	 of	 protective	 immunity,	 which	 may	 be	
manipulated	 to	 improve	 oral	 vaccine	 immunogenicity.	 Here,	 we	 have	 assessed	 cellular	
immunity	in	vaccinated	volunteers	and	controls	at	the	duodenal	and	colonic	mucosa	and	in	
peripheral	blood	after	18	days.	We	have	compared	and	correlated	peripheral	and	mucosal	
cellular	responses	with	peripheral	humoral	measures	of	vaccine	efficacy,	providing	a	unique	
insight	into	the	relationship	between	human	mucosal	and	peripheral	immune	defence.	
3.1.1. Hypotheses	
We	hypothesised	that:	
• Responses	at	the	intestinal	mucosa	would	be	stronger	than	those	in	peripheral	
blood	
• Responses	would	be	observed	at	the	intestinal	mucosa	which	were	not	apparent	
in	peripheral	blood	 	
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3.2. Methods	
Full	details	of	the	methods	used	to	produce	the	data	which	are	presented	within	this	chapter	
can	be	found	in	Chapter	2.	Some	data	which	are	pertinent	to	this	chapter	are	included	for	
ease	of	reference.	
3.2.1. Ethical	approval	and	recruitment	
Full	details	can	be	found	in	section	2.1.	The	following	is	a	table	of	volunteer	demographics:	
Table	3.1.	Chapter	3	volunteer	demographics	
Group	 n	 Gender	(M:F)	
Control	 12	 3:9	
Vaccine	 11	 6:5	
	
3.2.1. Vaccination	
Full	details	can	be	found	in	section	2.3.	
3.2.2. Clinical	sampling	
Full	 details	 of	 venesection	 and	 endoscopy	 can	 be	 found	 in	 sections	 2.4.2	 and	 2.4.3,	
respectively.	
3.2.3. Serum	isolation	
Full	details	can	be	found	in	section	2.5.4.	
3.2.4. ELISA	
Full	details	of	ELISAs	specific	for	LPS	and	influenza-virus	can	be	found	in	sections	2.5.12	and	
2.5.13,	respectively.	
3.2.5. PBMC	isolation	
Full	details	can	be	found	in	section	2.5.5.	
CHAPTER	2	
72	
3.2.6. MMC	isolation	
Full	details	can	be	found	in	section	2.5.7.	
3.2.7. Ex	vivo	cell	stimulation	and	staining	
Full	details	of	the	antigens	used	for	stimulation	can	be	found	in	section	2.5.9.	Antigens	used	
in	the	chapter	include:	
Table	3.2.	Antigens	used	for	in	vitro	stimulation	
Description	 Preparation	of	stimuli	
Negative	control	 100	µL	complete	medium	
Heat-killed	Ty21a	(Vivotif)	 100	µL	complete	medium	containing	1	×	10
6	CFU	heat-
killed	Ty21a	
Subunit	Influenza	(Influvac)	
100	µL	complete	medium	containing	45	ng	
hemagglutinin	and	neuraminidase	from,	in	equal	
quantities,	a	A/Brisbane/59/2007	H1N1-like	strain,	a	
A/Brisbane/10/2007	H3N2-like	strain	and	a	
B/Brisbane/60/2008-like	strain	
SEB	 100	µL	complete	medium	containing	100	ng	SEB	
	
Full	details	of	the	stimulation	and	staining	protocol	can	be	found	in	section	2.5.10.	Antibodies	
used	in	this	chapter	include:	
Table	3.3.	Dyes	and	antibodies	used	for	analysis	of	intracellular	cytokine	production	
	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 Pacific	Blue	 LifeTechnologies	 1	µL	
Extracellular	
CD3	 HIT3a	 APC	 BD	Biosciences	 10	µL	
CD4	 SK3	 APC/Cy7	 BD	Biosciences	 5	µL	
CD8	 RPA-T8s	 PE/Cy7	 BD	Biosciences	 1	µL	
Integrinβ7	 FIB504	 PE/Cy5	 BD	Biosciences	 2	µL	
CD14	 M5E2	 HorizonV450	 BD	Biosciences	 2	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 2	µL	
Intracellular	
IFN-γ	 B27	 AF700	 BD	Biosciences	 1	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2.5	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 10	µL	
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3.2.8. Flow	cytometric	acquisition	and	analyses	
Full	details	can	be	found	in	section	2.5.11.	
3.2.9. Data	management	and	statistical	analysis	
Full	details	can	be	found	in	section	2.6.		 	
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3.3. Results	
3.3.1. Serum	immunoglobulin	specificity	
Ty21a-mediated	protection	is	dependent	upon	the	expression	of	LPS	(Germanier	and	Fuer,	
1975),	and,	in	field	trials,	humoral	responses	to	LPS	were	shown	to	correlate	with	vaccine	
efficacy	(Levine	et	al.,	1989).	We	compared	levels	of	serum	anti-LPS	IgG	and	IgA	prior	to	and	
following	vaccination.	We	also	measured	 levels	of	serum	IgG	and	 IgA	specific	to	 influenza	
virus,	a	 common	naturally	encountered	pathogen,	 to	assess	 the	 impact	of	vaccination	on	
humoral	 immunity	 to	 a	 heterologous	 pathogen.	 Influenza	 virus	 was	 selected	 since	 the	
majority,	if	not	all,	volunteers	would	have	been	exposed	to	this	pathogen	in	the	community.	
While	 levels	 of	 anti-LPS	 serum	 IgG	 and	 IgA	 among	 unvaccinated	 volunteers	 were	 not	
different	between	day	18	and	day	0,	among	the	vaccinated	levels	of	anti-LPS	serum	IgG	were	
3-fold	higher	and	levels	of	levels	of	anti-LPS	serum	IgG	were	also	3	-fold	higher	at	day	18	than	
at	day	0	(P	=	.03	and	P	=	.01;	Figure	3.1A).	Levels	of	anti-influenza	serum	IgG	or	IgA	among	
the	unvaccinated	and	the	vaccinated	volunteers	were	not	different	between	day	18	and	day	
0	(Figure	3.1B).	
		
	
Figure	3.1.	Levels	of	serum	immunoglobulin	(Ig)G	and	IgA	to	Salmonella	Typhi	lipopolysaccharide	(LPS)	and	influenza	virus	
The	levels	of	IgG	and	IgA	specific	to	Salmonella	Typhi	LPS	(A)	and	influenza	virus	(B)	in	serum,	expressed	in	arbitrary	units	(AU).	For	control	(C;	closed	squares	and	circles	[LPS	n	=	12,	Influenza	n	=	12])	and	vaccinated	
(V;	open	squares	and	circles	[LPS	n	=	11,	Influenza	n	=	11])	volunteers,	paired	comparisons	were	made	between	day	0	and	day	18	values.	Horizontal	bars	represent	mean	values	(paired	t	tests	were	performed	using	
logarithmically	transformed	data).	Abbreviation:	ns,	not	significant.	
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3.3.2. Peripheral	blood	and	gut	mucosal	cellular	responses	
We	 compared	 the	 frequency	 of	 Ty21a-responsive	 T	 cells	 in	 vaccinated	 volunteers	 and	
controls,	at	the	duodenal	and	colonic	mucosa	and	in	peripheral	blood.	We	also	measured	the	
frequency	of	influenza	virus-responsive	T	cells.	A	combinatorial	gating	strategy	was	used	to	
identify	the	proportion	of	CD4+	and	CD8+	T	cells	positive	for	any	combination	of	IFN-γ,	TNF-
α,	and/or	IL-2	(Figure	3.2).	Cytokine	production	in	non-stimulated	samples	(negative	control)	
was	 minimal,	 did	 not	 differ	 between	 vaccinated	 and	 unvaccinated	 volunteers	 and	 was	
subsequently	 subtracted	 from	 other	 conditions.	 Cytokine	 production	 in	 SEB–stimulated	
samples	(positive	control)	was	high	and	did	not	differ	between	vaccinated	and	unvaccinated	
volunteers.	
		
	
Figure	3.2	(A).	Representative	flow	cytometric	gating	
strategy	for	intracellular	cytokine	analysis	
Dot	 plots	 are	 shown	 for	 cells	 isolated	 from	 the	 duodenal	
mucosa.	Dead	cells,	B	cells	and	monocytes	were	removed	by	
staining	for	viability	(LIVE/DEAD),	CD19	and	CD14	and	gating	
on	the	negative	population.	T	cells	were	identified	according	
to	the	expression	of	CD3.	T	cells	were	classified	according	to	
the	 expression	 of	 CD4	 and	 CD8	 and	 the	 expression	 of	
interferon	γ	 (IFN-γ),	 tumor	necrosis	 factor	α	 (TNF-α),	and/or	
interleukin	 2	 (IL-2)	 assessed	 in	 non-stimulated	 and	 in	 live-
attenuated	Salmonella	 Typhi	strain	Ty21a	(Ty21a)-,	 influenza	
virus-	 and	 staphylococcal	 enterotoxin	 B	 (SEB)-stimulated	
samples.	 The	 expression	 intensity	 of	 integrin	 β7	 was	 also	
assessed.	
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Figure	3.2	(B).	Representative	flow	cytometric	gating	
strategy	for	intracellular	cytokine	analysis	
Dot	plots	are	shown	for	cells	 isolated	from	peripheral	blood.	
Dead	cells,	B	cells	and	monocytes	were	removed	by	staining	
for	 viability	 (LIVE/DEAD),	 CD19	 and	 CD14	 and	 gating	 on	 the	
negative	population.	T	cells	were	identified	according	to	the	
expression	 of	 CD3.	 T	 cells	 were	 classified	 according	 to	 the	
expression	of	CD4	and	CD8	and	the	expression	of	interferon	γ	
(IFN-γ),	tumor	necrosis	factor	α	(TNF-α),	and/or	interleukin	2	
(IL-2)	 assessed	 in	 non-stimulated	 and	 in	 live-attenuated	
Salmonella	 Typhi	 strain	 Ty21a	 (Ty21a)-,	 influenza	 virus-	 and	
staphylococcal	 enterotoxin	 B	 (SEB)-stimulated	 samples.	 The	
expression	intensity	of	integrin	β7	was	also	assessed.	
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At	day	0,	in	peripheral	blood,	the	frequency	of	Ty21a-responsive	and	heterologous	influenza	
virus-responsive	CD4+	and	CD8+	T	cells	in	the	vaccinated	group	was	not	different	from	the	
frequency	 in	 the	unvaccinated	control	group	 (Figure	3.3).	These	data	suggest	 that	groups	
were	well	matched	for	prior	exposure	to	Ty21a	and	 influenza	virus	antigens	and	that	any	
differences	observed	thereafter	may	be	attributed	to	an	effect	of	vaccination	with	Ty21a.	
Paired	 comparisons	 between	 day	 0	 and	 day	 18	 were	 not	 made	 in	 peripheral	 blood,	 as	
overnight	fasting,	required	prior	to	endoscopy,	is	known	to	influence	cytokine	production	in	
response	to	re-stimulation	with	bacterial	and	viral	antigens	(van	den	Brink	et	al.,	2002).	
	
Figure	3.3.	Antigen-specific	cytokine-producing	populations	at	day	0	
The	frequency	of	CD4+	and	CD8+	live-attenuated	Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	heterologous	influenza	
virus-responsive	populations	expressing	any	combination	of	interferon	γ,	tumor	necrosis	factor	α,	and/or	interleukin	2	above	
background.	Staphylococcal	enterotoxin	B	(SEB)-stimulated	control	data	are	also	included.	For	control	(C;	closed	squares,	circles	
and	triangles	[Ty21a	n	=	11,	Influenza	n	=	10,	SEB	n	=	9])	and	vaccinated	(V;	open	squares,	circles	and	triangles	[Ty21a	n	=	11,	
Influenza	n	=	11,	SEB	n	=	11])	volunteers,	measurements	were	made	in	peripheral	blood.	Horizontal	bars	represent	mean	values	
(comparisons	were	made	using	unpaired	t	tests).	Abbreviation:	ns,	not	significant.	
	
At	day	18,	at	the	duodenal	mucosa,	the	frequency	of	Ty21a-responsive	CD4+	T	cells	was	3-
fold	higher	and	the	frequency	of	Ty21a-responsive	CD8+	T	cells	5-fold	higher	in	vaccinated	
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volunteers,	compared	with	unvaccinated	volunteers	(P	=	.007	and	P	=	<.0001,	respectively;	
Figure	3.4A).	The	frequency	of	heterologous	influenza	virus-responsive	CD4+	T	cells	was	5-
fold	higher	and	the	frequency	of	heterologous	influenza	virus-responsive	CD8+	T	cells	6-fold	
higher	in	vaccinated	volunteers,	compared	with	unvaccinated	volunteers	(P	=	.005	and	P	=	
.01,	 respectively;	 Figure	3.4A).	At	 the	colonic	mucosa,	 there	was	no	 significant	difference	
between	the	frequencies	of	Ty21a-responsive	or	heterologous	influenza	virus-responsive	T	
cells	in	vaccinated	volunteers,	compared	with	unvaccinated	volunteers	(Figure	3.4B).	
In	 peripheral	 blood,	 the	 frequency	 of	 Ty21a-responsive	 CD4+	 T	 cells	was	 4-fold	 higher	 in	
vaccinated	 volunteers,	 compared	 with	 unvaccinated	 volunteers	 (P	 =	 .019;	 Figure	 3.4C).	
Vaccination	did	not	influence	the	frequency	of	peripheral	Ty21a-responsive	CD8+	T	cells,	nor	
the	frequency	of	heterologous	influenza	virus-responsive	CD4+	or	CD8+	T	cells	at	day	18.	
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Figure	3.4.	Antigen-specific	cytokine-producing	populations	at	day	18	
The	frequency	of	CD4+	and	CD8+	live-attenuated	Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	heterologous	influenza	
virus–responsive	populations	expressing	any	combination	of	interferon	γ,	tumor	necrosis	factor	α,	and/or	interleukin	2	above	
background.	Staphylococcal	enterotoxin	B	(SEB)-stimulated	control	data	are	also	included.	For	control	(C;	closed	squares,	circles	
and	triangles	[duodenal	mucosa;	Ty21a	n	=	12,	Influenza	n	=	12,	SEB	n	=	12]	[colonic	mucosa;	Ty21a	n	=	9,	Influenza	n	=	9,	SEB	
n	=	8]	[peripheral	blood;	Ty21a	n	=	12,	 Influenza	n	=	12,	SEB	n	=	12])	and	vaccinated	(V;	open	squares,	circles	and	triangles	
[duodenal	mucosa;	Ty21a	n	=	8,	Influenza	n	=	7,	SEB	n	=	7]	[colonic	mucosa;	Ty21a	n	=	8,	Influenza	n	=	7,	SEB	n	=	7]	[peripheral	
blood;	Ty21a	n	=	9,	Influenza	n	=	9,	SEB	n	=	9])	volunteers,	measurements	were	made	at	the	duodenal	mucosa	(A),	the	colonic	
mucosa	(B)	and	in	peripheral	blood	(C).	Horizontal	bars	represent	mean	values	(comparisons	were	made	using	unpaired	t	tests).	
Abbreviation:	ns,	not	significant.	
	
3.3.3. Characteristics	and	functionality	of	cellular	responses	
Polyfunctional	T	cells,	defined	as	cells	that	express	multiple	cytokines	simultaneously,	have	
been	 shown	 to	 correlate	 with	 vaccine-mediated	 protection	 against	 other	 intracellular	
infections	 (Darrah	 et	 al.,	 2007,	 Kannanganat	 et	 al.,	 2007).	 We	 compared	 the	 cytokine	
expression	profile	of	vaccinated	volunteers	with	that	of	unvaccinated	volunteers	to	assess	
the	functionality	of	responses	to	Ty21a	and	influenza	virus	antigens.	
At	the	duodenal	mucosa,	the	CD4+	T-cell	response	to	Ty21a	was	functionally	heterogeneous,	
with	the	frequency	of	cells	expressing	one,	two,	or	three	cytokines	being	higher	in	vaccinated	
volunteers,	 compared	 with	 unvaccinated	 volunteers	 (P=.006,	 P	 =	 .018	 and	 P	 =	 .031,	
respectively;	 Figure	 3.5A).	 The	 duodenal	 CD8+	 T-cell	 response	 to	 Ty21a	 antigens	 was,	 in	
contrast,	 largely	attributable	to	cells	expressing	just	one	cytokine	(P	=	.0004;	Figure	3.5A).	
Duodenal	CD4+	and	CD8+	T-cell	responses	to	influenza	virus	antigens	were	also	functionally	
heterogeneous,	with	 the	 frequency	of	cells	expressing	one,	 two,	or	 three	cytokines	being	
higher	in	vaccinated	volunteers,	compared	with	unvaccinated	volunteers	(CD4+	T	cells,	P	=	
.008,	P	=	.005	and	P	=	.005,	respectively;	CD8+	T	cells,	P	=	.0008,	P	=	.010	and	P	=	.011;	Figure	
3.5B).	
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In	 peripheral	 blood,	 the	 CD4+	 T-cell	 response	 to	 Ty21a	 antigens	 was	 functionally	
heterogeneous,	with	 the	 frequency	of	cells	expressing	one,	 two,	or	 three	cytokines	being	
higher	in	vaccinated	volunteers,	compared	with	unvaccinated	volunteers	(P	=	.026,	P	=	.028	
and	P	=	.008,	respectively;	Figure	3.5C).	Analysis	of	expression	profiles	by	individual	cytokine	
demonstrated	that	responses	to	Ty21a	and	influenza	virus	antigens	were	attributable	to	cells	
producing	 combinations	of	 IFN-γ,	 TNF-α	and	 IL-2	but	 that	no	one	 cytokine	predominated	
(Figure	3.6).	
		
Figure	 3.5.	 Combinations	 of	 antigen-specific	
cytokine	production	at	day	18	
The	 frequency	 of	 CD4+	 and	 CD8+	 live-attenuated	
Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	
heterologous	 influenza	 virus-responsive	 populations	
expressing	one	(+),	two	(++),	or	three	(+++)	cytokines	
(interferon	 γ,	 tumor	 necrosis	 factor	 α,	 and/or	
interleukin	2)	above	background.	For	control	(C;	closed	
squares	and	circles	[duodenal	mucosa;	Ty21a	n	=	12,	
Influenza	 n	 =	 12]	 [peripheral	 blood;	 Ty21a	 n	 =	 12,	
Influenza	n	=	12])	and	vaccinated	(V;	open	squares	and	
circles	[duodenal	mucosa;	Ty21a	n	=	8,	Influenza	n	=	7]	
[peripheral	 blood;	 Ty21a	 n	 =	 9,	 Influenza	 n	 =	 9])	
volunteers,	measurements	were	made	at	the	duodenal	
mucosa	(A	and	B)	and	in	peripheral	blood	(C	and	D).	
Horizontal	 bars	 represent	mean	values	 (comparisons	
were	made	using	unpaired	 t	 tests).	Abbreviation:	 ns,	
not	significant.	
CH
AP
TE
R	
2	
84
	
		
Figure	 3.6.	 Antigen-specific	 production	 of	
individual	cytokines	at	day	18	
The	 frequency	 of	 CD4+	 and	 CD8+	 live-attenuated	
Salmonella	Typhi	strain	Ty21a	(Ty21a)-responsive	and	
heterologous	 influenza	 virus-responsive	 populations	
expressing	IFN-γ,	TNF-α,	or	IL-2	above	background.	For	
control	 (C;	 closed	 squares	 and	 circles	 [duodenal	
mucosa;	 Ty21a	 n	 =	 12,	 Influenza	 n	 =	 12]	 [peripheral	
blood;	Ty21a	n	=	12,	Influenza	n	=	12])	and	vaccinated	
(V;	open	squares	and	circles	[duodenal	mucosa;	Ty21a	
n	=	8,	Influenza	n	=	7]	[peripheral	blood;	Ty21a	n	=	9,	
Influenza	 n	 =	 9])	 volunteers,	 measurements	 were	
made	 at	 the	 duodenal	 mucosa	 (A	 and	 B)	 and	 in	
peripheral	blood	(C	and	D).	Horizontal	bars	represent	
mean	values.	
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3.3.4. Correlations	 between	 cellular	 populations	 at	 the	 duodenal	
mucosa	
We	explored	the	relationship	between	the	generation	of	Ty21a-responsive	and	heterologous	
influenza	 virus-responsive	 T	 cells	 at	 the	 duodenal	 mucosa.	 The	 frequencies	 of	 Ty21a-
responsive	CD4+	and	CD8+	T	cells	were	correlated	(r2	=	0.537	and	P	=	.015;	Table	3.4),	as	were	
the	frequencies	of	heterologous	influenza	virus-responsive	CD4+	and	CD8+	T	cells	(r2	=	0.930	
and	P	=	<.0001;	Table	1).	The	 frequencies	of	Ty21a-responsive	CD4+	and	CD8+	T	cells	also	
correlated	robustly	with	the	frequencies	of	corresponding	influenza	virus-responsive	T	cells	
(CD4+	T	cells,	r2	=	0.74	and	P	=	.0003;	CD8+	T	cells,	r2	=	0.677	and	P	=	.001;	Table	3.4).	
3.3.5. Correlations	between	peripheral	and	mucosal	immunity	
We	explored	the	relationship	between	the	generation	of	peripheral	and	duodenal	immune	
responses.	 The	 frequency	 of	 peripheral	 Ty21a-responsive	 CD4+	 T	 cells	 was	 modestly	
correlated	with	the	frequency	of	duodenal	Ty21a-responsive	CD4+	T	cells	(r2	=	0.530	and	P	=	
.024;	Table	3.4)	but	not	with	the	 frequency	of	duodenal	Ty21a-responsive	CD8+	T	cells	or	
with	the	frequency	of	heterologous	influenza	virus-responsive	CD4+	and	CD8+	T	cells.	Levels	
of	serum	anti-LPS	IgG	and	IgA	correlated	with	the	frequency	of	duodenal	Ty21a-responsive	
CD4+	T	cells	(IgG,	r2	=	0.542	and	P	=	.014;	IgA,	r2	=	0.710	and	P	=	.0004;	Table	3.4).	Levels	of	
serum	 IgA	 specific	 to	 LPS	 also	 correlated	 with	 the	 frequency	 of	 duodenal	 heterologous	
influenza	virus-responsive	CD4+	and	CD8+	T	cells	(CD4+	T	cells,	r2	=	0.512	and	P	=	.025;	CD8+	T	
cells,	r2	=	0.585	and	P	=	.008;	Table	3.4).	Levels	of	anti-influenza	virus	IgG	and	IgA	did	not,	
however,	correlate	with	either	the	frequency	of	Ty21a-responsive	or	heterologous	influenza	
virus-responsive	T	cells	at	the	duodenal	mucosa	in	either	subset.		
		
Table	3.4.	Pearson	correlation	analysis	of	cellular	and	humoral	immune	responses	
	 DUODENAL	MUCOSA	 PERIPHERAL	BLOOD	 SERUM	
Ty21a	 Influenza	 Ty21a	 Influenza	 S.	Typhi	LPS	 Influenza	
CD4+	 CD8+	 CD4+	 CD8+	 CD4+	 CD8+	 CD4+	 CD8+	 IgG	 IgA	 IgG	 IgA	
DU
O
DE
NA
L	M
UC
O
SA
	
Ty21a	
CD4+	 1	 0.537	*	
0.741	
**	
0.724	
**	
0.530	
*	
0.319	
NS	
-0.102	
NS	
-0.223	
NS	
0.542	
*	
0.710	
*	
0.160	
NS	
0.008	
NS	
CD8+	 	 1	 0.587	**	
0.677	
**	
0.395	
NS	
0.126	
NS	
-0.117	
NS	
-0.232	
NS	
0.315	
NS	
0.396	
NS	
0.177	
NS	
-0.348	
NS	
Influenza	
CD4+	 	 	 1	 0.929	**	
0.327	
NS	
0.299	
NS	
-0.025	
NS	
-0.122	
NS	
0.392	
NS	
0.512	
*	
-0.245	
NS	
-0.228	
NS	
CD8+	 	 	 	 1	 0.394	NS	
0.515	
NS	
0.099	 0.080	 0.392	 0.585	
**	
-0.149	
NS	
-0.300	
NS	NS	 NS	 NS	
Abbreviation:	ns,	non-significant;	*P	<.05;	**P	<.001
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3.3.6. Cellular	potential	for	mucosal	homing	and	residence		
Integrin	 β7	 plays	 a	 prominent	 role	 in	 mucosal	 cellular	 immune	 defence;	 α4β7	 facilitates	
peripheral	 trafficking	 to	 the	 intestinal	 mucosa	 and	 αεβ7	 helps	 maintain	 resident	
intraepithelial	 lymphocyte	 populations	 (Berlin	 et	 al.,	 1993,	 Cepek	 et	 al.,	 1994).	 Since	
duodenal	CD4+	and	CD8+	T-cell	responses	to	Ty21a	and	influenza	virus	antigens	were	closely	
correlated,	we	assessed	the	cellular	capacity	for	mucosal	homing	and	residence,	which	is	a	
potential	mechanism	 by	 which	 Ty21a	 vaccination	may	 have	 influenced	 trafficking	 to	 the	
duodenal	mucosa.	We	assessed	integrin	β7	expression	intensity,	a	component	of	both	α4β7	
in	peripheral	blood	and	αεβ7	at	the	duodenal	mucosa.	A	combinatorial	gating	strategy	was	
used	to	determine	the	level	of	integrin	β7	expression	among	CD4+	and	CD8+	T-cell	populations	
(Figure	3.2).		
At	the	duodenal	mucosa,	integrin	β7	expression	was	more	intense	among	the	total	CD4+	T-
cell	population	than	among	the	total	CD8+	T-cell	population	(P	=	<.0001;	Figure	3.7A).	Integrin	
β7	expression	intensity	among	Ty21a-responsive	and	influenza	virus-responsive	CD4+	T-cell	
subpopulations	was	not	different	from	that	among	the	total	mucosal	CD4+	T-cell	population.	
In	 contrast,	 integrin	 β7	 expression	 intensity	 among	 Ty21a-responsive	 and	 influenza	 virus-
responsive	CD8+	T-cell	subpopulations	was	greater	than	that	among	the	total	mucosal	CD8+	
T-cell	population	(P	=	.0002	and	P	=	<.0001,	respectively;	Figure	3.7A).	
In	contrast	with	observations	made	at	the	duodenal	mucosa,	integrin	β7	expression	was	more	
intense	among	the	total	CD8+	T-cell	population	than	among	the	total	CD4+	T-cell	population	
in	peripheral	blood	(P	=	.0005;	Figure	3.7B).	While	integrin	β7	expression	intensity	among	the	
Ty21a-responsive	CD4+	T-cell	subpopulation	was	greater	than	that	among	the	total	CD4+	T-
cell	 population	 (P	 =	 .002;	 Figure	 3.7B),	 expression	 intensity	 among	 the	 influenza	 virus-
responsive	CD4+	T-cell	subpopulation	was	not	different	from	that	among	the	total	CD4+	T-
cell	 population.	 Integrin	 β7	 expression	 intensity	 among	 the	 Ty21a-responsive	 and	
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heterologous	 influenza	virus-responsive	CD8+	T-cell	 subpopulations	was	greater	 than	 that	
among	the	total	CD8+	T-cell	population	(P	=	.004	and	P	=	.041,	respectively;	Figure	3.7B).	
		
	
Figure	3.7.	Integrin	β7	expression	intensity	among	T-cell	populations	at	day	18	
Geometric	mean	fluorescence	intensity	(MFI)	expression	of	integrin	β7	among	non-stimulated	total	CD4+	and	total	CD8+	T-cell	populations	(control	volunteers,	closed	diamonds	[duodenal	mucosa;	n	=	7]	[peripheral	
blood;	n	=	7];	vaccinated	volunteers,	open	diamonds	[duodenal	mucosa;	n	=	6]	[peripheral	blood;	n	=	6])	and	in	live-attenuated	Salmonella	Typhi	strain	Ty21a	(Ty21a)-stimulated	(control	volunteers,	closed	squares;	
vaccinated	volunteers	[duodenal	mucosa;	n	=	7]	[peripheral	blood;	n	=	7],	open	squares	[duodenal	mucosa;	n	=	6]	[peripheral	blood;	n	=	6])	and	heterologous	influenza	virus-stimulated	(control	volunteers,	closed	
circles	[duodenal	mucosa;	n	=	7]	[peripheral	blood;	n	=	7];	vaccinated	volunteers,	open	circles	[duodenal	mucosa;	n	=	6]	[peripheral	blood;	n	=	6])	cytokine-producing	subpopulations.	Measurements	were	made	at	the	
duodenal	mucosa	(A)	and	in	peripheral	blood	(B).	Horizontal	bars	represent	mean	values	(comparisons	were	made	using	unpaired	t	tests).	Abbreviation:	ns,	not	significant.	
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3.4. Discussion	
We	have	described,	for	the	first	time,	the	cellular	response	to	oral	vaccination	with	Ty21a	at	
the	 human	 intestinal	 mucosa.	 We	 demonstrate	 that	 Ty21a	 vaccination	 generates	 both	
polyfunctional	Ty21a-responsive	and	heterologous	influenza	virus-responsive	T	cells	at	the	
duodenal	mucosa.	The	frequency	of	Ty21a-responsive	and	influenza	virus-responsive	T	cells	
at	the	duodenal	mucosa	were	robustly	and	consistently	correlated.	In	contrast,	cellular	and	
humoral	measurements	made	in	peripheral	blood	were	poorly	correlated	with	one	another	
and	did	not	provide	 insight	 into	the	 induction	of	heterologous	responses	at	 the	duodenal	
mucosa.	
While	robust	Ty21a	and	heterologous	influenza	virus-responsive	CD4+	and	CD8+	T	cells	were	
observed	at	the	duodenal	mucosa,	no	cellular	response	was	observed	at	the	colonic	mucosa	
to	 either	 antigen	 in	 either	 T-cell	 subset.	 This	 suggests	 that	 duodenal	 responses	 were	
compartmentalised	 to	 the	 embryological	midgut,	 which	 includes	 the	 terminal	 ileum,	 the	
likely	 site	 of	 active	 invasion	 by	 Ty21a	 (Parry	 et	 al.,	 2002).	 Interestingly,	 the	 frequency	 of	
Ty21a-responsive	CD4+	and	CD8+	T	cells	correlated	robustly	with	one	another	and	with	the	
frequency	of	heterologous	influenza	virus-responsive	CD4+	and	CD8+	T	cells	at	the	duodenal	
mucosa.	This	suggests	that	the	mechanisms	responsible	for	the	generation	of	these	mucosal	
responses	 were	 localised	 and	 capable	 of	 influencing	 T	 cells	 of	 different	 phenotypes	 and	
specificities.	
Polyfunctionality	among	Ty21a-responsive	T	cells	at	the	duodenal	mucosa	and	in	peripheral	
blood	may	point	toward	an	important	mechanism	through	which	Ty21a	confers	protection	
against	disease	(Darrah	et	al.,	2007,	Kannanganat	et	al.,	2007).	Further,	the	generation	of	
anti-LPS	 immunoglobulin,	 an	 indication	 of	 vaccine	 efficacy,	 was	 closely	 associated	 with	
cellular	responses	at	the	duodenal	mucosa,	suggesting	that	mucosal	cellular	activity	may	be	
associated	with	the	generation	of	protective	immunity.	
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In	murine	models,	influenza	virus	infection	results	in	the	recruitment	of	previously	primed	
heterologous	T	cells	to	the	lung	(Chapman	et	al.,	2005).	We	propose	that	a	similar	mechanism	
was	 responsible	 for	 the	 generation	 of	 heterologous	 responses	 at	 the	 duodenal	 mucosa.	
Although	only	2	individuals	had	previously	been	vaccinated	against	influenza,	all	were	likely	
to	have	been	exposed	to	this	mucosal	pathogen	in	the	community	–	indeed,	at	baseline,	anti-
influenza	virus	IgG	and	IgA,	as	well	as	influenza	virus-responsive	CD4+	T	cells,	were	detected	
in	all	volunteers,	not	just	those	who	had	been	previously	vaccinated	against	influenza.	
Trafficking	to	the	mucosa	is	 largely	dependent	upon	the	expression	of	α4β7	and	its	 ligand,	
MAdCAM-1,	as	well	as	CCR9	and	its	ligand,	CCL25	(Mavigner	et	al.,	2012).	We	hypothesize	
that	vaccination	with	Ty21a	upregulated	the	expression	of	mucosal	homing	ligands	resulting	
in	the	nonspecific	migration	of	previously	primed	heterologous	influenza	virus-responsive	T	
cells,	carrying	mucosal	homing	receptors,	to	the	duodenal	mucosa.	This	effect	may	or	may	
not	be	restricted	to	influenza	virus-responsive	T-cell	subsets	and	further	study	is	warranted.	
We	observed	that	integrin	β7	expression	intensity	was	generally	higher	among	both	Ty21a-
responsive	 and	 influenza	 virus-responsive	 cells,	 compared	 with	 total	 cell	 populations,	 in	
peripheral	blood	and	at	the	intestinal	mucosa.	Multiphasic	peripheral	CD8+	T-cell	responses	
have	 previously	 been	 described	 and	 attributed	 to	 the	 trafficking	 of	 immune	 cells	 from	
peripheral	blood	to	the	mucosa	(Salerno-Goncalves	et	al.,	2010,	McArthur	and	Sztein,	2012).	
In	 keeping	 with	 this,	 integrin	 β7	 expression	 among	 peripheral	 CD8+	 T	 cells,	 particularly	
antigen-specific	subpopulations,	was	more	intense	than	that	among	peripheral	CD4+	T	cells.	
Integrin	β7	expression	among	CD4+	T-cell	subsets	was	highly	polarised,	being	relatively	low	
among	 peripheral	 subsets	 and	 high	 among	 duodenal	 subsets.	 Differential	 integrin	 β7	
expression	among	antigen-specific	CD4+	T-cell	populations	may	ensure	that	some	peripheral	
T	 cells	 persist	 in	 blood	 and	 avoid	 sequestration.	We	 and	 others	 have	 demonstrated	 the	
presence	of	intracellular	intravascular	and	bone-marrow	bacteria	in	early,	late	and	recurrent	
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invasive	 Salmonella	 disease	 (Wain	 et	 al.,	 1998,	 Gordon	 et	 al.,	 2010).	 Thus,	 while	 T	 cells	
trafficking	to	the	mucosa	likely	play	a	key	role	in	the	early	response	to	invasion,	CD4+	T-cell	
populations	that	persist	in	peripheral	blood	may	help	to	prevent	intravascular	dissemination	
and	persistence	at	secondary	systemic	sites	of	infection.	
Prior	to	vaccination,	all	volunteers	had	detectable	baseline	levels	of	serum	immunoglobulin	
specific	to	S.	Typhi	LPS.	This	may	be	caused	by	immunoglobulin	binding	to	the	core	or	a	result	
of	environmental	exposure	to	non-typhoidal	strains	bearing	the	same	LPS	O-antigens	as	S.	
Typhi	(O-9	and	O-12);	S.	enterica	serovar	Enteritidis	expresses	both	O-9	and	O-12	antigens	
and	S.	enterica	serovar	Typhimurium	expresses	the	O-12	antigen	(Kantele	et	al.,	2012).	Not	
all	vaccinated	volunteers	generated	peripheral	humoral	anti-LPS	responses,	which	is	likely	a	
reflection	of	the	limited	efficacy	of	this	vaccine	(Anwar	et	al.,	2014).	It	was	interesting	that	
mucosal	 cellular	 responses	 correlated	 strongly	 with	 serum	 anti-LPS	 immunoglobulin	
responses,	as	humoral	responses	to	LPS	have	been	associated	with	vaccine	efficacy	(Levine	
et	al.,	1989).	This	suggests	that,	in	individuals	in	whom	Ty21a	vaccination	is	not	efficacious,	
the	failure	encompasses	both	cellular	and	humoral	mechanisms	of	defence.	It	has	previously	
been	 demonstrated	 that	 the	 generation	 of	 immunoglobulin	 following	 oral	 vaccination	 is	
dependent	upon	α4β7	(Wyant	et	al.,	2015).	Thus,	the	close	association	between	cellular	and	
humoral	 immune	 responses	 suggests	 that	 the	 strength	 of	 each	 volunteer’s	 cellular	 and	
humoral	 response	 to	 vaccination	 was	 influenced	 by	 a	 mucosal	 mechanism,	 possibly	 the	
expression	intensity	of	α4β7	and/or	MAdCAM-1	at	the	time	of	vaccination.		
It	is	possible	that,	through	TLR	engagement,	vaccination	may	have	non-specifically	activated	
mucosal	 antigen-presenting	 cells	 and	 T	 cells,	 resulting	 in	 enhanced	 cytokine	 production	
following	experimental	 re-stimulation	 (Lore	et	 al.,	 2003,	Caron	et	 al.,	 2005).	However,	 as	
background	 cytokine	 production	 in	 the	 negative	 control	 was	 minimal	 and	 as	 cytokine	
production	in	the	positive	control	was	not	different	in	the	vaccinated	volunteers	as	compared	
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to	 the	 unvaccinated	 volunteers,	 we	 believe	 this	 is	 unlikely	 to	 be	 the	 primary	 factor	
responsible	for	the	observed	heterologous	cellular	response.	Owing	to	the	invasive	nature	
of	endoscopic	biopsy,	we	were	limited	to	sampling	from	intestinal	sites	at	a	single	time	point.	
Data	 presented	 here	 and	 elsewhere	 (McArthur	 and	 Sztein,	 2012)	 indicate	 that	 the	
assessment	of	mucosal	immunity	at	alternate	time	points	could	provide	further	insight	into	
the	 generation	 of	 protective	 immune	 responses.	 We	 assessed	 the	 expression	 of	 just	 3	
cytokines	and,	as	a	result,	the	T-cell	populations	identified	here	are	unlikely	to	represent	the	
responsive	populations	in	their	entirety.	Variation	within	the	human	population	may	mean	
that	we	are	underpowered	to	observe	some	other	important	biological	effects.	 	
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3.5. Conclusion	
Taken	 together,	our	data	demonstrate	 that	oral	 vaccination	with	Ty21a	generates	Ty21a-
responsive	T	cells	as	well	as	heterologous	influenza	virus-responsive	T	cells	at	the	duodenal	
mucosa.	We	propose	that	heterologous	influenza	virus-responsive	T	cells	previously	primed	
through	 natural	 exposure	 were	 recruited	 to	 the	 duodenal	 mucosa	 through	
compartmentalised	upregulation	of	homing	ligands.	The	direct	evaluation	of	mucosal	cellular	
immune	defence	provides	the	opportunity	to	identify	functional	correlates	of	protection	and	
may	offer	new	insights	into	mechanisms	that	may	be	manipulated	to	improve	oral	vaccine	
immunogenicity,	either	through	the	development	of	oral	adjuvants	or	the	development	of	
multivalent	Salmonella	based	vectors.
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CHAPTER	4: THE	 ADAPTIVE	 IMMUNE	 RESPONSE	 TO	 TY21A	 AT	
APPROXIMATELY	1.5	YEARS	
	
4.1. Introduction	
Ty21a	is	able	to	induce	humoral	and	cellular	immune	responses,	both	of	which	have	been	
implicated	in	protection	against	disease.	The	peripheral	humoral	response	to	Ty21a	has	not	
previously	been	assessed	beyond	42	days	(Lundgren	et	al.,	2009);	however,	one	novel	live-
attenuated	 oral	 vaccine	 candidate,	 CVD	 909,	 has	 demonstrated	 the	 capacity	 to	 generate	
memory	 B	 cells	which	 persist	 for	 at	 least	 1	 year	 (Wahid	 et	 al.,	 2011).	 Peripheral	 cellular	
responses	targeting	soluble	S.	Typhi	 flagella	(FliC)	as	well	as	 infected	host	cells	have	been	
assessed	following	vaccination	with	Ty21a,	and	data	indicate	that	T	cells	can	persists	for	at	
least	2	years	post-vaccination	(Salerno-Goncalves	et	al.,	2002,	Salerno-Goncalves	et	al.,	2010,	
McArthur	and	Sztein,	2012).	Recently,	it	has	been	demonstrated	that	polyfunctional	CD8+	T	
cells	are	associated	with	protection	against	 typhoid	 fever	 (Fresnay	et	al.,	2016).	We	have	
previously	demonstrated	that	vaccination	with	Ty21a	generates	robust	CD4+	and	CD8+	T-cell	
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responses	at	the	duodenal	mucosa	at	day	18	(Pennington	et	al.,	2016);	however,	whether	
early	duodenal	responses	persist	in	the	long-term	has	yet	to	be	determined.	
An	 increased	 understanding	 of	 the	 longevity	 of	 immune	 responses	 both	 at	 the	 intestinal	
mucosa	and	 in	peripheral	blood	may	allow	us	 to	 identify	 functional	correlates	of	vaccine-
mediated	 protection,	 which	 are	 currently	 unknown.	 Here,	 we	 have	 assessed	 cellular	
immunity	 in	vaccinated	volunteers	at	 the	duodenal	mucosa	and	 in	peripheral	blood	after	
approximately	1.5	years	and	compared	responses	with	those	observed	in	a	control	group.	
We	have	compared	and	correlated	peripheral	and	mucosal	cellular	responses	with	peripheral	
levels	of	anti-LPS	IgG	and	IgA,	an	 indication	of	vaccine	efficacy,	providing	a	unique	 insight	
into	the	longevity	of	human	mucosal	and	peripheral	immune	defence.	
4.1.1. Hypotheses	
We	hypothesised	that:	
• Responses	 to	 Ty21a	 at	 the	 intestinal	 mucosa	 and	 in	 peripheral	 blood	 would	
persist	 	
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4.2. Methods	
Full	details	of	the	methods	used	to	produce	the	data	which	are	presented	within	this	chapter	
can	be	found	in	Chapter	2.	Some	data	which	are	pertinent	to	this	chapter	are	included	for	
ease	of	reference.	
4.2.1. Ethical	approval	and	recruitment	
Full	details	can	be	found	in	section	2.1.	The	following	is	a	table	of	volunteer	demographics:	
Table	4.1.	Chapter	4	volunteer	demographics	
Group	 n	 Gender	(M:F)	
Control	 10	 5:5	
Vaccine	 8	 3:5	
	
4.2.2. Vaccination	
Full	details	can	be	found	in	section	2.3.	
4.2.3. Clinical	sampling	
Full	 details	 of	 venesection	 and	 endoscopy	 can	 be	 found	 in	 sections	 2.4.2	 and	 2.4.3,	
respectively.	
4.2.4. Serum	isolation	
Full	details	can	be	found	in	section	2.5.4.	
4.2.5. ELISA	
Full	details	of	ELISAs	specific	for	LPS	can	be	found	in	section	2.5.12.	
4.2.6. PBMC	isolation	
Full	details	can	be	found	in	section	2.5.5.	
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4.2.7. MMC	isolation	
Full	details	can	be	found	in	section	2.5.7.	
4.2.8. Ex	vivo	cell	stimulation	and	staining	
Full	details	of	the	antigens	used	for	stimulation	can	be	found	in	section	2.5.9.	Antigens	used	
in	the	chapter	include:	
Table	4.2.	Antigens	used	for	in	vitro	stimulation	
Description	 Preparation	of	stimuli	
Negative	control	 100	µL	complete	medium	
Heat-killed	Ty21a	 100	µL	complete	medium	containing	1	×	10
6	CFU	heat-killed	
Ty21a	
Flagella	(FliC)	 100	µL	complete	medium	containing	5	µg	FliC	protein	
SEB	 100	µL	complete	medium	containing	100	ng	SEB	
	
Full	details	of	the	stimulation	and	staining	protocol	can	be	found	in	section	2.5.10.	Details	of	
the	dyes	and	antibodies	used	in	this	chapter:	
Table	4.3.	Dyes	and	antibodies	used	for	analysis	of	intracellular	cytokine	production	
	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 Pacific	Blue	 LifeTechnologies	 0.02	µL	
Extracellular	
CD3	 OCT3	 BV/510	 BioLegend	 1	µL	
CD4	 SK3	 PE/Cy7	 BD	Biosciences	 1	µL	
CD8	 SK1	 APC/H7	 BD	Biosciences	 1	µL	
CD14	 MφP9	 HorizonV450	 BD	Biosciences	 1	µL	
CD19	 HIB19	 HorizonV450	 BD	Biosciences	 1	µL	
Intracellular	
CD69	 FN50	 PE/CF594	 BD	Biosciences	 2	µL	
MIP-1β	 24006	 APC	 R&D	Systems	 2	µL	
IFN-γ	 B27	 AF700	 BD	Biosciences	 2	µL	
TNF-α	 MAb11	 AF488	 BD	Biosciences	 2	µL	
IL-2	 MQ1-17H12	 PE	 BD	Biosciences	 2	µL	
IL-17A	 eBio64DEC17	 PerCP/Cy5.5	 eBioscience	 2	µL	
	
4.2.9. Flow	cytometric	acquisition	and	analyses	
Full	details	can	be	found	in	section	2.5.11.	A	BD	LSR	II	was	used	for	the	acquisition	of	data.	
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4.2.10. Data	management	and	statistical	analysis	
Full	details	can	be	found	in	section	2.6.	 	
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4.3. Results	
4.3.1. Recruitment	and	sampling	
Volunteers	who	had	previously	been	vaccinated	as	part	of	past	 studies	were	 recalled	 for	
sampling.	 The	 period	 between	 vaccination	 and	 sampling	 varied,	 with	 the	median	 period	
between	vaccination	and	sampling	at	1.5	years	(Table	4.4).	
Table	4.4.	Volunteer	vaccination	and	sampling	information	
Study	Number	 Time	from	Vaccination	to	Sampling	Days	 Years	 Median	(Years)	
4539/02	 599	 1.6	
1.5	
4539/03	 515	 1.4	
4539/05	 522	 1.4	
4539/07	 412	 1.1	
4539/09	 550	 1.5	
4539/12	 585	 1.6	
4539/13	 550	 1.5	
4539/14	 1,350	 3.7	
	
4.3.2. Serum	immunoglobulin	specificity	
Ty21a-mediated	protection	is	dependent	upon	the	expression	of	LPS	(Germanier	and	Fuer,	
1975)	and,	 in	 field	trials,	humoral	 responses	to	LPS	were	shown	to	correlate	with	vaccine	
efficacy	(Levine	et	al.,	1989).	We	measured	levels	of	serum	anti-LPS	IgG	and	IgA	in	vaccinated	
volunteers	and	controls.		
At	 day	 0	 (baseline),	 levels	 of	 anti-LPS	 IgG	 and	 IgA	did	not	 differ	 between	 vaccinated	 and	
unvaccinated	volunteers	(Figure	4.1).	Among	vaccinated	volunteers,	levels	of	anti-LPS	serum	
IgG	 were	 6-fold	 higher	 at	 day	 11	 (T1),	 5-fold	 higher	 at	 day	 18	 (T2)	 and	 2-fold	 higher	 at	
approximately	1.5	years	(T3)	([bootstrapped	95%	confidence	interval	(CI)	based	on	arbitrary	
units	 (AU)]:	 -54874	to	 -7404,	 -44577	to	 -5922	and	-8911	to	 -317,	 respectively;	Figure	4.1)	
than	at	baseline	(T0).		
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Similarly,	 among	 vaccinated	 volunteers,	 levels	 of	 anti-LPS	 serum	 IgA	 were	 3-fold	 higher	
among	vaccinated	volunteers	at	day	11	and	2-fold	at	day	18	(-97104	to	-27173	and	-41746	
to	 -12843,	 respectively;	 Figure	 4.1)	 than	 at	 baseline.	 Levels	 of	 anti-LPS	 serum	 IgA	 at	
approximately	1.5	years	were	comparable	with	baseline.		
	
Figure	4.1.	Levels	of	serum	immunoglobulin	(Ig)G	and	IgA	to	Salmonella	Typhi	lipopolysaccharide	(LPS)	
The	levels	of	IgG	and	IgA	specific	to	Salmonella	Typhi	LPS	in	serum,	expressed	in	arbitrary	units	(AU).	Unpaired	comparisons	
were	made	between	control	(C;	closed	squares	[n	=	9])	and	vaccinated	(V;	open	squares	[T0	n	=	8;	T1	n	=	8;	T2	n	=	8;	T3	n	=	7])	
volunteers	at	baseline	 (unpaired	 t	 tests	were	performed	using	 logarithmically	 transformed	data).	Paired	comparisons	were	
made	between	baseline	(T0)	and	day	11	(T1),	day	18	(T2)	and	approximately	1.5	years	(T3)	(paired	t	tests	were	performed	using	
logarithmically	transformed	data).	Abbreviation:	ns,	not	significant;	*,	bootstrapped	95%	confidence	interval	does	not	cross	0.	
	
4.3.3. Peripheral	blood	and	gut	mucosal	cellular	responses	
We	compared	the	frequency	of	Ty21a-responsive	and	FliC-responsive	T	cells	 in	vaccinated	
volunteers	and	controls,	at	the	duodenal	mucosa	and	in	peripheral	blood.	A	combinatorial	
gating	strategy	was	used	to	identify	antigen-responsive	cell	populations;	these	were	defined	
as	the	proportion	of	CD4+	and	CD8+	T	cells	positive	for	any	combination	of	IFN-γ	±	TNF-α	±	IL-
2	 ±	 IL-17A	 ±	 MIP-1β	 following	 re-stimulation	 (Figure	 4.2).	 Cytokine	 production	 in	 non-
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stimulated	samples	(negative	control)	was	minimal,	did	not	differ	between	vaccinated	and	
unvaccinated	volunteers	and	was	subsequently	subtracted	from	other	conditions.	Cytokine	
production	in	SEB-stimulated	samples	(positive	control)	was	high	and	did	not	differ	between	
vaccinated	and	unvaccinated	volunteers.	
		
	
Figure	4.2	(A).	Representative	flow	cytometric	gating	
strategy	for	intracellular	cytokine	analysis	
Dot	 plots	 are	 shown	 for	 cells	 isolated	 from	 the	 duodenal	
mucosa.	 Dead	 cells	 were	 removed	 by	 staining	 for	 viability	
(LIVE/DEAD)	 and	 gating	 on	 the	 negative	 population.	 T	 cells	
were	 identified	 according	 to	 the	 expression	 of	 CD3.	 T	 cells	
were	classified	according	to	the	expression	of	CD4	and	CD8	and	
the	 expression	 of	 IFN-γ,	 TNF-α,	 IL2,	 IL-17A,	 and	 MIP-1β	
assessed	 in	 non-stimulated	 (NS)	 and	 in	 Ty21a,	 FliC	 and	 SEB	
stimulated	samples.	
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Figure	4.2	(B).	Representative	flow	cytometric	gating	
strategy	for	intracellular	cytokine	analysis	
Dot	plots	are	shown	for	cells	 isolated	from	peripheral	blood.	
Dead	cells	were	removed	by	staining	for	viability	(LIVE/DEAD)	
and	gating	on	the	negative	population.	T	cells	were	identified	
according	 to	 the	 expression	 of	 CD3.	 T	 cells	 were	 classified	
according	to	the	expression	of	CD4	and	CD8	and	the	expression	
of	 IFN-γ,	 TNF-α,	 IL2,	 IL-17A,	 and	 MIP-1β	 assessed	 in	 non-
stimulated	(NS)	and	in	Ty21a,	FliC	and	SEB	stimulated	samples.	
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Approximately	1.5	years	following	vaccination,	at	the	duodenal	mucosa,	the	frequencies	of	
Ty21a-responsive	and	FliC-responsive	CD4+	and	CD8+	T	cells	in	the	vaccinated	group	was	not	
different	from	the	unvaccinated	control	group	(Figure	4.3A).		
Since	 overnight	 fasting,	 required	 prior	 to	 endoscopy,	 is	 known	 to	 influence	 cytokine	
production	in	peripheral	blood	in	response	to	re-stimulation	with	bacterial	antigens	(van	den	
Brink	 et	 al.,	 2002),	 we	 acquired	 non-fasting	 peripheral	 blood	 samples	 6	 days	 prior	 to	
gastroscopy.	In	peripheral	blood,	the	frequency	of	Ty21a-responsive	CD4+	and	CD8+	T	cells	
was	not	significantly	higher	in	the	vaccinated	group	compared	to	the	unvaccinated	control	
group	(Figure	4.3B).	The	frequency	of	FliC-responsive	CD4+	T	cells	was	6-fold	higher	and	CD8+	
T	cells	2-fold	higher	in	the	vaccinated	group,	compared	with	the	unvaccinated	control	group	
(([bootstrapped	95%	CI	based	on	percentage	positive	for	combination	of	cytokine]:	-3.48161	
to	-0.05863	and	-5.46152	to	-0.22464,	respectively;	Figure	4.3B).	
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Figure	4.3.	Antigen-specific	cytokine-producing	populations	at	1.5	years	
The	 frequency	 of	 CD4+	and	 CD8+	Salmonella	 Typhi	 strain	 Ty21a-responsive	 and	 FliC-responsive	 populations	 expressing	 any	
combination	of	IFN-γ	±	TNF-α	±	IL-2	±	IL-17A	±	MIP-1β	above	background.	SEB-stimulated	control	data	are	also	included.	For	
control	(C;	closed	squares,	diamonds	and	triangles	[duodenal	mucosa;	Ty21a	n	=	9,	FliC	n	=	5,	SEB	n	=	7]	[peripheral	blood;	Ty21a	
n	=	9,	FliC	n	=	6,	SEB	n	=	9])	and	vaccinated	(V;	open	squares,	diamonds	and	triangles	[duodenal	mucosa;	Ty21a	n	=	7,	FliC	n	=	6,	
SEB	n	=	7]	[peripheral	blood;	Ty21a	n	=	8,	FliC	n	=	7,	SEB	n	=	8])	volunteers,	measurements	were	made	at	the	duodenal	mucosa	
(A),	and	in	peripheral	blood	(B).	Horizontal	bars	represent	mean	values	(comparisons	were	made	using	unpaired	t	tests).	
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4.3.4. Characteristics	and	functionality	of	cellular	responses	
Polyfunctional	 T	 cells,	 defined	 as	 cells	 that	 express	 multiple	 cytokines/chemokines	
simultaneously,	 have	 been	 shown	 to	 correlate	 with	 vaccine-mediated	 protection	 against	
other	intracellular	infections	(Darrah	et	al.,	2007,	Kannanganat	et	al.,	2007).	After	comparing	
the	 proportions	 of	 antigen-responsive	 populations,	 we	 assessed	 the	 cytokine	 expression	
profile	 of	 vaccinated	 volunteers	 with	 that	 of	 unvaccinated	 volunteers.	 Specifically,	 we	
assessed	 the	 functionality	 of	 the	 response	 as	 well	 as	 individual	 cytokine/chemokine	
production.		
Consistent	with	our	published	data	(Pennington	et	al.,	2016),	responses	among	CD8+	T	cells	
comprised	 far	 fewer	polyfunctional	 subpopulations,	 both	 at	 the	duodenal	mucosa	 and	 in	
peripheral	blood	(Figure	4.4	and	4.6).	Of	the	cytokines/chemokines	studied	here,	MIP1β	was	
consistently	 the	most	 commonly	 expressed	 among	 Ty21a-responsive	 and	 FliC-responsive	
CD4+	and	CD8+	T-cell	populations,	at	the	duodenal	mucosa	and	in	peripheral	blood	(Figure	
4.5	and	4.7).		
At	the	duodenal	mucosa,	the	frequencies	of	Ty21a-responsive	or	FliC-responsive	CD4+	and	
CD8+	T	cells	expressing	one,	two,	three,	four	or	five	cytokines/chemokines	in	the	vaccinated	
group	was	not	different	from	the	unvaccinated	control	group	(Figure	4.4).	Of	the	cytokines	
studied	 here,	 no	 discernible	 difference	 was	 observed	 between	 groups	 at	 the	 duodenal	
mucosa	among	either	CD4+	and	CD8+	T	cells	(Figure	4.5).	
		
	 	
Figure	 4.4.	 Combinations	 of	 antigen-specific	
cytokine	production	at	the	duodenal	mucosa	
The	 frequency	 of	 CD4+	 and	 CD8+	 Salmonella	 Typhi	
strain	Ty21a-responsive	(A	and	B)	and	FliC-responsive	
(C	 and	 D)	 populations	 expressing	 one	 (+),	 two	 (++),	
three	 (+++),	 four	 (++++)	 or	 five	 (+++++)	
cytokines/chemokines	(IFN-γ	±	TNF-α	±	IL-2	±	IL-17A	±	
MIP-1β)	 above	 background.	 For	 control	 (C;	 closed	
squares	and	diamonds	 [Ty21a	 n	=	9,	FliC	n	=	5])	and	
vaccinated	(V;	open	squares	and	diamonds	[Ty21a	n	=	
7,	 FliC	 n	 =	 6])	 volunteers.	 Horizontal	 bars	 represent	
mean	values	(comparisons	were	made	using	unpaired	
t	tests).	
	
CH
AP
TE
R	
4	
10
9	
		
Figure	 4.5.	 Antigen-specific	 production	 of	
individual	cytokines	at	the	duodenal	mucosa	
The	 frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	
and	 B)	 and	 FliC-responsive	 (C	 and	 D)	 populations	
expressing	IFN-γ,	TNF-α,	IL-2,	IL-17A,	or	MIP-1β	above	
background.	 For	 control	 (C;	 closed	 squares	 and	
diamonds	[Ty21a	n	=	9,	FliC	n	=	5])	and	vaccinated	(V;	
open	squares	and	diamonds	[Ty21a	n	=	7,	FliC	n	=	6])	
volunteers.	Horizontal	bars	represent	mean	values	
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In	peripheral	blood,	the	frequency	of	polyfunctional	Ty21a-responsive	CD4+	T	cells	expressing	
four	and	five	cytokines/chemokines	was	significantly	higher	 in	vaccinated	volunteers	than	
controls	(-0.04385	to	-0.00047	and	-0.00810	to	-0.00016,	respectively;	Figure	4.6).	Consistent	
with	the	polyfunctional	nature	of	these	responses,	the	frequency	of	IFN-γ,	TNF-α,	IL-2,	IL17	
and	MIP-1β	expression	among	Ty21a-responsive	CD4+	T	cells	was	increased	(Figure	4.7).	This	
suggests	 that	 the	 increased	 frequency	 of	 polyfunctional	 Ty21a-responsive	 CD4+	 T	 cells	
generated	in	response	to	vaccination	persists	for	at	least	1.5	years.	
The	frequency	of	FliC-responsive	CD4+	T	cells	expressing	one	and	two	cytokines/chemokines	
was	higher	 in	vaccinated	volunteers	 than	controls	 (-3.1896	 to	 -0.52607	and	 -0.03688	 to	 -
0.00417,	respectively;	Figure	4.6).	Analysis	by	individual	cytokine	revealed	that	the	frequency	
of	 IFN-γ,	 TNF-α,	 IL-2,	 and	 MIP-1β	 expression	 among	 FliC-responsive	 CD4+	 T	 cells	 was	
increased	(Figure	4.7).	
		
	
Figure	 4.6.	 Combinations	 of	 antigen-specific	
cytokine	production	in	peripheral	blood	
The	 frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	
and	 B)	 and	 FliC-responsive	 (C	 and	 D)	 populations	
expressing	one	(+),	two	(++),	three	(+++),	four	(++++)	or	
five	(+++++)	cytokines/chemokines	(IFN-γ	±	TNF-α	±	IL-
2	±	IL1-7	±	MIP-1β)	above	background.	For	control	(C;	
closed	squares	and	diamonds	[Ty21a	n	=	9,	FliC	n	=	6])	
and	vaccinated	(V;	open	squares	and	diamonds	[Ty21a	
n	=	8,	FliC	n	=	7])	volunteers.	Horizontal	bars	represent	
mean	values	(comparisons	were	made	using	unpaired	
t	tests).	
	
CH
AP
TE
R	
4	
11
2	
		
Figure	 4.7.	 Antigen-specific	 production	 of	
individual	cytokines	in	peripheral	blood	
The	frequency	of	CD4+	and	CD8+	Ty21a-responsive	 (A	
and	 B)	 and	 FliC-responsive	 (C	 and	 D)	 populations	
expressing	IFN-γ,	TNF-α,	IL-2,	IL-17A,	or	MIP-1β	above	
background.	 For	 control	 (C;	 closed	 squares	 and	
diamonds	[Ty21a	n	=	9,	FliC	n	=	6])	and	vaccinated	(V;	
open	squares	and	diamonds	[Ty21a	n	=	8,	FliC	n	=	7])	
volunteers.	Horizontal	bars	represent	mean	values.	
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4.3.5. Correlations	between	peripheral	and	mucosal	immunity	
We	 explored	 the	 relationship	 between	 peripheral	 humoral	 responses	 as	 well	 as	 the	
peripheral	and	duodenal	cellular	immune	responses.		
No	correlation	was	observed	between	levels	of	anti-LPS	serum	IgG	or	IgA	at	any	time	point	
and	the	frequency	of	peripheral	Ty21a-responsive	or	FliC-responsive	CD4+	or	CD8+	T	cells	at	
1.5	 years.	 Levels	 of	 anti-LPS	 serum	 IgA	were,	 however,	 associated	with	 the	 frequency	 of	
duodenal	FliC-responsive	CD8+	T	cells	(data	not	shown).	No	other	correlations	were	observed	
with	duodenal	T-cell	populations.	 	
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4.4. Discussion	
We	have	previously	described	the	early	mucosal	response	to	live	oral	vaccination	with	Ty21a	
at	the	human	duodenal	mucosa,	here	we	assessed	the	long-term	cellular	response	to	Ty21a	
at	 the	 same	 site	 and	 compared	 duodenal	 responses	 with	 peripheral	 responses.	 We	
demonstrate	that,	while	peripheral	polyfunctional	cellular	responses	persist	for	at	least	1.5	
years,	duodenal	responses	–	which	we	have	previously	observed	at	day	18	(Pennington	et	
al.,	2016)	–	do	not	persist.	The	strength	of	early	peripheral	humoral	responses	to	S.	Typhi	
LPS,	which	have	previously	been	associated	with	protective	efficacy	 (Levine	et	 al.,	 1989),	
were	not	associated	with	the	strength	of	peripheral	cellular	responses	at	approximately	1.5	
years.	
We	have	previously	reported	the	generation	of	Ty21a-responsive	CD4+	and	CD8+	T	cells	at	
the	 duodenal	mucosa	 18	days	 following	 vaccination	with	 Ty21a.	Here,	 approximately	 1.5	
years	following	vaccination,	no	response	was	observed	at	the	duodenal	mucosa	in	either	T-
cell	 subset.	 Interestingly,	 however,	 peripheral	 polyfunctional	 T-cell	 responses,	 generated	
through	vaccination	with	Ty21a,	do	persist	for	at	least	1.5	years.	This	suggests	that	duodenal	
responses	are	more	transient	than	peripheral	responses.	
For	some	time	the	generation	of	polyfunctional	T	cells	has	been	believed	to	be	an	important	
factor	in	conferring	protection	against	typhoid	fever	(McArthur	and	Sztein,	2012,	Maybeno	
et	al.,	2012,	Fresnay	et	al.,	2016,	Wahid	et	al.,	2016).	Recently	it	has	been	demonstrated	that,	
indeed,	 polyfunctional	 CD8+	 T	 cells	 are	 associated	 with	 protection	 against	 typhoid	 fever	
(Fresnay	 et	 al.,	 2016).	 Consistent	 with	 our	 previously	 published	 data	 (Pennington	 et	 al.,	
2016),	 the	frequency	of	responsive	cells	 tended	to	be	higher	amongst	CD4+	T	cells;	 this	 is	
likely	 due	 to	 our	 use	 of	 soluble	 antigen	 preparations,	 which	 are	 dependent	 upon	 cross-
presentation	to	engage	cytotoxic	CD8+	T	cells	(Salerno-Goncalves	et	al.,	2003,	Wahid	et	al.,	
2008,	Salerno-Goncalves	and	Sztein,	2009).	Interestingly,	while	Ty21a-responsive	CD4+	T	cells	
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comprised	subsets	which	simultaneously	expressed	four	and	five	cytokine/chemokines,	FliC-
responsive	 CD4+	 T	 cells	 tended	 to	 express	 just	 one	 or	 two	 cytokines/chemokines.	 This	
suggests	 that	 the	 FliC	 antigen	 is	 not	 responsible	 for	 the	 generation	 of	 polyfunctional	
responses	and	that	other	antigens,	which	are	present	in	the	heat-killed	Ty21a	preparation,	
are	responsible	for	the	induction	of	polyfunctional	responses.		
The	 fact	 that	 duodenal	 responses	 are	 transient,	 may	 indicate	 that	 the	 composition	 of	
mucosal	 T-cell	 populations	 is	 subject	 to	 considerable	 change.	 This	 may	 be	 due	 to	 the	
relatively	high	frequency	with	which	different	pathogens	are	encountered	at	the	intestinal	
mucosa.	It	has	previously	been	demonstrated	that	peripheral	responses,	generated	through	
vaccination	 with	 Ty21a,	 with	 increased	 mucosal	 homing	 potential,	 persist	 in	 peripheral	
circulation	 for	 at	 least	 90	 days	 (Wahid	 et	 al.,	 2008).	 Thus,	 if	 S.	 Typhi	 were	 to	 be	 re-
encountered	 at	 the	 intestinal	mucosa,	 long-lived	 peripheral	 cell	 populations	would	 likely	
possess	 an	 enhanced	 capacity	 to	 rapidly	migrate	 to	 the	mucosal	 surface	 through	 innate	
signalling	and	homing	receptor	up	regulation	(De	Calisto	et	al.,	2012).	
Consistent	 with	 our	 previously	 published	 observations	 (Pennington	 et	 al.,	 2016),	 all	
volunteers	had	detectable	baseline	levels	of	serum	immunoglobulin	specific	to	S.	Typhi	LPS.	
This	is	likely	the	result	of	immunoglobulin	binding	to	the	core,	or	as	a	result	of	environmental	
exposure	to	non-typhoidal	strains	bearing	the	same	LPS	O-antigens	as	S.	Typhi	(O-9	and	O-
12)	(Kantele	et	al.,	2012).	Not	all	vaccinated	volunteers	generated	peripheral	humoral	anti-
LPS	responses;	likely	a	reflection	of	the	known	limited	efficacy	of	this	vaccine	(Anwar	et	al.,	
2014).	While	levels	of	serum	anti-LPS	IgG	were	significantly	higher	across	all	3	time	points,	
the	 strength	 of	 early	 responses	 steadily	 declined.	 Similarly,	 early	 anti-LPS	 IgA	 responses	
steadily	declined,	being	significantly	higher	at	day	11	and	day	18,	but	returning	to	a	 level	
which	was	comparable	with	baseline	at	1.5	years.	In	humans,	memory	B-cells	can	essentially	
persist	 for	 the	 life	 of	 the	 host	 (more	 than	 50	 years);	 however,	 typically,	 immunoglobulin	
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responses	decline	rapidly	following	clearance	of	the	antigen	(Schittek	and	Rajewsky,	1990,	
Hammarlund	et	al.,	2003,	Crotty	et	al.,	2003).	Thus,	 if	the	antigen	is	not	reencountered	 in	
vivo,	immunoglobulin	responses	are	unlikely	to	be	detected	in	the	long-term.	
The	assessment	of	baseline	immunoglobulin	levels	indicates	that	groups	were	well	matched	
for	prior	exposure	 to	S.	Typhi.	We	have	previously	observed	 that	heterologous	 influenza-
responsive	 T-cell	 responses	 are	 generated	 at	 the	 duodenal	 mucosa	 18	 days	 following	
vaccination	with	Ty21a.	Unfortunately,	we	were	unable	to	determine	the	longevity	of	these	
responses	in	this	study	as	the	majority	of	the	vaccinated	cohort	had	been	vaccinated	against	
influenza	in	the	period	since	being	vaccinated	with	Ty21a	(data	not	shown).	We	assessed	the	
expression	of	four	cytokines	and	one	chemokine,	as	a	result,	the	T-cell	populations	identified	
here	are	unlikely	to	represent	the	responsive	populations	in	their	entirety.	Variation	within	
the	 human	 population	 may	 mean	 that	 we	 are	 underpowered	 to	 observe	 some	 other	
important	biological	effects.	 	
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4.5. Conclusions	
Taken	together,	our	data	demonstrate	that	early	duodenal	responses	do	not	persist	in	the	
long-term.	The	fact	that	oral	vaccination	does	generate	peripheral	populations	which	persist	
for	at	least	1.5	years	supports	the	development	of	next-generation	oral	vaccines	targeting	
typhoid,	since	it	demonstrates	longevity	of	orally	induced	cellular	responses.	Data	presented	
elsewhere	indicate	that	populations	generated	through	oral	vaccination	express	the	homing	
molecules	 necessary	 to	 rapidly	 migrate	 to	 the	 intestinal	 mucosa	 following	 pathogenic	
exposure	(Wahid	et	al.,	2008).	Controlled	human	infection,	post-vaccination,	may	allow	us	
to	identify	mechanisms	responsible	for	efficacious	defence	against	pathogens	encountered	
at	the	intestinal	mucosa	and	in	the	periphery.	 	
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CHAPTER	5: TRAINED	 IMMUNITY	 –	 NON-SPECIFIC	 EFFECTS	 OF	
ORAL	VACCINATION	WITH	TY21A	
	
5.1. Introduction	
Epidemiological	 evidence	 has	 demonstrated	 that	 live-attenuated	 vaccines	 can	 reduce	 all-
cause	mortality	(Benn	et	al.,	2013,	Goodridge	et	al.,	2016).	The	strongest	evidence	has	been	
collected	 in	 resource-poor	 settings	 following	vaccination	with	BCG	 (Flanagan	et	al.,	 2013,	
Aaby	et	al.,	2014).	Similar	effects	have	been	observed	following	vaccination	with	measles	
containing	vaccines	and	oral	polio	vaccines	in	both	resource-poor	and	resource-rich	settings	
(Aaby	et	al.,	2010,	Lund	et	al.,	2015,	Sorup	et	al.,	2014,	de	Castro	et	al.,	2015).	
These	non-specific	beneficial	effects	are	believed	to	be,	in	part,	conferred	through	epigenetic	
modifications	 among	 innate	 immune	 cell	 populations	 (Ramirez-Carrozzi	 et	 al.,	 2006,	
Ramirez-Carrozzi	et	al.,	2009,	Krawczyk	et	al.,	2010,	Pantel	et	al.,	2014).	These	changes	may	
manifest	 themselves	 in	 the	 form	 of	 phenotypic	 variation	 among	 circulating	 innate	 cell	
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populations	as	well	as	altered	cytokine	production	 in	 response	 to	 in	vitro	cell	 stimulation	
(Kleinnijenhuis	et	al.,	2014).	
TLR-5	engagement	at	the	mucosal	surface	of	the	gastrointestinal	tract	is	known	to	enhance	
immune	responses	to	influenza	vaccination	(Oh	et	al.,	2014).	It	has	been	demonstrated	that	
the	live-attenuated	oral	typhoid	vaccine,	Ty21a,	has	the	capacity	to	aid	in	the	regression	of	
bladder	cancer,	which	is	believed	to	be	the	result	of	TLR	engagement	(Domingos-Pereira	et	
al.,	 2015).	We	 have	 also	 observed	 enhanced	 cellular	 responses	 to	 influenza-virus	 at	 the	
duodenal	mucosa	18	days	following	vaccination	with	Ty21a	(Pennington	et	al.,	2016).	We,	
therefore,	 hypothesised	 that	 oral	 vaccination	 with	 Ty21a	 may	 possess	 the	 capacity	 to	
generate	innate	immune	memory	and	alter	responses	to	nonrelated	pathogens.	
The	identification	of	bacteria	able	to	induce	trained	immunity	may	lead	to	the	development	
of	adjuvants	capable	of	enhancing	vaccines	targeting	a	wide	array	of	pathogens.	Here	we	
have	assessed	the	impact	of	vaccination	with	Ty21a	on	the	expression	intensity	of	several	
receptors	 expressed	 on	 the	 surface	 of	 on	 innate	 immune	 cells	 isolated	 from	 healthy	
volunteers	at	day	14,	month	3	and	month	6.	 In	addition,	we	have	assessed	the	 impact	of	
vaccination	on	IFN-γ	(TH1),	IL-4	(TH2),	IL-17A	(TH17),	TGF-β	(TREG)	and	TNF-α	(TH1)	production	
among	monocytes,	TCRγδ,	MAIT	T	cells,	CD4+	T	cells,	CD8+	T	cells	and	CD20+	B	cells	following	
in	vitro	stimulation.	
5.1.1. Hypotheses	
We	hypothesised	that:	
• Vaccination	 with	 Ty21a	 would	 enhance	 the	 expression	 of	 surface	 receptors	
engaged	by	Ty21a	on	circulating	CD14+	monocytes	
• Vaccination	 with	 Ty21a	 would	 enhance	 cytokine	 responses	 to	 nonrelated	
pathogens	 	
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5.2. Methods	
Full	details	of	the	methods	used	to	produce	the	data	which	are	presented	within	this	chapter	
can	be	found	in	Chapter	2.	Some	data	which	are	pertinent	to	this	chapter	are	included	for	
ease	of	reference.	
5.2.1. Ethical	approval	and	recruitment	
Full	details	can	be	found	in	section	2.1.	The	following	is	a	table	of	volunteer	demographics:	
Table	5.1.	Chapter	5	volunteer	demographics	
Group	 n	 Gender	(M:F)	
Control	 13	 2:11	
Vaccine	 17	 4:13	
	
5.2.2. Vaccination	
Full	details	can	be	found	in	section	2.3.	
5.2.3. Clinical	sampling	
Full	 details	 of	 venesection	 and	 endoscopy	 can	 be	 found	 in	 sections	 2.4.2	 and	 2.4.3,	
respectively.	
5.2.4. Serum	isolation	
Full	details	can	be	found	in	section	2.5.4.	
5.2.5. ELISA	
Full	details	of	ELISAs	specific	for	LPS	and	influenza-virus	can	be	found	in	sections	2.5.12	and	
2.5.13,	respectively	
5.2.6. PBMC	isolation	
Full	details	can	be	found	in	section	2.5.5.	
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5.2.1. PBMC	thawing	and	overnight	‘rest’	
Full	details	can	be	found	in	section	2.5.6.	
5.2.2. Phenotypic	analyses	of	‘rested’	monocytes	
Full	 details	 can	 be	 found	 in	 section	 2.5.8.	 Dyes	 and	 antibodies	 used	 for	 purposes	 of	
phenotypic	analysis	of	monocytes	in	this	chapter	include:	
Table	5.2.	Dyes	and	antibodies	used	for	analysis	of	monocyte	phenotype	
	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 PacificOrange	 LifeTechnologies	 0.02	µL	
Extracellular	
CD14	 FcγRIII	 PerCP/Cy5.5	 BD	Biosciences	 3.5	µL	
CD16	 HI10a	 APC/Cy7	 BioLegend	 3.5	µL	
CD64	 TS1/18	 BV605	 BioLegend	 3.5	µL	
CD18	 ICRF44	 PE/Cy7	 BioLegend	 3.5	µL	
CD11b	 Bu15	 AF700	 BD	Biosciences	 3.5	µL	
CD11c	 6H6	 Pacific	Blue	 BioLegend	 3.5	µL	
CD123	 19.2	 BV711	 BioLegend	 3.5	µL	
CD206	 HTA125	 PE/CF594	 BD	Biosciences	 3.5	µL	
CD284	 624915	 APC	 BioLegend	 3.5	µL	
CD285	 201A	 FITC	 R&D	Systems	 3.5	µL	
CD303	 L243	 PE	 BioLegend	 3.5	µL	
	
5.2.3. Ex	vivo	cell	stimulation	and	staining	
Full	details	of	the	antigens	used	for	stimulation	can	be	found	in	section	2.5.9.	Antigens	used	
in	the	chapter	include:	
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Table	5.3.	Antigens	used	for	in	vitro	stimulation	
Description	 Preparation	of	stimuli	
Complete	medium	 100	µL	complete	medium	
Heat-killed	Ty21a	 100	µL	complete	medium	containing	2	×	10
6	CFU	heat-
killed	Ty21a	
Heat-killed	C.	albicans	 100	µL	complete	medium	containing	2	×	10
6	CFU	heat-
killed	C.	albicans	
PPD	from	M.	tuberculosis	 100	µL	complete	medium	containing	5	µg	TB	PPD	
Tetanus	toxoid	 100	µL	complete	medium	containing	20	µg	tetanus	toxoid	
Split	Viron	Influenza		
100	µL	complete	medium	containing	180	ng	
hemagglutinin	from,	in	equal	quantities,	a	
A/California/7/2009	H1N1-like	strain,	a	
A/Texas/50/20122	H3N2-like	strain	and	a	
B/Massachusetts/2/2012-like	strain	
	
Full	details	of	the	stimulation	and	staining	protocol	can	be	found	in	section	2.5.10.	Dyes	and	
antibodies	used	for	purposes	of	intracellular	cytokine	staining	in	this	chapter	include:	
Table	5.4.	Dyes	and	antibodies	used	for	analysis	of	intracellular	cytokine	production	
	 Target	 Clone	 Fluorophore	 Manufacturer	 Per	test	
Viability	 Dead	cells	 N/A	 PacificOrange	 LifeTechnologies	 0.02	µL	
Extracellular	
CD3	 SK7	 APC/H7	 BD	Biosciences	 1	µL	
CD4	 SK3	 PerCP/Cy5.5	 BioLegend	 1	µL	
CD8	 SK1	 BV/650	 BioLegend	 1	µL	
CD14	 MφP9	 APC/H7	 BD	Biosciences	 1	µL	
CD20	 2H7	 Pacific	Blue	 BioLegend	 1	µL	
CD161	 HP-3G10	 BV/785	 BioLegend	 1	µL	
TCRγδ	 11F2	 PE/Cy7	 BD	Biosciences	 1	µL	
Vα7.2	 3C10	 PE/Dazzle594	 BioLegend	 1	µL	
Intracellular	
IFN-γ	 4S.B3	 PE	 BioLegend	 2	µL	
TNF-α	 MAb11	 FITC	 BioLegend	 2	µL	
IL-17A	 N49-653	 AF700	 BD	Biosciences	 2	µL	
IL-4	 MP4-25D2	 BV711	 BD	Biosciences	 2	µL	
TGF-β	 TW4-6H10	 APC	 BioLegend	 2	µL	
	
5.2.4. Flow	cytometric	acquisition	and	analyses	
Full	details	can	be	found	in	section	2.5.11.	A	BD	FACS	Aria	II	was	used	for	the	acquisition	of	
data.	
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5.2.5. Data	management	and	statistical	analysis	
Full	details	can	be	found	in	section	2.6.	
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5.3. Results	
5.3.1. Monocyte	phenotype	
We	measured	the	relative	expression	intensity	of	CD11b	(integrin	αM),	CD11c	(integrin	αX),	
CD14,	 CD16	 (FcRIII),	 CD18	 (integrin	 β2),	 CD64	 (FcγRI),	 CD123	 (IL-3RA),	 CD206	 (mannose	
receptor),	CD303	(BDCA-2),	HLA-DR,	TLR-4	and	TLR-5	on	the	surface	of	non-stimulated	CD14+	
monocytes	by	flow	cytometry.	A	sequential	gating	strategy	was	used	to	identify	populations	
of	 interest	 (Figure	 5.1).	 We	 compared	 the	 phenotypic	 properties	 of	 cells	 isolated	 from	
vaccinated	 volunteers	 and	 controls	 at	 day	 0	with	 those	 isolated	 at	 day	 14,	month	 3	 and	
month	6.	
We	observed	increased	expression	of	CD11b,	CD11c,	CD16,	CD64,	CD303,	TLR-4	and	TLR-5	
among	vaccinated	volunteers	at	day	14	(P	=	.002,	P	=	.026,	P	=	.005,	P	=	.008,	P	=	.027,	P	=	
.005	and	P	=	.007,	respectively;	Figure	5.2).	Increased	expression	of	CD11b,	CD16,	CD303	and	
TLR-4	was	observed	at	month	3	(P	=	.002,	P	=	.042,	P	=	.045	and	P	=	.043,	respectively;	Figure	
5.2).	 Expression	 of	 all	 receptors	 among	 vaccinated	 volunteers	 were	 comparable	 with	
baseline	at	month	6.	No	change	in	the	expression	intensity	of	CD14,	CD18,	CD123,	CD206	
and	HLA-DR	was	observed	among	the	vaccinated	group	at	any	time	point.	Among	control	
group	 volunteers,	 increased	 expression	 of	 CD11b	was	 observed	 at	 day	 14	 (P	 =	 .002).	 No	
change	 in	 the	expression	 intensity	of	any	other	 receptor	at	any	 time	point	was	observed	
among	the	control	group	(Figure	5.3).	
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Figure	5.1.	Representative	flow	cytometric	gating	strategy	for	phenotypic	analysis	of	CD14+	monocytes	
Dot	plots	and	histograms	are	shown	for	cells	isolated	from	peripheral	blood.	Dead	cells	were	removed	by	staining	for	viability	
(LIVE/DEAD)	 and	 gating	 on	 the	 negative	 population.	Monocytes	were	 identified	 according	 to	 the	 expression	 of	 CD14.	 The	
expression	intensity	of	CD11b	(integrin	αM),	CD11c	(integrin	αX),	CD14,	CD16	(FcRIII),	CD18	(integrin	β2),	CD64	(FcγRI),	CD123	
(IL-3RA),	CD206	(mannose	receptor),	CD303	(BDCA-2),	HLA-DR,	TLR-4	and	TLR-5	was	assessed	in	non-stimulated	samples.	
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Figure	5.2.	Surface	receptor	expression	intensity	among	CD14+	monocytes	isolated	from	volunteers	vaccinated	
with	Ty21a	
Geometric	mean	fluorescence	intensity	(MFI)	expression	of	CD11b	(integrin	αM),	CD11c	(integrin	αX),	CD14,	CD16	(FcRIII),	CD18	
(integrin	β2),	CD64	(FcγRI),	CD123	(IL-3RA),	CD206	(mannose	receptor),	CD303	(BDCA-2),	HLA-DR,	TLR-4	and	TLR-5	among	CD14+	
monocytes	isolated	from	volunteers	vaccinated	with	Salmonella	Typhi	strain	Ty21a	(open	circles).	Samples	were	collected	at	
day	0	(T0	n	=	12),	day	14	(T1	n	=	12),	month	3	(T2	n	=	12)	and	month	6	(T3	n	=	12).	Bars	represent	mean	values	(comparisons	
were	made	using	Wilcoxon	matched-pairs	signed	rank	tests).	Abbreviation:	ns,	not	significant.	
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Figure	5.3.	Surface	receptor	expression	intensity	among	CD14+	monocytes	isolated	from	unvaccinated	control	
group	volunteers	
Geometric	mean	fluorescence	intensity	(MFI)	expression	of	CD11b	(integrin	αM),	CD11c	(integrin	αX),	CD14,	CD16	(FcRIII),	CD18	
(integrin	β2),	CD64	(FcγRI),	CD123	(IL-3RA),	CD206	(mannose	receptor),	CD303	(BDCA-2),	HLA-DR,	TLR-4	and	TLR-5	among	CD14+	
monocytes	isolated	from	control	group	volunteers	(closed	circles).	Samples	were	collected	at	day	0	(T0	n	=	12),	day	14	(T1	n	=	
11),	month	3	(T2	n	=	11)	and	month	6	(T3	n	=	12).	Bars	represent	mean	values	(comparisons	were	made	using	Wilcoxon	matched-
pairs	signed	rank	tests).	Abbreviation:	ns,	not	significant.	
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5.3.2. Cytokine	production	
Cells	were	stimulated	in	vitro	with	a	range	of	bacterial,	fungal	and	viral	antigens.	Specifically,	
cells	were	stimulated	with	either	heat-killed	live-attenuated	Salmonella	Typhi	strain	Ty21a	
heat-killed	 C.	 albicans,	 split-viron	 influenza	 virus;	 PPD	 from	M.	 tuberculosis	 and	 tetanus	
toxoid.	We	then	assessed	the	production	of	IFN-γ,	IL-4,	IL-17A,	TGF-β	and	TNF-α	by	B	cells,	
CD4+	 T	 cells,	 CD8+	 T	 cells,	 monocytes,	MAIT	 cells,	 and	 TCRγδ	 cells	 by	 flow	 cytometry.	 A	
sequential	 gating	 strategy	 was	 used	 to	 identify	 populations	 of	 interest	 (Figure	 5.4).	 The	
frequency	of	each	population	positive	 for	each	 cytokine	was	multiplied	by	 the	 geometric	
mean	fluorescence	intensity	for	each	cytokine-positive	population	above	background	–	this	
well-established	 metric	 is	 known	 as	 the	 integrated	 mean	 fluorescence	 intensity	 (iMFI)	
(Darrah	et	al.,	2007).	Each	volunteer	was	assigned	a	numerical	value	based	on	whether	there	
was	a	reduction	in	output	(-1;	<80%	of	baseline),	no	change	in	output	(0;	between	£80%	and	
³120%	of	baseline),	or	increased	output	(+1;	<120%	of	baseline)	at	T1,	T2	and	T3.	
Temporal	variation	was	observed	in	both	the	vaccinated	group	and	the	control	group	(Figure	
5.5).	 Since	we	were	not	powered	 to	perform	comparisons	where	 temporal	 variation	was	
observed	within	the	control	group,	we	opted	to	model	the	data	using	DAPC	to	more	generally	
assess	whether	vaccination	had	influenced	heterologous	in	vitro	cytokine	production.	When	
all	stimuli	were	included	for	each	cell	type	and	cytokine,	the	model,	comprising	30	principal	
components,	reclassified	all	samples	with	an	accuracy	of	85.3%	(Figure	5.6).	Loadings	data	
revealed	 the	 largest	 contributing	 cell	 populations	 were	 B	 cells,	 TCRγδ	 and	 CD8+	 T	 cells.	
Interestingly,	when	the	Ty21a	stimulus	was	removed,	the	accuracy	of	the	model	was	virtually	
unchanged,	and	the	model,	comprising	30	principal	components,	reclassified	all	samples	with	
an	accuracy	of	83.3%	(Figure	5.7).	Once	more,	loadings	data	revealed	the	largest	contributing	
cell	populations	were	B	cells,	TCRγδ	and	CD8+	T	cells.	
		
Figure	5.4.	Representative	flow	cytometric	gating	strategy	for	
intracellular	cytokine	analysis	
Dot	plots	and	histograms	are	shown	for	cells	isolated	from	peripheral	
blood.	 (A)	 Dead	 cells	 were	 removed	 by	 staining	 for	 viability	
(LIVE/DEAD)	and	gating	on	the	negative	population.	The	CD3	positive	
population	 were	 defined	 as	 follows;	 TCRγδ	 cells	 were	 identified	
according	 to	 the	 expression	 of	 TCRγδ;	mucosal	 associated	 invariant	
(MAIT)	cells	were	identified	according	to	the	expression	of	CD161	and	
Vα7.2	not	already	identified	as	TCRγδ	cells;	CD4+	and	CD8+	T	cells	were	
identified	 according	 to	 the	 expression	 of	 CD4	 and	 CD8	 not	 already	
identified	as	TCRγδ	cells	or	MAIT	cells.	(B)	Monocytes	were	identified	
according	 to	 the	 expression	 of	 CD14	 as	 well	 as	 the	 intermediate	
expression	of	CD4	and	CD20.	 The	expression	of	 interferon	γ	 (IFN-γ),	
interleukin	 4	 (IL-4),	 IL-17A,	 transforming	 growth	 factor	 β	 (TGF-β),	
and/or	tumor	necrosis	factor	α	(TNF-α)	assessed	in	non-stimulated	and	
in	 heat-killed	 live-attenuated	 Salmonella	 Typhi	 strain	 Ty21a;	 heat-
killed	 Candida	 albicans;	 split-viron	 influenza;	 purified	 protein	
derivative	 from	 Mycobacterium	 tuberculosis;	 tetanus	 toxoid-
stimulated	samples.	
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Figure	5.5.	Heat	map	showing	change	in	integrated	mean	fluorescence	intensity	(iMFI)	amongst	unvaccinated	
control	group	volunteers	and	volunteers	vaccinated	with	Salmonella	Typhi	strain	Ty21a	
iMFI	(IFN-γ	was	assessed	at	day	14	(T1),	month	3	(T2),	month	6	(T3)	amongst	B	cells,	CD4+	T	cells,	CD8+	T	cells,	monocytes,	
mucosal	associated	invariant	(MAIT)	cells,	and	TCRγδ	cells	and	compared	with	baseline	(T0).	Data	were	compiled	for	each	of	
the	 following	 stimuli;	 heat-killed	 live-attenuated	 Salmonella	 Typhi	 strain	 Ty21a	 (Ty21a);	 heat-killed	 Candida	 albicans	 (C.	
albicans);	 split-viron	 influenza	 (Influenza);	 purified	 protein	 derivative	 from	Mycobacterium	 tuberculosis	 (TB	 PPD);	 tetanus	
toxoid.	For	each	volunteer	iMFI	was	calculated	and	each	volunteer	assigned	a	numerical	value	based	on	whether	there	was	a	
reduction	in	output	(-1;	<80%	of	baseline),	no	change	in	output	(0;	between	£80%	and	³120%	of	baseline),	or	increased	output	
(+1;	<120%	of	baseline)	at	T1,	T2	and	T3.	The	median	for	the	group	was	then	calculated	and	graphically	represented.		
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Figure	5.6.	Density	plots	showing	linear	discriminant	analysis	of	principal	components	(DAPC)	
A	model	was	built	using	data	collected	from	control	(C;	light-grey)	and	vaccinated	(V;	mid-grey)	volunteers.	Data	were	compiled	
for	 the	 following	 stimuli;	 live-attenuated	 Salmonella	 Typhi	 strain	 Ty21a,	Candida	 albicans,	 influenza	 virus,	 purified	 protein	
derivative	from	Mycobacterium	tuberculosis	and	tetanus	toxoid.	Cytokine	production	(IFN-γ,at	day	14	(T1),	month	3	(T2)	and	
month	6	(T3)	amongst	B	cells,	CD4+	T	cells,	CD8+	T	cells,	monocytes,	mucosal	associated	invariant	(MAIT)	cells,	and	TCRγδ	cells.	
	
	
Figure	5.7.	Density	plots	showing	linear	discriminant	analysis	of	principal	components	(DAPC)	using	unrelated	
non-vaccine	antigens	only	
A	model	was	built	using	data	collected	from	control	(C;	light-grey)	and	vaccinated	(V;	mid-grey)	volunteers.	Data	were	compiled	
for	the	following	stimuli,	Candida	albicans,	 influenza	virus,	purified	protein	derivative	from	Mycobacterium	tuberculosis	and	
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tetanus	toxoid,	with	the	notable	exclusion	of	the	live-attenuated	Salmonella	Typhi	strain	Ty21a	stimulus.	Cytokine	production	
(IFN-γat	day	14	(T1),	month	3	(T2)	and	month	6	(T3)	amongst	B	cells,	CD4+	T	cells,	CD8+	T	cells,	monocytes,	mucosal	associated	
invariant	(MAIT)	cells,	and	TCRγδ	cells.	
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5.4. Discussion	
Here	we	 have	 demonstrated	 that	 oral	 vaccination	with	 S.	 Typhi	 strain	 Ty21a	 can	 induce	
upregulation	 of	 CD11b,	 CD11c,	 CD16,	 CD64,	 CD303,	 TLR-4	 and	 TLR-5	 among	 CD14+	
monocytes	for	at	 least	3	months.	These	changes	are	indicative	of	the	induction	of	trained	
immunity.	 We	 have	 further	 demonstrated	 that	 vaccination	 with	 Ty21a	 alters	 cytokine	
production	 among	 various	 cell	 populations	 in	 response	 to	 stimulation	 with	 non-related	
pathogens.		
In	studies	assessing	the	generation	of	trained	immunity,	TLR4	as	well	as	CD14,	CD11b	and	
CD206	has	been	shown	to	be	upregulated	among	monocytes	for	at	 least	1	year	following	
vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).	Challenge	with	wild-type	S.	Typhi	has	been	
shown	to	induce	activation	of	circulating	monocytes	and	DCs	up	to	96	hours	following	onset	
of	disease	(Toapanta	et	al.,	2015).	Here	we	have	observed	the	increased	expression	of	TLR-4	
and	 TLR-5	 on	 monocytes	 following	 vaccination	 with	 Ty21a;	 likely	 a	 response	 to	 the	
engagement	of	these	TLRs	by	LPS	and	flagella,	respectively.	 In	addition	to	changes	among	
TLRs,	which	are	semi-pathogen-specific,	we	also	observed	the	upregulation	of	CD11b,	CD11c,	
CD16,	CD64	and	CD303,	the	upregulation	of	these	molecules	 is	associated	with	enhanced	
phagocytic	 function	 and	 antigen-presentation	 as	 well	 as	 enhanced	 chemotaxic	 potential	
(Solovjov	et	al.,	2005,	Georgakopoulos	et	al.,	2008,	Cheeseman	et	al.,	2016).	These	changes	
likely	 contribute	 towards	 the	 non-specific	 beneficial	 effects	 conferred	 through	 the	
generation	of	trained	immunity.	
Differences	in	expression	were	observed	for	at	least	3	months	following	vaccination.	Since	
monocytes	 typically	 only	 persist	 in	 circulation	 for	 a	 single	 day	 (Yona	 et	 al.,	 2013),	 it	 is	
reasonable	 to	 hypothesise	 that	 phenotypic	 changes	 observed	 as	 long	 as	 3	months	 after	
vaccination	were	 the	 result	 of	 changes	which	occurred	 at	 the	progenitor	 level.	However,	
since	no	effect	was	observed	at	6	months,	it	is	likely	that	monocytes	do	eventually	return	to	
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a	phenotype	more	in	line	with	the	individuals’	natural	immune	state.	Nevertheless,	in	the	3	
months	following	vaccination,	these	changes	are	likely	to	have	a	significant	impact	on	the	
capture	and	presentation	of	antigen	by	differentiated	monocytes	–	DCs	and	macrophages	–	
and	the	adaptive	immune	responses	which	are	subsequently	generated.	
Many	 factors	 influence	 human	 cytokine	 production;	 indeed,	 variation	 has	 been	 reported	
over	a	period	as	short	as	24	hours	(Edgar	et	al.,	2016).	We	have	observed	temporal	variation	
in	cytokine	production	in	the	unvaccinated	control	group	over	a	6	month	period.	It	is	possible	
that	 changes	 in	 the	 control	 group	may	be	 the	 result	 of	 seasonal	 variation	 in	 the	 relative	
frequency	with	which	different	pathogens	are	encountered.	In	order	to	ensure	that	effects,	
particularly	 those	 surrounding	 heterologous	 responses,	 are	 not	 wrongly	 attributed	 to	
vaccination	or	 clinical	 intervention,	 it	 is	 imperative	 that	 future	 studies	 include	 temporally	
matched-controls	in	order	to	account	for	temporal	variation,	as	was	the	case	in	this	study.	
This	 is	 important	since	temporal	variation	may,	at	 least	 in	part,	contribute	toward	altered	
cytokine	production	which	has	been	observed	elsewhere	(Kleinnijenhuis	et	al.,	2014).	
BCG,	 measles	 containing	 vaccines	 and	 oral	 polio	 vaccines	 have	 all	 been	 associated	 with	
reductions	in	all-cause	mortality	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	
Sorup	et	al.,	2014,	Lund	et	al.,	2015,	de	Castro	et	al.,	2015);	however,	it	is	unclear	whether	
these	 observations	 are	 the	 result	 of	 altered	 cytokine	 production.	 It	 has	 previously	 been	
demonstrated	that	cytokine	production	in	response	to	in	vitro	stimulation	with	heterologous	
antigens	is	altered	following	vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).	It	is	unclear	
whether	 changes	 in	 cytokine	 production	 are	 the	 result	 of	 altered	 antigen-presentation	
occurring	 in	 vitro,	 or	 whether	 these	 changes	 reflect	 altered	 immune	 cell	 population	
composition	 occurring	 in	 vivo.	 To	 our	 knowledge,	 this	 is	 the	 first	 instance	 where	 the	
assessment	of	cytokine	production	by	cell	type	has	been	attempted	in	the	context	of	trained	
immunity,	with	previous	studies	having	relied	upon	the	assessment	of	supernatants	collected	
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following	in	vitro	stimulation	(Kleinnijenhuis	et	al.,	2014).	The	use	of	DAPC	to	interrogate	our	
data	has	allowed	us	to	make	the	general	conclusion	that	vaccination	with	Ty21a	does	indeed	
alter	cytokine	production	to	non-related	pathogens.	Since,	DAPC	modelling	revealed	a	similar	
capacity	to	reassign	volunteers,	even	when	Ty21a	data	were	excluded,	we	can	assume	that	
the	specific	responses	generated	to	the	vaccine	were	not	the	only	responses	which	enabled	
discrimination	of	the	two	groups.	This	suggests	that	vaccination	with	Ty21a	did	indeed	alter	
cytokine	 responses	 to	 heterologous	 antigens.	 Unfortunately,	 since	we	 did	 not	 anticipate	
temporal	variation	within	the	control	group,	we	lacked	the	statistical	power	to	perform	the	
appropriate	statistical	comparisons	to	provide	detailed	insight	into	the	populations	driving	
this	 phenomenon.	 Variation	 within	 the	 human	 population	 may	 mean	 that	 we	 are	
underpowered	to	observe	some	other	important	biological	effects.	Evidence	does,	however,	
suggest	a	prominent	role	for	B	cells,	TCRγδ	and	CD8+	T	cells	in	the	altered	responses	which	
were	observed.	Further	study	is	warranted	to	more	fully	characterise	the	role	that	innate,	
proinflamatory	and	regulatory	cell	 types	and	effector	molecules	play	 in	 the	generation	of	
trained	immunity.	 	
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5.5. Conclusion	
Our	data	demonstrate	that	Ty21a	possess	the	potential	to	induce	changes	associated	with	
the	 generation	of	 trained	 immunity.	Although	BCG,	measles	 containing	 vaccines	 and	oral	
polio	 vaccines	 have	 all	 been	 associated	 with	 the	 induction	 of	 trained	 immunity	 and	 a	
reduction	in	all-cause	mortality	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	
Sorup	et	al.,	2014,	Lund	et	al.,	2015,	de	Castro	et	al.,	2015),	the	low	cost	and	ease	with	which	
Ty21a	may	 be	 administered	makes	 it	 a	 particularly	 attractive	 platform	 for	 development.	
However,	 to	 date,	 no	 data	 has	 been	 presented	 which	 demonstrates	 that	 these	 kind	 of	
immunological	observations	are	clinically	relevant	and	are	responsible	for	a	reduction	in	all-
cause	mortality	 in	humans	(Pollard	et	al.,	2017).	Data	presented	here	would	 indicate	that	
studies	to	determine	whether	vaccination	with	Ty21a	also	impacts	all-cause	mortality	should	
be	undertaken.	
Further	study	is	required	to	determine	whether	Ty21a	may,	be	administered	alongside	other	
vaccines	to	enhance	their	efficacy.	Since	trained	innate	immune	cells	persist	for	at	 least	3	
months	following	vaccination	with	Ty21a,	other	pathogens/antigens	encountered	during	this	
period	would	be	subject	to	altered	recognition	and	presentation.	As	a	result,	the	relatively	
short-lived	impact	of	trained	immunity	–	observed	for	just	3	months	here	–	may	well	lead	to	
lasting	effects	on	subsequently	generated	adaptive	immune	responses,	which	can	persist	for	
the	life	of	the	host.	These	data	support	the	development	of	S.	Typhi	as	a	vector	to	deliver	
unrelated	antigens,	since,	through	the	induction	of	trained	immunity,	S.	Typhi	based	vectors	
may	confer	additional	benefits	beyond	those	originally	envisioned	during	the	earliest	stages	
of	their	development.	
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CHAPTER	6: GENERAL	DISCUSSION	
	
This	thesis	describes	the	assessment	of	the	human	immune	response	to	oral	vaccination	with	
live-attenuated	S.	Typhi	strain	Ty21a	in	peripheral	blood	and	at	the	intestinal	mucosa.	The	
three	overarching	objectives	of	this	thesis	were:	
• To	characterise	the	short-term	impact	of	Ty21a	on	adaptive	human	immunity	in	
peripheral	blood	and	at	the	duodenal	and	colonic	mucosa	
• To	characterise	the	long-term	impact	of	Ty21a	on	adaptive	human	immunity	in	
peripheral	blood	and	at	the	duodenal	mucosa	
• To	characterise	the	non-specific	effects	of	Ty21a	on	innate	cell	phenotype	and	
its	impact	on	immune	responses	to	an	array	of	pathogens	
6.1. Discussion	of	key	findings	
S.	Typhi	remains	a	considerable	threat	to	global	health.	Although	the	efficacy	of	the	Ty21a	
vaccine	is	limited	(Anwar	et	al.,	2014),	a	considerable	amount	of	data	have	been	collected	
concerning	the	peripheral	cellular	and	humoral	immune	response	to	Ty21a,	which	has	been	
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used	to	inform	the	development	of	next-generation	vaccines.	This	thesis,	however,	explores	
areas	previously	unexplored,	and	is	the	first	instance	where	the	impact	of	Ty21a	on	cellular	
immunity	at	the	human	intestinal	mucosa	has	been	assessed,	and	where	the	 induction	of	
trained	immunity	has	been	associated	with	administration	of	this	vaccine.	
We	have	also	demonstrated	that	Ty21a	may	be	used	as	an	 immunological	probe	to	study	
mucosal	 immune	defence,	 and	 that	 Ty21a	may	be	used	 to	 confer	 benefits	 beyond	 those	
specific	to	S.	Typhi.	
6.1.1. Peripheral	 cellular	 immune	 responses	 do	 not	 fully	 reflect	
cellular	immune	responses	at	the	intestinal	mucosa	
Responses	were	observed	at	the	duodenal	mucosa	which	were	stronger	and	more	diverse	
than	those	observed	in	peripheral	blood.	The	assessment	of	novel	vaccines	using	peripheral	
sampling	techniques	alone	may	not	fully	reflect	immunogenicity.	Indeed,	with	regards	orally-
administered	 vaccines	 targeting	 mucosal	 pathogens,	 the	 direct	 assessment	 of	 mucosal	
immune	defence	is	a	more	relevant	measure	of	immunogenicity,	which	may	more	accurately	
reflect	 some	 aspects	 of	 oral	 vaccine	 efficacy.	 The	 mechanisms	 through	 which	 adaptive	
immune	 responses	 are	 generated	 during	 early	 exposure	 at	 the	 intestinal	 mucosa	merits	
further	study,	including,	but	not	limited	to,	the	study	of	a	wider	range	of	cell	types	and	the	
assessment	of	transcriptomic	signals	observed	during	early	responses.	
6.1.2. Intestinal	cellular	immune	responses	are	compartmentalised	
At	the	intestinal	mucosa,	cellular	responses	were	observed	at	the	duodenal	mucosa	which	
were	 not	 observed	 at	 the	 colonic	 mucosa.	 The	 total	 surface	 area	 of	 the	 adult	 human	
gastrointestinal	mucosa	is	estimated	to	be	between	30	and	40	m2	(Helander	and	Fandriks,	
2014);	 thus,	 compartmentalisation	 of	 immune	 cell	 trafficking	 likely	 ensures	 that	 cell	
populations	accumulate	in	regions	where	they	were	initially	primed	and	are,	therefore,	more	
likely	to	play	an	active	role	in	immune	defence.	
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6.1.3. Heterologous	cellular	immune	responses	are	observed	at	the	
human	intestinal	mucosa	
Cellular	immune	responses	were	observed	to	Ty21a	as	well	as	viral	influenza	antigens	at	the	
duodenal	mucosa.	We	hypothesise	that	TLR	engagement	and	cellular	activity	at	the	intestinal	
mucosa	generates	an	innate	response,	which	results	in	the	migration	of	competent	adaptive	
immune	cells	into	the	local	space.	This	likely	ensures	that	adaptive	immune	responses	to	any	
pathogen	are	generated	as	soon	as	possible	following	exposure.		
6.1.4. Peripheral,	but	not	intestinal,	cellular	responses	persist	in	the	
long-term	
Cellular	 immune	 responses	were	 observed	 to	 persist	 in	 peripheral	 blood,	 but	 not	 at	 the	
duodenal	 mucosa	 approximately	 1.5	 years	 following	 vaccination.	 Due	 to	 the	 non-sterile	
nature	 of	 the	 intestinal	 mucosa,	 and	 the	 relative	 frequency	 with	 which	 pathogens	 are	
encountered	at	this	site,	the	turnover	of	cells	of	various	cell	specificities	is	likely	to	be	greater	
and	more	dynamic	than	in	peripheral	blood.	Thus,	immune	responses	generated	in	response	
to	vaccination,	at	the	intestinal	mucosa,	may	be	more	difficult	to	detect	in	the	long-term.	
6.1.5. Trained	 immunity	 is	 conferred	 and	 immune	 responses	 to	
heterologous	antigens	are	altered	
Monocyte	phenotype	and	cytokine	expression	profiles	are	altered	following	vaccination	with	
Ty21a.	Data	presented	here	are	 the	 first	which	demonstrate	 that	Ty21a	generates	 innate	
immune	memory.	Phenotypic	analysis	of	monocytes	demonstrated	increased	expression	of	
surface	molecules	engaged	by	Ty21a,	as	well	as	other	associated	which	are	indicative	of	a	
heightened	 immune	 state.	 Similar	 effects	 have	 previously	 been	 observed	 following	
vaccination	with	BCG	(Kleinnijenhuis	et	al.,	2014).	The	low	cost	and	ease	with	which	Ty21a	
may	 be	 administered,	 compared	 with	 other	 vaccines	 which	 have	 been	 shown	 to	 confer	
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innate	 immune	 memory,	 makes	 Ty21a	 a	 particularly	 attractive	 platform	 for	 further	
development	(Aaby	et	al.,	2010,	Flanagan	et	al.,	2013,	Aaby	et	al.,	2014,	Sorup	et	al.,	2014,	
Lund	 et	 al.,	 2015,	 de	 Castro	 et	 al.,	 2015).	 The	 administration	 of	 Ty21a	 alongside	 other	
vaccines	could	improve	their	efficacy.	Further	study	is	warranted	to	explore	the	impact	of	
Ty21a	on	immune	responses	to	co-administered	vaccine	antigens.	Evidence	would	indicate	
that,	 for	 example,	 administration	 of	 Ty21a	 could	 enhance	 responses	 to	 parenterally-
administered	vaccines	through	TLR	engagement	(Oh	et	al.,	2014).	
6.2. Future	work	
Based	 on	 the	 data	 presented	 within	 this	 thesis,	 further	 investigation	 to	 more	 fully	
characterise	 the	complex	 interactions	between	S.	Typhi	and	 its	human	host	 is	warranted.	
Some	possible	avenues	of	exploration	include:	
6.2.1. The	assessment	of	peripheral	 and	mucosal	 immune	cellular	
responses	to	wild-type	S.	Typhi	
Our	use	 of	S.	Typhi	 strain	 Ty21a	has	 enabled	us	 to	 study	 host-pathogen	 interaction	with	
minimal	risk	to	volunteers	and	at	a	fraction	of	the	cost	that	would	have	been	incurred	if	we	
were	to	study	wild-type	S.	Typhi.	Unfortunately,	due	to	the	nature	of	its	generation,	Ty21a	
contains	a	number	of	mutations,	which	makes	it	an	imperfect	model	of	true	infection	and	
host	defence.	
Since	 the	 first	 models	 of	 controlled	 human	 infection	 were	 discontinued,	 technological	
advancements	have	made	it	possible	to	safely	acquire	previously	inaccessible	samples.	The	
acquisition	 and	 interrogation	 of	 these	 samples	 would	 allow	 for	 a	 more	 comprehensive	
assessment	of	host-pathogen	 interaction.	 The	 controlled	S.	Typhi	human	 infection	model	
now	 established	 at	 the	 University	 of	 Oxford,	 will	 utilise	 these	 advancements	 to	 study	
pathogenic	 wild-type	 S.	 Typhi	 in	 its	 natural	 host,	 both	 peripherally	 and	 at	 the	 intestinal	
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mucosa.	 These	 data	 will	 expand	 our	 understanding	 of	 disease	 pathogenesis	 and	 factors	
influencing	susceptibility	to	infection.	
6.2.1. Transcriptomic	analysis	of	peripheral	and	mucosal	responses	
S.	Typhi	strain	Ty21a	and	wild-type	S.	Typhi	
The	 assessment	 of	 the	 human	 transcriptome	 following	 exposure	 to	 Ty21a	 both	 at	 the	
intestinal	mucosa	and	in	peripheral	blood	could	yield	important	insight	into	the	mechanisms	
responsible	 for	 the	 generation	 of	 protective	 immune	 responses.	 Further,	 analysis	 of	 the	
transcriptome	 way	 provide	 insight	 into	 the	 mechanisms	 engaged	 which	 induce	 changes	
associated	with	the	generation	of	trained	immunity	–	this	could	lead	to	the	development	of	
refined	molecules	which	could	be	administered	alongside	countless	other	vaccines	as	next-
generation	adjuvants.	
The	assessment	of	the	human	transcriptome	following	exposure	to	wild-type	S.	Typhi	both	
at	 the	 intestinal	 mucosa	 and	 in	 peripheral	 blood	 would	 be	 of	 great	 interest.	 A	 greater	
understanding	 of	 factors	which	 influence	 host	 susceptibility	 to	 disease	 could	 lead	 to	 the	
development	 of	more	 effective	 vaccines	 targeting	 this	 pathogen.	 Transcriptomic	 analysis	
could	 also	 provide	 fresh	 insight	 into	 the	mechanisms	 which	 S.	 Typhi	 utilises	 in	 order	 to	
circumvent	human	immune	defence.	
6.2.2. Combined	delivery	of	Ty21a	alongside	other	vaccines	
Data	presented	here	would	suggest	that	combined	administration	of	Ty21a	alongside	other	
vaccines	may	enhance	their	efficacy.	Since	intestinal	TLR	engagement	is	known	to	enhance	
the	 efficacy	 intramuscular	 vaccines	 (Oh	 et	 al.,	 2014),	 oral	 administration	 of	 Ty21a	 may	
possess	the	capacity	to	influence	responses	to	a	range	of	vaccines,	not	just	those	which	are	
orally-administered.	
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A	double-blind	randomised	control	trial	would	be	required	to	test	this	hypothesis.	Recently,	
experimental	 human	 pneumococcal	 carriage	 has	 been	 used	 to	 successfully	 assess	 the	
efficacy	of	13-valent	pneumococcal	conjugate	vaccine	(PCV)	on	pneumococcal	colonisation,	
at	 a	 fraction	 of	 the	 cost	 associated	with	 full-scale	 field	 trials	 (Collins	 et	 al.,	 2015).	 If,	 for	
example,	 the	 administration	 of	 Ty21a	 alongside	 PCV	 resulted	 in	 increased	 vaccine	
immunogenicity	 and	 improved	 efficacy,	 it	 would	 have	 important	 implications	 for	 the	
development	of	novel	vaccines	targeting	the	pneumococcus,	as	well	as	for	the	development	
of	novel	adjuvants,	and	for	wider	vaccine	strategy.	
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6.3. Concluding	remarks	
We	have	demonstrated	that	Ty21a	can	be	used	to	safely	study	cellular	immune	defence	at	
the	human	intestinal	mucosa.	Thus,	oral	vaccination	with	Ty21a	could	be	used	as	a	model	to	
study	host-pathogen	interaction	at	the	human	intestinal	mucosa,	and	could	provide	insight	
into	 the	generation	of	mucosal	 immune	defence	and	 insight	 into	cellular	dynamics	at	 the	
intestinal	mucosa.	We	have	also	demonstrated	that	Ty21a	can	confer	additional	benefits,	
beyond	 those	 specific	 to	 the	 targeted	 pathogen,	 influencing	 immune	 responses	 to	 non-
related	pathogens.	These	findings	have	enhanced	our	understanding	of	immune	defence	and	
have	important	implications	for	vaccine	strategy	and	for	the	development	of	next-generation	
vaccine	adjuvants.	
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